PICLLC

PROMPTING INTEGRATION & CONSULTING L.L.C.

2025 Tool Jar

Generative AI can be a daunting potential system to integrate. Because it has so much potential, it has often been under-utilized, and over-hyped. There are a number of reasons for this, ranging from lack of buy-in from employees, to too much trust, where users can dull their skills. The hype often oversells a use-case and barely delivers an improvement. At Prompting Integration and Consulting LLC we've helped clean up some of these messes, and advise on routes out. What matters to us is that these tools are used ethically, efficiently, and responsibly. When a tool costs more than it benefits, that's not just inefficient, it's often unresponsible, due to the unseen costs of AI on the environment or unethical, as it might result in layoffs that later get clawed back. We've heard a lot of great ideas, a lot of weird ideas, and some ideas that can help change the game for a business. But one thing we realized last year, was that Generative AI, can be very obtuse to conceptualize.

Which is why we created the Tool Jar. Four tools that can be used as standalone or integrated into a system, the purpose for each of these tools was to help our clients and customers use them as a piece to a larger AI puzzle that they were working on. Sometimes that puzzle was an internal tool, other times one for their customers, but these tools from our tool jar were designed as places to start.

Connect with at promptingsolutions.org.

Second Glance

Second Glance: Ensuring Label Accuracy and Compliance

In industries governed by regulatory oversight, particularly those under the FDA, the accuracy and compliance of packaging labels are non-negotiable. Ensuring that every detail aligns with complex regulations and matches approved specifications is critical for consumer safety, brand integrity, and avoiding costly recalls or regulatory actions. Verifying this manually can be challenging and prone to error.

To enhance this crucial verification process, PICLLC provides Second Glance.

Second Glance is a Generative AI tool designed to meticulously analyze packaging labels, providing detailed insights into their content, specifics, and adherence to relevant FDA regulations. It serves as an intelligent layer of review and comparison for quality assurance.

Second Glance bolsters label integrity through these key capabilities:

- AI-Powered Label Analysis: Utilizes Generative AI to examine the specific details, content, and layout elements present on packaging labels.
- Regulatory Compliance Checks: Provides specific information regarding the label's alignment with appropriate and applicable FDA regulations and guidelines.
- Detailed Label Comparison: Facilitates the comparison between different label versions (e.g., proof vs. production, old vs. new), clearly identifying and detailing discrepancies.
- Visual Inspection Augmentation: Offers the capability to integrate with visual inspection systems or sensors, aiding in the comparison of approved digital label data against the final physical appearance of the product label during QC processes.
- Flexible Implementation: Functions effectively as a standalone analysis tool for specific checks or can be integrated into broader systems such as Quality Management Systems (QMS), packaging design workflows, or manufacturing control systems.

Applications & Use Cases:

Second Glance is valuable across various stages of the packaging lifecycle:

- Design & Development: Verifying label content and layout against regulatory requirements during the design phase.
- Pre-Production Approval: Conducting final checks on proofs against master specifications and regulations before mass printing.
- Incoming Quality Control: Inspecting labels on received packaging components to ensure they match approved versions.
- In-Process Quality Checks: Augmenting visual inspections on the production line for label accuracy and consistency.
- Discrepancy Investigation: Assisting in root cause analysis when label errors or inconsistencies are detected.

By incorporating Second Glance, organizations can significantly improve the accuracy, consistency, and compliance of their packaging labels, reducing risk and enhancing quality assurance efforts.



483 Inquiry

Search.Find.

483 Inquiry: Proactively Aligning Procedures with Regulatory Expectations

In FDA-regulated industries, maintaining compliance is not just a requirement but a continuous process. Staying abreast of regulatory expectations, particularly insights gleaned from FDA Form 483 inspection observations, and ensuring internal Standard Operating Procedures (SOPs) reflect current standards can be a complex and resource-intensive task. Generative AI can provide powerful assistance in navigating this landscape.

To meet this critical need, PICLLC offers 483 Inquiry.

483 Inquiry is a specialized Generative AI tool designed specifically for Quality Control (QC) professionals, regulatory affairs teams, and internal auditors. It facilitates the crucial process of cross-referencing internal procedures with relevant FDA 483 observations and regulatory requirements (like the Code of Federal Regulations - CFRs).

483 Inquiry helps organizations stay ahead of compliance demands through these key capabilities:

- Intelligent Cross-Referencing: Employs Generative AI to analyze internal SOPs and identify potentially related historical FDA 483 observations or relevant sections within the CFRs.
- Targeted Compliance Insights: Provides QC professionals with contextually relevant information drawn from regulatory findings, aiding in the proactive review, maintenance, and strengthening of SOPs.
- Informed Audit Planning: Delivers valuable data and trend insights derived from 483s, helping to inform the scope, focus, and effectiveness of internal audit programs.
- Project Risk Assessment Support: Offers insights into common compliance pitfalls related to specific processes or areas, assisting in early-stage risk identification for projects.
- Flexible Deployment: Can be utilized effectively as a standalone research and inquiry tool or integrated into existing Quality Management Systems (QMS), document control, or compliance platforms.

Applications & Use Cases:

483 Inquiry is a valuable asset for various quality and compliance functions:

- Proactive SOP Management: Regularly assessing and updating SOPs to align with current regulatory trends and findings.
- Internal Audit Strategy: Focusing audit resources on areas frequently cited or emerging areas of regulatory concern.
- Regulatory Risk Mitigation: Identifying potential compliance gaps before they become significant issues or findings.
- Compliance Training: Developing training materials that address real-world compliance observations relevant to specific roles or procedures.
- CAPA Development: Informing corrective and preventive actions by understanding related historical regulatory observations.

By leveraging 483 Inquiry, organizations can enhance their ability to proactively manage compliance, refine internal procedures, and strategically focus their quality resources based on relevant regulatory intelligence.



Connect. Grow. Together.

Ready Net Go

Life Sciences

Healthcare
Biopharma
Med Device

Ready Net Go: Engineering Meaningful Connections

In any professional environment, making the right connections is paramount – whether it's finding the ideal candidate, identifying a synergistic business partner, pairing mentors with mentees, or simply facilitating productive networking. However, navigating vast networks to find truly compatible matches can be time-consuming and often yields suboptimal results. Generative AI offers a way to make this process more intelligent and targeted.

To facilitate these crucial interactions, PICLLC provides Ready Net Go.

Ready Net Go is a Generative AI tool designed as a practical matchmaking engine. It goes beyond simple searches to help connect individuals, organizations, and resources that are genuinely well-suited for collaboration, mentorship, or other professional engagements.

Ready Net Go enhances connection-making through these core capabilities:

- AI-Powered Matchmaking: Leverages Generative AI to analyze profiles and requirements, identifying highly suitable pairings based on compatibility factors relevant to the specific goal.
- Context-Aware Suggestions: Delivers more fitting and relevant suggestions for sales leads, recruitment candidates, potential mentors/mentees, and general networking opportunities compared to traditional methods.

- Versatile Application: Functions as a practical engine adaptable to various needs, from ongoing organizational requirements to specific, time-bound objectives.
- Focus Adaptability: Can be specifically tailored for project-based needs (e.g., finding collaborators with specific skills) or for optimizing connections at events.
- Flexible Deployment: Operates effectively as a standalone tool or can be integrated into existing platforms like HR systems, CRMs, or event management software.

Applications & Use Cases:

Ready Net Go can be applied to streamline and improve outcomes in several areas:

- Talent Acquisition: Identifying and connecting with candidates who are not just qualified but also a strong cultural or team fit.
- Business Development: Pinpointing potential partners, clients, or resources with high synergistic potential.
- Mentorship Programs: Facilitating more effective and compatible pairings between mentors and mentees.
- Event Networking: Helping attendees make more relevant and valuable connections during conferences or meetings.
- Internal Collaboration: Assisting in forming project teams by identifying colleagues with complementary skills and experience.

By using Ready Net Go, organizations can foster more meaningful and productive connections, saving time and improving the quality of interactions across various professional functions.



PEAR: Cultivating Knowledge and Ensuring Readiness

Ensuring consistent, effective, and scalable training is crucial for organizational success, whether for onboarding new team members, maintaining compliance, or upskilling existing staff. Traditional methods can be time-consuming to develop and may not always adapt easily to individual learning paces. Generative AI presents an opportunity to enhance and streamline these vital processes.

To address this need, PICLLC offers the Parallel Education Assistance Resource (PEAR).

PEAR is a Generative AI tool specifically designed to augment and support learning systems. It excels at integrating diverse knowledge sets and creating high-quality training and assessment materials, making knowledge transfer more efficient and measurable.

PEAR helps organizations cultivate expertise through these key features:

- Versatile Knowledge Integration: Seamlessly incorporates information from a wide range of sources, including Standard Operating Procedures (SOPs), technical manuals, textbooks, literature PDFs, PowerPoint presentations, and reports.
- Robust Material Generation: Leverages Generative AI to create comprehensive training questions, quizzes, and other assessment materials based on the integrated knowledge.
- Streamlined SME Review: Produces structured learning and testing content that is easier and faster for Subject Matter Experts (SMEs) to review and validate for accuracy and relevance.
- Adaptive Learning Support: Helps align instructional content and assessments with the specific needs and demonstrated capabilities of the trainee or learner.

- Flexible Deployment: Can be used as a standalone tool or integrated into existing Learning Management Systems (LMS) or training workflows.
- Complements Practical Training: Designed to be used effectively in conjunction with hands-on training sessions but does not strictly require them.

Applications & Use Cases:

PEAR is adaptable to a wide variety of training scenarios:

- Employee Onboarding: Accelerates the integration of new hires by providing consistent foundational knowledge and checks.
- SOP & Compliance Training: Reinforces understanding of critical procedures and regulatory requirements.
- Safety Protocols: Ensures essential safety information is effectively learned and retained.
- General Skills Development: Supports continuous learning initiatives across various subjects.
- Enabling Advanced Methodologies: Facilitates techniques like Human-AI Training Parallelization (TPL). TPL utilizes PEAR for regular (e.g., daily) knowledge checks to keep teams or classes synchronized, allowing trainers or leads to monitor progress and identify knowledge gaps effectively. This approach is rooted in the "Three Aligned Minds" concept, fostering synchrony between the Subject Matter Expert (or curriculum), the Learner, and the Agentic PEAR tool.



By leveraging PEAR, organizations can enhance the quality, consistency, and efficiency of their training programs, ensuring personnel are knowledgeable, compliant, and prepared.

Screenshots of Beta Version

to follow on next page



Document Selection Screen



Chat with Uploaded Knowledge Screen

PICLLC
PROMPTING INTEGRATION & CONSULTING L.L.C.



Learning Screen



Testing Screen

PICLLC
PROMPTING INTEGRATION & CONSULTING L.L.C.



Testing Screen



Proctor Screen: Review

PICLLC
PROMPTING INTEGRATION & CONSULTING L.L.C.



Proctor Screen: Question Bank



Proctor Screen: Report



Proctor Screen: Curriculum



Proctor Screen: Modify Settings

COMPASS

Compass: Navigating Your Data Landscape

In today's information-rich environment, organizations often grapple with vast amounts of data stored in various formats and locations. Extracting meaningful insights efficiently can be a significant challenge. Generative AI offers potential, but requires tools that can intelligently process and report on this complex data landscape.

This is where Compass, another specialized tool from PICLLC, provides direction.

Compass is an agentic Generative AI reporting tool designed to process and analyze diverse datasets, whether structured or unstructured, even when spread across different folders or systems. While specific standards can help, Compass excels at making sense of varied information without rigid formatting requirements.



Compass empowers organizations to turn data into actionable intelligence through several key capabilities:

- Versatile Data Processing: Ingests and analyzes both structured and unstructured data from multiple sources, reducing the need for extensive pre-formatting.
- Agentic Query Generation: Features advanced AI that can independently generate relevant queries based on the context of the data provided, uncovering insights that might otherwise be missed.
- User-Guided Refinement: Allows users, potentially working alongside a dedicated AI assistant, to iteratively modify queries and reporting parameters to meet specific analytical needs.
- Intelligent Reporting: Efficiently searches, organizes, and restructures findings into clear, coherent reports tailored to the query objectives.
- Customizable Outputs: Generates reports that can be easily branded and structured to align with specific project requirements, SOPs, or organizational brand standards.
- Automated Data Collection: Can function as an agent to proactively identify, collect, and appropriately organize relevant materials for comprehensive reporting.

Applications & Use Cases:

Compass offers flexibility for various analytical tasks:

- Knowledge Preservation ("True North" Concept): Can be integrated with trained assistants and user input (e.g., trainees, specialists) to capture and structure critical "tribal knowledge" from lab notes, literature, and other project materials, ensuring continuity.
- Market & Competitive Intelligence: Analyzes data like SEC filings, industry reports, and other sources to assist in generating SWOT analyses or identifying sales channel opportunities. (Note: Insight quality is data-dependent).
- Compliance & Regulatory Analysis: Processes documents like FDA 483s to identify trends, patterns, or areas needing attention, even with minimal initial prompting.
- Information Management: Parses large volumes of communications, such as emails, to quickly assess relevance, identify key needs, and help prioritize responses or actions.
- Project Insight Generation: Rapidly extracts key findings and insights from project reports and accumulated data.

Whether used independently or integrated into broader systems, and potentially complementing methodologies like Training Parallelization, Compass provides a powerful capability for navigating complex data and generating the focused reports needed to make informed decisions.

Screenshots of COMPASS and Sample Reports to follow on next page



Intro Screen



Edit Questions (can be autogenerated)



Edit Tags (can be autogenerated)



Edit Categories for the Report (can be autogenerated)

Insulin Contamination Issues Report

Executive Summary

Several warning letters issued by the FDA highlight potential **contamination** issues related to insulin and related products. A recurring theme involves violations of current good manufacturing practice (CGMP) regulations. These violations span a range of deficiencies, including inadequate aseptic practices, poor cleanroom design, failures in environmental monitoring, and lack of proper quality control procedures. Manufacturing deficiencies can directly lead to **contamination** of sterile drug products, posing significant risks to patients. Another significant concern is the unlawful sale of unapproved and misbranded drugs, many of which claim to regulate blood sugar and insulin levels. These products, often sold online, may be **contaminated**, counterfeit, or contain incorrect ingredients. Injectable drug products, in particular, pose a heightened risk, as they bypass the body's natural defenses against toxic substances and dangerous organisms, potentially leading to severe conditions like septicemia or sepsis. There is a trend of companies marketing products with claims related to blood sugar regulation and insulin sensitivity without proper FDA approval. These products are often misrepresented as dietary supplements but are, in effect, unapproved new drugs. The FDA emphasizes that these products have not undergone the same rigorous safety and effectiveness evaluations as approved drugs and may present significant health risks to consumers. The unapproved products can be **contaminated**, counterfeit, or contain incorrect ingredients. Specific manufacturing deficiencies identified include the failure to establish adequate procedures for process control, validation, design changes, risk analysis, and corrective actions. These issues can lead to inconsistencies in product quality and potential harm to patients. The FDA mandates comprehensive investigations into data inaccuracies, risk assessments of the potential effects of failures on drug quality, and detailed corrective action plans to address these violations and prevent their recurrence. The failures in quality control and manufacturing standards are associated with the potential for **contamination**.

Insulin Contamination Issues Report

Tags Summary

Unapproved drugs and **FDA warning letters** appear with notable prevalence, suggesting potential compliance concerns. **Manufacturing standards**, **insulin**, and **contamination** show lower incidence. The disparity between the high occurrence of unapproved drugs and FDA warning letters versus the other categories warrants attention as it may point to a concentration of issues in those areas.

Tag Frequency



Document Relevancy



Insulin Contamination Issues Report

Questions And Answers

1. What are the potential health risks associated with the contamination issues described in this document?



2. What specific products are mentioned in this document that have faced contamination issues or regulatory action?



3. What is the overall impact of the contamination issues described in this document on the affected company's operations or reputation?



4. What testing or quality control procedures are discussed in this document related to preventing contamination?



5. What corrective actions were requested by the FDA or FTC related to contamination concerns outlined in this document?



6. What specific equipment or facilities are mentioned in this document as being involved in the contamination issues?



7. What manufacturing deficiencies are noted in this document that could lead to contamination of insulin products?



8. What types of violations or deviations from standard practices are highlighted in this document that could lead to insulin contamination?



Top Matches

FDA Warning Letter to Dexcom Regarding Manufacturing Practices

dexcom-inc-700835-03042025.txt

This FDA warning letter addresses significant violations of current good manufacturing practice requirements at Dexcom, Inc., concerning their G6 and G7 continuous glucose monitoring systems. The FDA's inspection revealed failures in establishing procedures for process control, validation, design input, design changes, risk analysis, and corrective actions. Specific issues include inadequate monitoring of glucose and acetaminophen concentrations, failure to validate manufacturing specifications, and the lack of hazard assessments for devices used with automated insulin dosing systems. A component change in the sensor's resistance layer also raised concerns about clinical performance. The company has been requested to provide justifications, data, and updates on corrective actions, and the FDA has expressed concerns about the adequacy of their responses. The violations could lead to regulatory actions and impact the approval of future devices. The document is highly relevant to the query as it discusses manufacturing deficiencies that could lead to contamination and regulatory actions taken in response.

FDA Warning Letter to Kobayashi Healthcare International

kobayashi-healthcare-international-inc-637313-01272023.txt

This document is a warning letter from the FDA to Kobayashi Healthcare International, Inc., addressing significant violations of Current Good Manufacturing Practice (CGMP) regulations at their drug manufacturing facility. The FDA inspection revealed failures in conducting appropriate laboratory testing for microbiological quality, inadequate quality control oversight, and the distribution of an unapproved new drug. The letter outlines specific violations, including the release of drug products without proper microbiological testing and the lack of an adequate quality control unit. The FDA mandates several corrective actions, such as providing microbiological specifications, conducting full microbiological testing of retain samples, and performing an independent assessment of microbiological test methods. The company's response to initial findings was deemed inadequate, and the FDA emphasizes the need for a comprehensive remediation plan to ensure the quality control unit's effectiveness. The warning letter also addresses the unapproved new drug, “ZIM’S HYDRO COOLING PAIN RELIEF PATCH,” citing its misbranding and violation of FD&C Act sections. The document is relevant to the query because it discusses contamination issues in drug manufacturing and the FDA's response to these issues.

FDA Warning Letter to USApeptide.com

usapeptidecom-696885-02262025.txt

This document is a warning letter from the FDA to USApeptide.com regarding the unlawful sale of unapproved and misbranded drugs to U.S. consumers over the Internet. The FDA observed that the website introduces into interstate commerce unapproved and misbranded semaglutide and tirzepatide drug products. These drugs are being marketed with claims of weight loss and blood sugar management, similar to FDA-approved drugs like Ozempic, Rybelsus, Wegovy, Mounjaro and Zepbound, but lack the necessary FDA approvals. The FDA emphasizes the inherent risks to consumers who purchase unapproved new drugs and misbranded drugs, as they may be contaminated, counterfeit, or contain incorrect ingredients. The warning letter also addresses the sale of prescription drugs without requiring a prescription, which jeopardizes patient safety and misbrands the drugs. The FDA requests that USApeptide.com cease offering any unapproved and misbranded drugs for sale to U.S. consumers to protect the public from harm. The letter highlights that injectable drug products can pose a serious risk of harm to users because they bypass many of the body's natural defenses against toxic ingredients, toxins, or dangerous organisms that can lead to serious and life-threatening conditions such as septicemia or sepsis. The unapproved drugs may be contaminated or counterfeit, which are contamination issues related to insulin.

FDA Warning Letter to Akorn, Inc. re: CGMP Violations

akorn-inc-558914-02042019.txt

This document is a warning letter from the FDA to Akorn, Inc. regarding significant violations of current good manufacturing practice (CGMP) regulations. The FDA inspected Akorn's drug manufacturing facility and observed violations such as poor aseptic practices, inadequate cleanroom design, and deficiencies in environmental monitoring and cleaning operations. The letter highlights specific issues like operators' improper handling of sterile materials, non-integral cleanroom materials, and inadequate smoke studies. It also mentions the firm's failure to follow written testing programs for drug product stability, specifically acetylcysteine injection 200 mg/mL, which led to a recall. The FDA requests a comprehensive investigation into the extent of data inaccuracies, a risk assessment of the potential effects of the failures on drug quality, and a detailed corrective action plan. The document is highly relevant to the query about common contamination issues related to insulin because it outlines various manufacturing deficiencies and failures in quality control that can lead to contamination of sterile drug products, including issues with aseptic technique, facility design, and material handling.

FDA Warning Letter to Medtronic on Insulin Pumps

medtronic-inc-617539-12092021.txt

This document is a warning letter from the FDA to Medtronic, Inc. regarding significant deficiencies in the manufacturing and reporting processes for their MiniMed insulin infusion pumps and related devices. The FDA found that Medtronic failed to adequately establish procedures for corrective and preventive action, particularly concerning complaints of damaged retainer rings in the MiniMed 600 Series Insulin Infusion Pumps, which could lead to over or under-delivery of insulin. The company also failed to adequately investigate complaints, including those related to cybersecurity vulnerabilities and glucose sensor failures. The FDA also noted that Medtronic failed to submit timely reports of device malfunctions and adverse events, as required by medical device reporting regulations. The company's risk management procedures were criticized for underestimating the probability of harm and for not adequately addressing all potential health risks. Corrective actions are underway, but the FDA has not yet determined their adequacy. This document is relevant to the query, as it discusses contamination issues related to insulin, specifically manufacturing deficiencies that could lead to contamination of insulin products, the health risks associated with these issues, and the corrective actions requested by the FDA.

FDA Warning Letter to Sooil Development Co., Ltd

sooil-development-co-ltd-607127-04162020.txt

This FDA warning letter, issued to Sooil Development Co., Ltd., addresses significant violations of current good manufacturing practice requirements related to their DANA Diabecare IIs insulin pump. The FDA inspection revealed failures in documenting corrective actions, controlling environmental conditions, establishing calibration procedures, ensuring the quality of purchased products and services, providing adequate training, conducting quality audits, and performing management reviews. The letter also cites the company's failure to furnish necessary information related to medical device reporting (MDR) procedures. The FDA requests a written response detailing corrective actions and a plan to prevent future violations. The violations noted in the letter suggest potential contamination issues could arise from not following proper manufacturing standards. The warning letter indicates serious deficiencies in the company's quality management systems, potentially affecting the safety and efficacy of their insulin pump.

FDA Warning Letter for Unapproved Semaglutide and Tirzepatide

wwwgorillahealingcom-664245-10022023.txt

This document is a warning letter from the FDA to www.gorillahealing.com regarding the unlawful sale of unapproved and misbranded drugs, specifically semaglutide and tirzepatide. The FDA emphasizes the risks of purchasing such drugs, including potential contamination, counterfeit ingredients, and varying amounts of active ingredients. The letter instructs the company to cease offering these drugs for sale and to take prompt action to address the violations. The FDA is concerned that the website offers injectable drugs without providing proper instructions, which could lead to serious health risks. The warning letter highlights the sale of unapproved drugs that claim to lower blood sugar levels and enhance insulin secretion, but lack FDA approval and carry potential health risks due to their unverified safety and effectiveness.

FDA Warning Letter to Deggeh Foods, Inc.

deggeh-foods-inc-628460-07292022.txt

This document is a warning letter from the FDA to Deggeh Foods, Inc. regarding serious violations of the Federal Food, Drug, and Cosmetic Act. The FDA inspection revealed that the company's Actibest® Health Plus Capsules, Best Hemorrhoids Rapid Action Herbal Healing Formula, StomachAID capsules, and Moringa Tea Bags are unapproved new drugs and misbranded drugs because they are intended for use in the cure, mitigation, treatment, or prevention of disease without prior FDA approval. Additionally, the company's facility inspection revealed serious violations of the FDA's regulations for Current Good Manufacturing Practice (CGMP) in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements. The company failed to establish specifications for received products and finished goods, lacked written procedures for quality control operations, and had inadequate procedures for handling product complaints and returned dietary supplements. These violations cause the dietary supplements to be adulterated. The FDA also found misbranding issues with the products' labeling, including incorrect serving sizes, missing information, and non-compliance with nutrition labeling requirements. The warning letter serves to notify the company of the violations and provides an opportunity to address them, failure to adequately address the violations may result in legal action. The document is relevant to the query because it discusses manufacturing deficiencies and regulatory actions that can lead to the contamination of products.

FDA Warning Letter to Glenmark Pharmaceuticals

glenmark-pharmaceuticals-limited-637314-11222022.txt

This FDA warning letter, issued to Glenmark Pharmaceuticals Limited on November 22, 2022, outlines significant violations of Current Good Manufacturing Practice (CGMP) regulations observed during an inspection from May 12, 2022, to May 20, 2022. The letter details failures in investigating discrepancies, inadequate written procedures for production and process control, and lapses in laboratory control mechanisms. Specific issues include failures in investigating out-of-specification results for desmopressin acetate tablets, inadequate validation of the manufacturing process for (b)(4) gel (b)(4) %, and deficiencies in chromatographic data processing. The FDA requests a comprehensive assessment and remediation plan to address these violations and prevent recurrence. The warning letter addresses multiple failures to meet manufacturing standards that could lead to contamination issues in pharmaceutical products, but does not directly mention insulin.

FDA Warning Letter to Polymer Technology Systems, Inc.

polymer-technology-systems-inc-576934-07312019.txt

This document is a warning letter from the FDA to Polymer Technology Systems, Inc. (PTS Diagnostics) regarding violations of the Federal Food, Drug, and Cosmetic Act. The FDA conducted an inspection of the firm's medical device operations and found that the devices were adulterated due to non-conformity with current good manufacturing practice requirements. The violations include failures in production process control, validation of processes, design change validation, and ensuring purchased products meet requirements. The FDA also noted issues with the PTS Detect Cotinine System, which was found to be adulterated and misbranded. Significant deviations in medical device reporting (MDR) procedures and failures to report corrections and removals were also highlighted. The company was instructed to take prompt action to correct these violations, which relate to contamination as it affects product quality and safety through manufacturing and quality control deficiencies.

FDA Warning Letter to Sol-Millennium Medical, Inc.

sol-millennium-medical-inc-677524-03182024.txt

This document is a warning letter from the FDA to Sol-Millennium Medical, Inc. The FDA conducted an inspection and found that the firm's sterile and non-sterile syringes and needles are adulterated and misbranded due to unapproved device violations and failure to meet registration and listing requirements. The firm made major changes to the intended use and design of their syringes without submitting premarket notifications, potentially leading to patient harm. The FDA also found violations of quality system regulations, including failures in design change control, complaint handling, and record-keeping. Additionally, the firm failed to comply with medical device reporting requirements, including not submitting reports in a timely manner. The warning letter outlines several manufacturing deficiencies that could lead to contamination, such as failures in design change control, complaint handling, and record-keeping. The FDA requests corrective actions to address these violations and prevent their recurrence. The document also mentions specific products that have faced quality issues, such as the InviroStripe Standard Luer Lock Syringes. This document does not directly discuss insulin, but it does focus on the manufacturing standards and potential for contamination in medical devices.

FDA Warning Letter to Lone Star Botanicals Inc.

lone-star-botanicals-inc-659735-11062023.txt

This document is a warning letter from the FDA to Lone Star Botanicals Inc. The FDA inspected the company's food manufacturing facility and found serious violations of Current Good Manufacturing Practice regulations. The company manufactures and repackages ready-to-eat seasoning blends. The FDA determined that the seasoning products are adulterated and misbranded. The company did not prepare or implement a food safety plan, including hazard analysis and preventive controls. They failed to identify allergens and environmental pathogens as hazards and lacked proper sanitation and supply-chain controls. The company's products were also found to be misbranded due to undeclared allergens, incorrect ingredient labeling, and improper nutrition facts labels. Certain products were also found to be unapproved new drugs due to claims made on the company website and product labels. The FDA is concerned about the potential for contamination and misbranding of the company's products. The company needs to implement a comprehensive food safety plan and correct its labeling practices to comply with FDA regulations. The warning letter addresses issues related to contamination, misbranding, and unapproved drug claims, highlighting the importance of adhering to manufacturing standards to ensure product safety and compliance.

FDA Warning Letter to Only Natural, Inc.

only-natural-inc-dba-bio-nutrition-inc-605076-06182020.txt

This document is an FDA warning letter issued to Only Natural, Inc. dba Bio Nutrition, Inc. The letter addresses serious violations of the Federal Food, Drug, and Cosmetic Act, including the marketing of unapproved new drugs and misbranded dietary supplements. The FDA found that several products made drug claims on their labels and websites, classifying them as drugs without prior FDA approval. Additionally, numerous products were found to be misbranded due to labeling violations, such as incorrect nutrition information and failure to identify plant parts in botanical ingredients. The company is required to take prompt action to correct these violations to avoid potential legal consequences. The document is relevant to the query because it discusses regulatory actions taken against a company for marketing unapproved products with claims related to blood sugar regulation, a function often associated with insulin. Although it does not directly address contamination issues, it highlights the importance of adhering to FDA regulations in the manufacturing and marketing of health-related products.

FDA Warning Letter to Supplement Science Corp

supplement-science-corp-dba-condemned-labz-613165-09222021.txt

This document is a warning letter from the FDA to Supplement Science Corp. (Condemned Labz) regarding significant violations of the Federal Food, Drug, and Cosmetic Act. The FDA found that the company's products, including Arsyn, ConvictStim, Humaslin, Thyrogenic, and DNA Dispatch, are being marketed as unapproved new drugs with claims related to disease treatment and prevention. Specifically, Humaslin is promoted for reducing blood sugar levels and optimizing insulin sensitivity. The FDA also determined that Arsyn and ConvictStim are adulterated dietary supplements due to the presence of unapproved ingredients like higenamine and 2-aminoisoheptane HCl. The letter instructs the company to address these violations and prevent their recurrence, or face potential legal action. The document is relevant to the query as it identifies Humaslin as a product marketed with claims related to insulin and blood sugar regulation, although the warning letter is not directly related to contamination of insulin but rather to the marketing of unapproved drugs.

FDA Warning Letter to Philosys Co. Ltd

philosys-co-ltd-582516-01142020.txt

This document is a warning letter issued by the FDA to Philosys Co. Ltd following an inspection of their manufacturing facility. The FDA found that the company's Self-Monitoring Blood Glucose (SMBG) test systems were misbranded due to the firm's failure to furnish material or information respecting the device that is required. The letter addresses the company's failure to submit timely and complete Medical Device Reports (MDRs), including a case where a patient using Lantus insulin experienced hypoglycemia due to potentially false high glucose readings from the company's Gmate VOICE blood glucose monitoring system. Additionally, the FDA noted nonconformances related to change control processes, specifically the inadequate verification or validation of changes to the Gmate glucose test strip production process. The firm also failed to submit initial and supplemental reports to the FDA in an electronic format that the FDA can process, review, and archive. The FDA requests that Philosys Co. Ltd take corrective actions to address these violations and prevent similar violations from occurring again. The document is related to medical device manufacturing and reporting deficiencies, and only mentions insulin in the context of a complaint related to a blood glucose monitoring system, not contamination of insulin itself.

FDA Warning Letter to Dr Jen Hartley, LLC

dr-jen-hartleyhealing-artistry-llc-590265-10292019.txt

This document is a warning letter from the FDA to Dr. Jen Hartley/Healing Artistry, LLC, concerning the marketing and sale of unapproved drugs, including an "Insulin Balance Tincture." The FDA found that the company's products were being marketed with claims that qualify them as drugs under the Federal Food, Drug, and Cosmetic Act (FD&C Act) without the required FDA approval. The letter instructs the company to correct the violations and warns of potential enforcement action if they fail to do so. The warning letter addresses the marketing of an "Insulin Balance Tincture" as an unapproved drug with claims to help regulate blood sugar and insulin levels. The FDA's primary concern is the marketing and sale of unapproved drugs with therapeutic claims, which is a violation of federal law.

FDA and FTC Warning Letter to Lysulin, Inc.

lysulin-inc-614517-09072021.txt

This document is a warning letter from the FDA and FTC to Lysulin, Inc. regarding their "Lysulin" products, including shakes, chewables, liquids, capsules, and powders marketed for diabetes and pre-diabetes. The FDA states that the company is introducing new drugs into interstate commerce without prior approval, as the products are not generally recognized as safe and effective for their intended uses. They are also considered misbranded because they lack adequate directions for use by a layperson. The FTC is concerned that Lysulin's claims about preventing, treating, or curing diabetes are not substantiated by scientific evidence and has issued a cease and desist demand. The company is required to notify both agencies within 15 working days of the steps they will take to address these concerns. Failure to comply may result in legal action, including seizure, injunction, civil penalties, and consumer refunds. The document is relevant to the query because it involves products intended to affect insulin resistance and blood sugar levels, though it does not directly address contamination issues.

FDA Warning Letter to Moor Herbs, Inc.

moorish-science-temple-divine-and-national-movement-north-america-inc-13-moorish-american-national.txt

This document is a warning letter from the FDA to Moor Herbs, Inc. regarding violations of the Federal Food, Drug, and Cosmetic Act (FD&C Act) and FDA regulations. The FDA conducted an inspection of the company's manufacturing facility and reviewed its website, revealing serious violations related to unapproved new drugs, misbranded drugs, and adulterated dietary supplements. The company's products, such as "Full Body Antibiotic," "Anti-Viral," and "Lungs & Respiratory," are cited for making unproven claims. The FDA also found significant violations of the Current Good Manufacturing Practice (CGMP) regulation for dietary supplements. These violations include the failure to establish specifications for components, dietary supplement labels, and finished batches; the lack of written procedures for quality control operations; the absence of master manufacturing records; incomplete batch production records; and the failure to establish written procedures for handling product complaints, returned dietary supplements, and holding/distributing operations. The warning letter requests that Moor Herbs, Inc. take immediate corrective actions to address these violations and prevent future violations. The company's response to the FDA's initial observations was deemed inadequate because it did not provide sufficient evidence or supporting documentation. The document is relevant to the query because it discusses contamination issues in the context of manufacturing violations and regulatory actions, although it does not directly address insulin contamination.

FDA Warning Letter to MYA International, Inc.

mya-international-inc-619877-02242022.txt

This FDA warning letter to MYA International, Inc. addresses significant violations of the Federal Food, Drug, and Cosmetic Act. The letter outlines that several products including Hygly, Diapro-Z, Bioampixilina, Penalin, Colloidal Silver, Tea (Tea Cellular), Quiebra Piedras, Shark Cartilage, and Helper are unapproved new drugs and misbranded drugs because they are not generally recognized as safe and effective for their intended uses. The FDA inspection also revealed violations of Current Good Manufacturing Practice (CGMP) regulations for dietary supplements, including failures to establish specifications for the identity, purity, strength, and composition of finished batches and components. The company also failed to maintain complete batch production records and properly identify equipment used in manufacturing. Additionally, several products were found to be misbranded due to labeling issues, such as failing to declare a domestic address or phone number for reporting adverse events, not providing required label information in both languages (if applicable), and not complying with nutrition information presentation requirements. The warning letter urges the company to investigate and correct these violations to avoid potential legal action. The document does not contain information about insulin, but it does describe contamination risks associated with poor manufacturing practices such as failing to properly identify equipment.

FDA Warning Letter to New Green Nutrition

new-green-nutrition-inc-615846-10142021.txt

This FDA warning letter addresses New Green Nutrition, Inc. for marketing unapproved drugs, specifically "Xiao Ke Wan," "Diabetee-Care," and "Specific Jiang Tang Remedy," with claims to treat diabetes. The FDA has determined that these products are unapproved new drugs and misbranded drugs because they are not generally recognized as safe and effective for their intended uses and lack adequate directions for use. The letter highlights that "Xiao Ke Wan" contains glibenclamide, a prescription drug, and is being dispensed without a prescription, jeopardizing patient safety. The company is required to respond within fifteen working days with corrective actions to prevent recurrence of these violations, or face potential legal action, including seizure or injunction. The warning letter emphasizes the company's responsibility to comply with all federal laws and FDA regulations. The document is related to the query because it discusses unapproved drugs intended to treat diabetes, but it does not address contamination issues related to insulin.

FDA Warning Letter to Ozempen.com on Unapproved Drugs

ozempencom-684435-06242024.txt

This document is a warning letter from the FDA to Ozempen.com regarding the unlawful sale of unapproved and misbranded semaglutide drugs to U.S. consumers. The FDA observed that the website introduces into interstate commerce unapproved and misbranded semaglutide drug products, like "4mg Semaglutide Pen" and "8mg Semaglutide Pen". The letter states that these unapproved drugs do not carry the same assurances of safety and effectiveness as FDA-approved drugs and may be contaminated, counterfeit, or contain incorrect ingredients. The FDA requests that Ozempen.com cease offering these drugs for sale to protect the public from harm. It mentions that offering these drugs violates sections of the Federal Food, Drug, and Cosmetic Act. The FDA is concerned about the inherent risks to consumers who purchase misbranded and unapproved new drugs and requires a written response within 15 working days detailing corrective actions. The primary issues are the sale of unapproved and misbranded semaglutide products, potential safety risks to consumers, and violations of the FD&C Act.

FDA Warning Letter to Summit Research Peptides

summit-research-peptides-695607-12102024.txt

This warning letter from the FDA to Summit Research Peptides addresses the company's marketing and sale of unapproved new drugs, including Semaglutide, Retatrutide, Cagrilintide, Tirzepatide, and Mazdutide. The FDA has determined that these products are being marketed as drugs for human use, with claims related to treating conditions like type 2 diabetes and obesity. The letter states that introducing these unapproved drugs into interstate commerce violates the Federal Food, Drug, and Cosmetic Act. Summit Research Peptides has been asked to respond within fifteen working days, outlining the steps they will take to address these violations and prevent recurrence. The warning specifically calls out the marketing claims made on the company's website and social media pages related to the therapeutic benefits of these products.

FDA Warning Letter to www.dashpct.com

wwwdashpctcom-679727-04242024.txt

This document is a warning letter from the FDA to www.dashpct.com regarding the unlawful sale of unapproved and misbranded drugs to U.S. consumers over the Internet. The FDA observed that the website introduces into interstate commerce unapproved and misbranded semaglutide drug products, such as “Rybelsus 14mg” and “Rybelsus 7mg.” These drugs are unapproved because they have not undergone the same safety and effectiveness assurances as FDA-approved drugs and may be contaminated, counterfeit, or contain incorrect ingredients. The FDA requests that www.dashpct.com cease offering these unapproved drugs for sale to protect the public from harm. The letter states that the sale of these drugs violates sections of the Federal Food, Drug, and Cosmetic Act. The company is urged to review its website and product labels to ensure compliance with the FD&C Act and to address any violations promptly to avoid legal action. The warning emphasizes the risks associated with purchasing unapproved drugs, including potential contamination and lack of safety assurances, but does not specifically mention insulin contamination issues.

FDA Warning Letter for Unapproved Semaglutide Sales

wwwsemaspacecom-665848-10022023.txt

This document is a warning letter from the FDA to www.semaspace.com regarding the unlawful sale of unapproved and misbranded drugs, specifically semaglutide products. The FDA observed that the website introduces unapproved semaglutide drug products into interstate commerce, posing risks to consumers due to the lack of safety and effectiveness assurances. These drugs may be contaminated, counterfeit, or contain incorrect ingredients. The FDA requests that www.semaspace.com cease offering these drugs for sale. The letter also addresses the misbranding of drugs due to inadequate directions for use and the dispensing of prescription drugs without a prescription, heightening public health concerns, especially with injectable products. The FDA emphasizes that these actions violate the Federal Food, Drug, and Cosmetic Act. The warning letter highlights the potential for drugs that have circumvented regulatory safeguards to be contaminated, counterfeit or contain varying amounts of active ingredients. This is relative to the query because the document specifies drugs that may be contaminated.

FDA Warning Letter to Boehringer Ingelheim on Senvelgo

boehringer-ingelheim-animal-health-usa-674535-03012024.txt

This document is a warning letter from the FDA to Boehringer Ingelheim Animal Health USA regarding false and misleading claims in the promotional communications for Senvelgo (velagliflozin oral solution), a veterinary drug used to improve glycemic control in cats with diabetes mellitus. The FDA found that the promotional material, specifically a Vet Detailer, made claims that Senvelgo was safe and effective in previously insulin-treated cats, which contradicts the product's labeling and clinical trial data. The labeling includes a boxed warning about the increased risk of diabetic ketoacidosis (DKA) or euglycemic DKA in cats treated with Senvelgo, especially those previously treated with insulin, potentially leading to death. The FDA requests that Boehringer Ingelheim cease any violations of the Federal Food, Drug, and Cosmetic Act (FD&C Act) and submit a written response addressing the concerns outlined in the letter. The document is related to the query because it involves a drug indicated for diabetes (similar to insulin), and the warning letter addresses concerns about the safety and effectiveness claims made in the promotional material, which could have implications for how the drug is used and perceived by veterinarians and pet owners.

FDA Warning Letter to Immune & Genetics Protocols

immune-genetics-protocols-llc-611042-03302021.txt

This document is a warning letter from the FDA to Immune & Genetics Protocols, LLC, regarding their product 'Immune Bio Green Cell'. The FDA reviewed the company's website and social media pages and determined that the product is being marketed as a drug without the necessary FDA approval. The letter cites claims made by the company that the product can treat various diseases, including diabetes by regenerating pancreatic cells to produce insulin, which positions it as a drug under the Food, Drug, and Cosmetic Act. The FDA also notes that the company falsely claims the product is approved by the USDA and manufactured in an FDA-approved laboratory. The warning letter instructs the company to take corrective action and notify the FDA of the steps taken to address the violations. The document is relevant to the query because it involves claims related to insulin regulation and the treatment of diabetes, although it does not directly address contamination issues.

FDA Warning Letter to Beeyoutiful.com, LLC

beeyoutifulcom-llc-613682-07122021.txt

This document is a warning letter from the FDA to Beeyoutiful.com, LLC, addressing the marketing and sale of various products as unapproved new drugs. The FDA reviewed the company's website and found that claims made about products like Vitex w/ Dong Quai, Berry Well, and others, indicated they were intended for use in the cure, mitigation, treatment, or prevention of disease, thus classifying them as drugs under the Federal Food, Drug, and Cosmetic Act. The letter states that these products cannot be legally introduced into interstate commerce without prior FDA approval, which requires scientific data demonstrating their safety and effectiveness. Additionally, the products are considered misbranded because they lack adequate directions for use by a layperson, as they are intended for conditions that require supervision by a licensed practitioner. The FDA requests that the company take corrective actions to address these violations, prevent their recurrence, and comply with all federal laws and regulations, or face potential legal action. The document pertains to the query because it involves regulatory action related to health products, specifically addressing the sale and marketing of unapproved drugs with claims of therapeutic benefits.

FDA & FTC Warning Letter to Curalife Ltd

radhanite-llc-dba-curalife-ltd-614542-09072021.txt

This document is a warning letter from the FDA and FTC to Radhanite, LLC, regarding their CuraLin product. The FDA states that claims on the company's website and social media sites establish the product as a drug because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease. The FDA notes that the product is not generally recognized as safe and effective for its intended uses, making it a "new drug" that requires prior approval. The letter also states that the product is misbranded because it fails to bear adequate directions for its intended use, as it is intended for the treatment of diseases not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. The FTC is concerned that one or more of the efficacy claims cited above may not be substantiated by competent and reliable scientific evidence. The letter demands that Radhanite cease and desist from making any claim that their product can prevent, treat, or cure diabetes without proper scientific evidence. The document primarily focuses on the unapproved drug claims and the lack of scientific evidence supporting the product's advertised benefits, rather than contamination issues.

FDA Warning Letter to Robbins Instruments, LLC

robbins-instruments-llc-687984-01212025.txt

This document is a warning letter from the FDA to Robbins Instruments, LLC, concerning the Dermo-Jet Needleless Injector. The FDA has determined that the firm is marketing the device without necessary approvals, thus violating the Federal Food, Drug, and Cosmetic Act. The FDA inspection revealed several violations of the Quality System regulation, including failures in process validation, design change procedures, complaint handling, device history records, acceptance activities, and labeling controls. The letter also highlights violations related to medical device reporting, failure to submit required information to the Global Unique Device Identification Database (GUDID), and inadequate annual registration and listing. The FDA requests immediate action to address these violations, warning of potential regulatory actions such as seizure, injunction, and civil money penalties if the issues are not resolved. The document addresses manufacturing deficiencies and lack of adherence to quality standards that could lead to inconsistencies in product quality and potential harm to patients. It does not directly discuss insulin, so the relevance to the query is limited to general contamination and manufacturing standard issues.

FDA Warning Letter to TKTX Store re: Unapproved Drugs

tktx-store-698371-02252025.txt

This FDA warning letter, dated February 25, 2025, addresses TKTX Store's distribution of unapproved drug products, including "Mithra+ 10% Lidocaine," "J-PRO Cream," and TKTX branded numbing creams. These products are marketed as external analgesics for use before and during cosmetic procedures like tattooing and laser treatments. The FDA found these products to be unapproved new drugs and misbranded drugs in violation of the Federal Food, Drug, and Cosmetic Act (FD&C Act). The products contain lidocaine concentrations exceeding permissible limits for over-the-counter external analgesics and include combinations of active ingredients not conforming to established monographs. The FDA has safety concerns about the potential for increased absorption of these products through the skin, especially when used without supervision by trained health professionals. The letter instructs TKTX Store to address the violations and prevent their recurrence, or face potential legal action. The letter specifically addresses the unapproved use of lidocaine and prilocaine in concentrations and combinations that do not meet FDA standards, as well as the marketing of these products for uses not covered by existing monographs, such as for numbing skin before tattoos. This is important to the query because it highlights how deviations from approved drug standards can lead to the distribution of unapproved and potentially harmful products.

FDA Warning Letter to Immusist, LLC Regarding Unapproved Drugs

immusist-llc-610053-10162020.txt

This document is a warning letter from the FDA to Immusist, LLC, concerning their products IMMUSIST Original and IMMUSIST Natural. The FDA states that these products are being marketed as drugs without the necessary FDA approval, based on claims made on the company's website and in customer testimonials. These claims suggest the products can cure, mitigate, treat, or prevent diseases such as acid reflux, cancer, diabetes, and psoriasis. The FDA asserts that marketing these products as drugs without approval violates the Federal Food, Drug, and Cosmetic Act. The letter instructs Immusist, LLC to take prompt corrective action and respond in writing within fifteen working days, detailing the steps taken to address the violations and prevent their recurrence. Failure to comply may result in legal action, including seizure and injunction. The document is related to the query because it involves a company facing regulatory action for marketing unapproved products with claims to treat various conditions, including diabetes, which raises concerns about product safety and efficacy.

FDA Warning Letter to Desert Alchemist LLC

desert-alchemist-llc-609680-12042020.txt

This FDA warning letter, issued to Desert Alchemist LLC on December 4, 2020, addresses violations related to the marketing and sale of unapproved drugs through their etsy.com webpage and social media platforms. The FDA determined that products like Fortify, Lion's Mane, The Great Work, Mind Ease, Sweet Balance, Happy Heart, Flair Snare, and Cordycepts sinensis double extract are being marketed with claims that establish them as drugs under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act because they are intended for use in the cure, mitigation, treatment, or prevention of disease. The warning letter cites examples of claims made on the company's website and social media, such as assertions that Fortify has immuno-modulating, antiviral, anti-fungal, and anti-bacterial properties, or that Sweet Balance assists in blood sugar control for people with diabetes. The FDA emphasizes that these products are not generally recognized as safe and effective for their intended uses and, therefore, are considered new drugs that require prior approval before being introduced into interstate commerce. The company was given fifteen working days to respond with corrective actions. The document is related to the query because it involves regulatory action against a company for marketing unapproved products with drug-like claims, which is relevant to understanding potential contamination issues in the context of pharmaceutical regulation and consumer safety.

FDA Warning Letter to GeroNova Research Inc.

geronova-research-inc-612777-11182021.txt

This document is a warning letter from the U.S. Food and Drug Administration (FDA) to GeroNova Research Inc. The letter addresses violations related to the marketing and sale of products including CARNITINE PLUS Vegcaps, GeroNova Beauté Infinie Elixir, R-Lipoic Acid Vegcaps 300 mg, and R-Lipoic Acid Vegcaps 100 mg. The FDA determined that claims made on the company's websites and social media pages, such as Facebook and Twitter, establish that these products are drugs under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease. The FDA considers these products to be unapproved new drugs and misbranded drugs, as they are not generally recognized as safe and effective for their intended uses and lack adequate directions for use. The letter instructs GeroNova Research Inc. to take corrective action within 15 working days to address the violations and prevent their recurrence. The company is required to notify the FDA in writing of the specific steps taken, including an explanation of each step and copies of related documentation. The warning letter pertains to unapproved drugs, but does not relate to contamination issues.

FDA Warning Letter to Glenn Burkett Naples Corporation

glenn-burkett-naples-corporation-613126-01192022.txt

This FDA warning letter addresses Glenn Burkett Naples Corporation for marketing unapproved and misbranded drug products. The FDA reviewed the company's websites and social media and found numerous products, including Colloidal Silver solutions, Daily Detox, and various kits (Candida, Cardiovascular, Diabetes), being promoted with claims that qualify them as drugs under the Federal Food, Drug, and Cosmetic Act. These products are not FDA-approved and are misbranded, with claims to cure, treat, or prevent diseases like COVID-19, diabetes, and cardiovascular issues. The warning emphasizes that many of these products lack adequate directions for safe use by a layperson and contain colloidal silver, which is not generally recognized as safe and effective for OTC use. The letter also addresses concerns about animal drug products. The company has been asked to cease the sale of these unapproved products and provide a written response within 15 days detailing corrective actions.

FDA Warning Letter to Je Dois Lavoir LLC

je-dois-lavoir-llc-616016-08112021.txt

This document is a warning letter from the FDA to Je Dois Lavoir LLC regarding their "365 Skinny High Intensity" product. The FDA found that the product contains undeclared sibutramine, a drug previously withdrawn from the market due to increased risk of heart attack and stroke. The FDA considers this product an unapproved new drug and misbranded under the Federal Food, Drug, and Cosmetic Act (FD&C Act). The letter states that the product is marketed as a dietary supplement but contains an article authorized for investigation as a new drug. Claims on the company's website and social media suggest it is intended for weight loss, anxiety control, appetite suppression, and more. The FDA notes the product lacks adequate directions for use and warnings, and its labeling fails to reveal the sibutramine content. The FDA requested that the company investigate the violations, prevent recurrence, and comply with federal law. The company voluntarily recalled some products. The warning letter addresses the presence of undeclared sibutramine in a weight loss product, which led to the FDA classifying the product as an unapproved new drug and a misbranded drug.

FDA Warning Letter to Muscle Sports Products LLC

muscle-sports-products-llc-625731-09232022.txt

This document is a warning letter from the FDA to Muscle Sports Products, LLC, addressing significant violations of the Federal Food, Drug, and Cosmetic Act. The FDA reviewed the company's websites and social media and found that they were marketing unapproved new drugs and misbranded drugs with claims to cure, mitigate, treat, or prevent diseases, including COVID-19. The letter highlights specific products like CardioBurn For Her Powder, Rhino Rampage Capsules™, Joint Revolution™ Capsules, and others, detailing claims that position them as drugs without FDA approval. The company has been asked to cease the sale of these unapproved products and address the violations outlined in the letter. The warning letter indicates that the company is in violation of marketing unapproved drugs and misbranded drugs.

FDA Warning Letter to New Sun Inc.

new-sun-inc-626254-06082022.txt

This document is a warning letter from the FDA to New Sun Inc. regarding violations related to the marketing and labeling of their products. The FDA conducted an inspection and reviewed the company's website, finding that several products, including those containing CBD, were being marketed as drugs without FDA approval. These products were claimed to treat or prevent diseases, which classifies them as drugs under the Federal Food, Drug, and Cosmetic Act. The FDA also noted that the company's CBD products were being marketed as dietary supplements, which is not permitted under the Act because CBD is an active ingredient in an approved drug. The letter requests that New Sun Inc. address these violations and prevent their recurrence, or face legal action. The document does not relate to insulin contamination but rather to violations concerning unapproved drug claims and misbranding of dietary supplements.

FDA Warning Letter to Nutra Pharma

nutra-pharma-563949-03112019.txt

This document is a warning letter issued by the FDA to Nutra Pharma regarding their Nyloxin products. The FDA has determined that these products are unapproved new drugs and misbranded drugs under the Federal Food, Drug, and Cosmetic Act (FD&C Act). The letter addresses concerns about the products' claims to treat various conditions, including chronic pain, arthritis, and even cancer, without proper FDA approval. The FDA emphasizes that marketing and selling unapproved opioid addiction treatment products poses a significant threat to public health, especially given the existing nationwide public health emergency related to the opioid crisis. The letter also points out that the company falsely claims its products are "FDA Registered," which is misleading since only drug establishments are subject to registration, not the products themselves. The warning letter instructs Nutra Pharma to take prompt action to correct the violations and prevent their recurrence, or face potential legal action, including seizure and injunction. The document is relevant to the query as it highlights regulatory issues and potential health risks associated with unapproved drug products, but does not mention insulin or contamination issues related to insulin. The focus is on the lack of FDA approval for the mentioned products and their misleading marketing claims.

FDA Warning Letter to Plant Organix Regarding CBD Products

organix-industries-inc-dba-plant-organix-593512-11222019.txt

This document is a warning letter from the FDA to Organix Industries, regarding the marketing and sale of unapproved new drugs and adulterated food products containing cannabidiol (CBD). The FDA reviewed Organix Industries' website and social media and found that the company was making unapproved drug claims for its CBD products, including Classic Peanut Butter 300 mg CBD, CBD Hibiscus Tea, and several other food and tincture products. The FDA also determined that the company's Hemp Pet Tinctures and Hemp Pet Treats are unapproved new animal drugs. The FDA stated that the company's CBD products are adulterated because they contain an unsafe food additive and that the company is violating the Federal Food, Drug, and Cosmetic Act (FD&C Act). The FDA requested that Organix Industries take prompt action to correct the violations cited in the letter. The document highlights the FDA's concerns regarding the safety and legality of CBD-containing products and the importance of complying with federal regulations.

FDA and FTC Warning Letter to Pharmaganics LLC

pharmaganics-llc-614576-09072021.txt

This document is a warning letter from the FDA and FTC to Pharmaganics LLC regarding their "Diabetes Doctor Pre-Diabetes" and "Diabetes Doctor Blood Sugar 24 Hour" products. The FDA has determined that the products are being marketed as drugs without the necessary FDA approval, based on claims made on the company's website, social media pages, and product listings on Walmart and Amazon. These claims suggest the products can treat or prevent diabetes, which classifies them as drugs under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act. The FTC is concerned that the efficacy claims regarding the products' ability to prevent, treat, or cure diabetes may not be substantiated by competent and reliable scientific evidence. The letter demands that Pharmaganics LLC cease making such claims without proper scientific backing. The company has been asked to respond within 15 working days, detailing the steps taken to address the violations and prevent their recurrence. The FDA and FTC are primarily concerned with unsubstantiated claims and misbranding of dietary supplements, rather than contamination issues.

FDA Warning Letter to Phoenix Nutritionals, Inc

phoenix-nutritionals-inc-613909-07012021.txt

This document is a warning letter issued by the FDA to Phoenix Nutritionals, Inc. The letter addresses violations related to the marketing and sale of several products, including High Vitality Full Spectrum Liquid Multi-Vitamin, High Vitality Caps, Best Cholesterol Support, Blood Sugar Support, Maximum Stress Support, Complete Joint Support, Natural Anti-Inflammatory Support, and Best Immune Support. The FDA states that these products are being marketed with claims that qualify them as drugs under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act because they are intended for use in the cure, mitigation, treatment, or prevention of disease. The FDA also notes that the products are not generally recognized as safe and effective for their intended uses and are therefore considered new drugs without prior FDA approval. The warning letter highlights specific claims made on the company's websites and social media that promote the products as treatments for various conditions, including cancer, heart disease, diabetes, and COVID-19. The FDA requests that Phoenix Nutritionals take immediate action to cease the sale of any unapproved and unauthorized products and address the violations to avoid legal action. The document does not contain information about contamination issues related to insulin, as it primarily focuses on unapproved drug claims and misbranding violations.

FDA Warning Letter to Safari Stem Cell, LLC

safari-stem-cell-llc-661023-04052024.txt

This document is a warning letter from the FDA to Safari Stem Cell, LLC, addressing significant deviations from Current Good Manufacturing Practice (CGMP) regulations. The FDA conducted an inspection of Safari's facility and found that the firm was marketing unapproved new animal drugs. These drugs, including stem cell products derived from canine and feline donors, are intended to treat various diseases in animals. The warning letter outlines several CGMP violations, including the failure to establish written procedures for production and process control, in-process controls, and cleaning and maintenance of equipment. It also mentions a lack of environmental monitoring in aseptic processing areas and failure to perform appropriate laboratory testing for microorganisms. The FDA requests corrective actions within 15 working days to address these violations and prevent recurrence, or face potential legal action. The document does not refer to insulin contamination issues, but rather to CGMP violations in the production of stem cell products for animals, which could lead to various contamination issues.

FDA Warning Letter to Swisschems re Unapproved Drugs

swisschems-695663-12102024.txt

This document is a warning letter from the FDA to Swisschems, addressing the sale of unapproved new drugs, specifically Semaglutide and Retatrutide. The FDA reviewed Swisschems' website and social media and found that these products were being marketed as drugs for human use, violating the Federal Food, Drug, and Cosmetic Act. The letter states that these products are not generally recognized as safe and effective and lack the necessary FDA approval for introduction into interstate commerce. The letter instructs Swisschems to respond within fifteen working days, outlining the steps taken to correct the violations and prevent their recurrence. Failure to comply may result in legal action, including seizure and injunction. The warning focuses on the unapproved status of the drugs and their marketing for uses that classify them as drugs under the FD&C Act. The document does not discuss contamination issues related to insulin.

FDA Warning Letter to Synthetix Inc.

synthetix-inc-dba-helix-chemical-supply-668918-02072024.txt

This FDA warning letter, issued to Synthetix Inc. (DBA Helix Chemical Supply), addresses the sale of unapproved new drugs, specifically Semaglutide and Tirzepatide. The FDA states that these products are being introduced into interstate commerce in violation of the Federal Food, Drug, and Cosmetic Act (FD&C Act). The letter emphasizes that these products are not recognized as safe and effective for their intended uses and lack the required FDA approval. Additionally, the products are misbranded due to inadequate directions for use. The FDA requests a written response from Synthetix Inc. within 15 working days, detailing the steps taken to address the violations and prevent their recurrence. The warning letter pertains to the sale of unapproved drugs and does not mention insulin or contamination issues.

FDA Warning Letter to US Chem Labs

us-chem-labs-669074-02072024.txt

This document is a warning letter from the FDA to US Chem Labs regarding the sale of unapproved new drugs, specifically Semaglutide, Tirzepatide, and Thymalin. The FDA states that these products are being marketed as drugs for human use without the necessary FDA approval, violating sections of the Federal Food, Drug, and Cosmetic Act. The letter highlights that the products are misbranded due to a lack of adequate directions for use and raises concerns about marketing Thymalin for use in children without proper evaluation for safety and effectiveness. The warning letter instructs US Chem Labs to address these violations within 15 working days, including preventing their recurrence, or face potential legal action. The document does not directly relate to insulin contamination issues; rather, it addresses the sale of unapproved drugs and misbranding violations.

FDA Warning Letter to World Nutrition, Inc.

world-nutrition-inc-610003-10272020.txt

This document is a warning letter from the FDA to World Nutrition, Inc. regarding the marketing and sale of several unapproved drug products. The FDA reviewed the company's website and found that products like Vitälzȳm Extra Strength, Vitälzȳm Systemic and Digestive Formula, Vitälzȳm Cardio, and others were being marketed with claims that classify them as drugs under the Federal Food, Drug, and Cosmetic Act. These claims suggest the products are intended for use in the cure, mitigation, treatment, or prevention of disease. The letter states that these products are not generally recognized as safe and effective for their intended uses and are therefore considered new drugs that require prior approval from the FDA. The FDA also alleges that the products are misbranded because they lack adequate directions for use by a layperson. The warning letter instructs World Nutrition, Inc. to take prompt action to correct these violations and to provide written notification of the steps taken within fifteen working days. The document is relevant because it involves regulatory action against a company for marketing unapproved products with drug-like claims.

FDA Warning Letter to Ayuryoga, Inc.

ayuryoga-inc-628168-05192022.txt

This warning letter from the FDA to Ayuryoga, Inc. addresses the marketing and sale of unapproved new drugs through their website and social media platforms. The FDA reviewed the company's online presence and found that various Ayurvedic products, such as "Arjuna Arishtam" and "Ashwagandha Arishtam," are being promoted with claims that position them as treatments for diseases, thus classifying them as unapproved drugs in violation of the FD&C Act. The letter outlines specific examples of claims made on the company's website and social media channels that establish the intended use of these products as drugs. The FDA has requested that Ayuryoga, Inc. respond in writing within 15 working days, detailing the steps taken to address these violations and prevent their recurrence, or face potential legal action. The focus of the document is on unapproved drugs, not contamination issues related to insulin.

FDA Warning Letter to CAJ Food Products Inc.

caj-food-products-inc-624051-03112022.txt

This document is a warning letter from the FDA to CAJ Food Products Inc. regarding the marketing and sale of various juice products, including Biotta and Juice Performer brands. The FDA determined that claims made on the company's websites and Amazon storefronts establish that these products are drugs under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act because they are intended for use in the cure, mitigation, treatment, or prevention of disease. The FDA cites specific examples of claims for each product that suggest they can treat conditions such as cancer, high blood pressure, heart disease, and respiratory illnesses. The FDA asserts that these products are not generally recognized as safe and effective for the claimed uses and are therefore considered 'new drugs' that require prior approval. Additionally, the products are deemed misbranded because they lack adequate directions for use by a layperson for the intended purposes. The letter requests that CAJ Food Products Inc. notify the FDA in writing within 15 working days of the steps taken to address the violations and prevent their recurrence. The document indicates the company is in violation of selling unapproved drugs.

FDA Warning Letter to Hanna's Herb Shop

hannas-herb-shop-569309-03052019.txt

This FDA warning letter to Hanna's Herb Shop addresses the marketing of various herbal products as unapproved drugs with claims to cure, mitigate, treat, or prevent diseases. The FDA found that these products were being sold with claims that classify them as drugs under the Federal Food, Drug, and Cosmetic Act, without the necessary FDA approval. The letter cites examples of claims made on the company's website for products like Kroeger Herb Kolester, St. John’s Wort, and others, which suggest uses for treating conditions like depression, dementia, and heart disease. Additionally, the FDA noted that some products were misbranded because they lacked adequate directions for use, as they are intended for conditions that require supervision by a licensed practitioner. The company was directed to take prompt corrective action and respond to the FDA within fifteen working days. The document does not relate to insulin contamination, but rather to the marketing of unapproved drugs and misbranding violations. The document focuses on regulatory violations related to unapproved drug claims and misbranding rather than contamination issues.

FDA and FTC Warning Letter to Live Good Inc.

live-good-inc-614575-09072021.txt

This document is a warning letter from the FDA and FTC to Live Good Inc. regarding their "Berry Gen Sugar Control" product. The FDA states that the product is being marketed as a drug without proper approval because it claims to treat diabetes and regulate blood sugar and insulin levels. The FTC is concerned that these claims are not substantiated by scientific evidence and has issued a cease and desist demand. The company is required to respond within 15 days with a plan to address these violations. This document is about unapproved drugs and makes no mention of insulin contamination.

FDA and FTC Warning Letter to TEK Naturals

tek-naturals-565026-02052019.txt

This document is a warning letter from the FDA and FTC to TEK Naturals regarding the misbranding and unapproved drug claims of their products BURN4Her, BurnerTEK, Mind Ignite, TEK Male, and TestoTEK. The letter states that claims on the company's websites and social media pages establish that these products are drugs under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act because they are intended for use in the cure, mitigation, treatment, or prevention of disease. The FDA asserts that these products are not generally recognized as safe and effective for their intended uses and, therefore, are considered new drugs that require prior approval from the FDA before being introduced into interstate commerce. The letter cites specific examples of claims made on the company's websites and social media pages that promote the products for various health conditions, including heart disease, obesity, diabetes, anxiety, Alzheimer's, and erectile dysfunction. The FDA concludes that the products are misbranded under section 502(f)(1) of the Act because they fail to bear adequate directions for their intended use, as they are intended for the treatment of diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. The document does not contain any information about insulin contamination issues.

FDA Warning Letter to Mushroom Revival, Inc.

mushroom-revival-inc-610361-12012020.txt

This document is a warning letter from the FDA to Mushroom Revival, Inc. The FDA reviewed the company's website and found that products like Cordyceps Militaris, Reishi, and Mush-10 were being marketed as drugs without FDA approval. The claims on the website suggested these products could cure, mitigate, treat, or prevent diseases, which classifies them as drugs under the Federal Food, Drug, and Cosmetic Act. The FDA stated that these products are not generally recognized as safe and effective for their advertised uses and are therefore considered new drugs that require prior approval. The company was also cited for misbranding the drugs by not providing adequate directions for their intended use, as they are intended for the treatment of diseases that require supervision by a licensed practitioner. The warning letter instructs Mushroom Revival, Inc. to take prompt action to correct these violations and prevent their recurrence, or face potential legal action.

FDA and FTC Warning Letter to Phytag Labs

phytag-labs-614514-09072021.txt

This document is a warning letter from the FDA and FTC to Phytag Labs regarding their GLUCOTYPE2 product, a dietary supplement marketed for blood sugar control. The FDA determined that the product is an unapproved new drug because it is marketed with claims to treat diabetes without FDA approval. The FTC is concerned that the efficacy claims may not be substantiated by scientific evidence and issued a cease and desist demand. The letter states that the company's claims violate the Federal Food, Drug, and Cosmetic Act and the FTC Act. The company is required to respond within 15 days with corrective actions. The document does not relate to insulin contamination but rather to the marketing of an unapproved drug with unsubstantiated claims.

FDA Warning Letter to Natural Wonder Products Corp

natural-wonder-products-corp-592699-09232019.txt

This warning letter, issued by the FDA to Natural Wonder Products Corp on September 23, 2019, addresses the company's marketing of unapproved new animal drugs. The FDA reviewed the company's websites and determined that products such as Daily Sure Multi-Herbal, Denta Sure, and others are intended for use in the treatment or prevention of diseases in animals, thus classifying them as drugs under the Federal Food, Drug, and Cosmetic Act. The letter states that these products are not generally recognized as safe and effective for their intended uses and are not the subject of an approved new animal drug application. The core issue is that Natural Wonder Products Corp is marketing products with claims to treat or prevent animal diseases without the required FDA approval, rendering them unsafe and adulterated under the FD&C Act. The FDA requests a written response within fifteen working days detailing the steps the company will take to correct these violations and ensure compliance with the law.

FDA Warning Letter to Earth Turns, LLC

earth-turns-llc-566232-02052019.txt

This document is a warning letter issued by the FDA to Earth Turns, LLC, concerning violations of the Federal Food, Drug, and Cosmetic Act. The FDA reviewed the company's website and determined that products such as Green Tea Extract, Cogni-Flex, GlucoFit 48mg, Fundamental D3 1000, and Fundamental Omega-3 were being marketed as drugs without FDA approval, based on claims made on the website and social media. These claims suggested the products could be used to treat or prevent diseases such as Alzheimer's, diabetes, and cancer. The FDA stated that these products are considered "new drugs" and cannot be legally introduced into interstate commerce without prior approval. The company was also cited for misbranding the drugs by failing to provide adequate directions for their intended use. The warning letter instructs Earth Turns, LLC to take prompt action to correct the violations and prevent their recurrence, including providing a written response within fifteen working days detailing the steps taken. This document does not address any contamination issues related to insulin, but rather focuses on the marketing of unapproved drugs.

FDA/FTC Warning Letter to GlutaGenic

glutagenic-607271-05062020.txt

This document is a warning letter from the FDA and FTC to GlutaGenic and Advanced Biome Corp. regarding the sale of unapproved and misbranded products, specifically Viral Protection Kits, marketed for the prevention and treatment of COVID-19. The letter states that these products are in violation of the Federal Food, Drug, and Cosmetic Act (FD&C Act) and the FTC Act because they are being sold without approval and with unsubstantiated claims. The companies are requested to cease the sale of these products and correct the violations, or face legal action, including seizure and injunction. The FDA is advising consumers not to purchase or use such unapproved products, and the companies will be added to a list of firms receiving warning letters for COVID-19 related products. The document does not relate to insulin contamination but rather to unapproved drugs for COVID-19.

FDA Warning Letter to Holographic Health, Inc.

holographic-health-inc-613874-09102021.txt

This document is a warning letter from the FDA to Holographic Health, Inc. regarding the marketing of several unapproved new drugs and misbranded drugs. The FDA reviewed the company's website and found that products such as Glyco-Well, Pan-Gest, Heart-Line, and others were being marketed with claims that classify them as drugs under the Federal Food, Drug, and Cosmetic Act. These products are intended for use in the cure, mitigation, treatment, or prevention of disease, and/or intended to affect the structure or function of the body. The warning letter states that Holographic Health's products are not generally recognized as safe and effective for their intended uses and, therefore, are considered "new drugs" that require FDA approval before being introduced into interstate commerce. The company is also cited for misbranding drugs by failing to provide adequate directions for use, as the conditions they are offered for are not amenable to self-diagnosis and treatment by individuals who are not medical practitioners. The FDA requests that Holographic Health, Inc. take corrective actions to address these violations and prevent their recurrence, including ceasing the marketing of unapproved new drugs and misbranded drugs. The company must respond in writing within 15 working days, detailing the steps taken to address the violations and prevent their recurrence. The document focuses on regulatory violations and the marketing of unapproved and misbranded drugs, with no discussion of insulin or contamination issues.

FDA Warning Letter to Watershed Wellness Center

spartan-enterprises-inc-dba-watershed-wellness-center-642030-03082023.txt

This document is a warning letter from the FDA to Spartan Enterprises Inc. dba Watershed Wellness Center regarding serious violations of the Federal Food, Drug, and Cosmetic Act. The FDA inspected their dietary supplement manufacturing facility and reviewed their websites, identifying unapproved new and misbranded drugs. The claims on their product labels, websites, and YouTube channel establish that these products are intended for use in the cure, mitigation, treatment, or prevention of disease, which violates the Act. The inspection also revealed violations of CGMP regulations for dietary supplements, including failure to establish specifications, not following master manufacturing records, and failing to maintain a clean and sanitary physical plant. The products are also misbranded due to non-compliance with labeling requirements. The letter requests corrective actions to address these violations. This document does not discuss insulin or related contamination issues; it is focused on dietary supplements and the company's violations of manufacturing and labeling standards.

FDA and FTC Warning Letter to Ar-Rahman Pharm LLC

ar-rahman-pharm-llc-614578-09072021.txt

This document is a warning letter from the FDA and FTC to Ar-Rahman Pharm LLC regarding their "Diabetes Support" product. The FDA states that the product is an unapproved new drug because it is marketed to treat diabetes without FDA approval, based on claims made on the company's website and social media. The FDA also states the product is misbranded because it does not have adequate directions for use by a layperson. The FTC is concerned that the company is advertising that the product can prevent, treat, or cure diabetes without competent and reliable scientific evidence. The letter instructs the company to cease making unsubstantiated claims and to notify the FDA and FTC of the steps taken to address these concerns. The document is related to regulatory actions against a company for marketing an unapproved product with claims to support diabetes, which is relevant to the query about contamination issues related to insulin because it shows how the FDA regulates products related to diabetes and insulin.

FDA Warning Letter to Bee Healthy Farms LLC

bee-healthy-farms-llc-644012-05032023.txt

This document is a warning letter from the FDA to Bee Healthy Farms LLC, addressing violations related to drug claims made on their website for products like Bee Healthy Farms Bee Propolis Capsules, Royal Jelly Capsules, and Organic Clover Honey Sticks. The FDA asserts that these products are being marketed as drugs without proper approval, based on claims of treating or preventing diseases. The letter highlights specific examples of claims made on the website, such as propolis alleviating depressive symptoms and treating respiratory infections. The FDA states that these products are not generally recognized as safe and effective for the advertised uses, making them 'new drugs' that require prior approval. The company is urged to take corrective actions, including ceasing the marketing of unapproved drugs and ensuring compliance with federal law and FDA regulations. The document is related to the query because it involves regulatory action against a company for marketing unapproved products with drug claims, indicating a failure to meet required standards.

FDA Warning Letter to Xcel Research LLC

xcel-research-llc-694608-12102024.txt

This FDA warning letter, issued to Xcel Research LLC on December 10, 2024, addresses the company's marketing and sale of unapproved new drugs, including “RETA” (Retatrutide), “CagriLean” (Cagrilintide and Semaglutide), “CAGRILINTIDE,” “MAZDUTIDE,” “SEMA” (Semaglutide), “SURVODUTIDE,” and “SERMORELIN.” The FDA has found these products to be in violation of sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) because they are being marketed for uses such as weight management, blood sugar regulation, and cardiovascular protection without the necessary FDA approvals. The company's claims on its website, such as enhanced insulin sensitivity and improved lipid profiles, position these products as drugs intended for human use, which requires prior FDA approval. The letter instructs Xcel Research LLC to take immediate corrective action and notify the FDA within fifteen working days of the steps taken to address the violations. Failure to comply may result in legal action, including seizure and injunction. The FDA emphasizes that the company is responsible for ensuring compliance with all federal laws and regulations. The warning letter does not discuss contamination issues directly; instead, it focuses on the lack of FDA approval for the drugs being marketed. Therefore, the company must address the marketing and sale of unapproved new drugs to comply with FDA regulations.

FDA and FTC Warning Letter to Aceva, LLC

aceva-llc-614539-09072021.txt

This document is a warning letter from the FDA and FTC to Aceva, LLC, regarding their product 'Sugar Balance'. The FDA has determined that Aceva is marketing Sugar Balance as a drug without proper approval, based on claims that it improves insulin sensitivity and enhances blood sugar control. The FDA asserts that the product is a 'new drug' and is misbranded because it lacks adequate directions for use by a layperson. The FTC is concerned that Aceva's claims about Sugar Balance preventing, treating, or curing diabetes are not substantiated by scientific evidence. The FTC demands that Aceva cease and desist from making such claims without proper scientific support. The letter warns of potential legal action, including injunctions, civil penalties, and consumer refunds, if the violations are not addressed. The document focuses on regulatory violations related to unsubstantiated health claims and misbranding, not contamination issues.

FDA Warning Letter to Ambaya Gold Health Products

ambaya-gold-health-products-llc-648130-12052023.txt

This document is a warning letter from the FDA to Ambaya Gold Health Products, LLC, addressing violations related to the marketing and sale of unapproved new drugs and misbranded drugs. The FDA reviewed the company's website and social media and found that products like Brain Balance, Immune System Boost, Dentist In A Bottle, Essensiac, Fulvic Green, Silver Solution, Detox Cleanse Renew, Magnesium Oil Spray, Silver Spray, and Pet Health+ were being marketed with claims that qualify them as drugs under the Federal Food, Drug, and Cosmetic Act. These products were found to be unapproved new drugs, misbranded drugs, or unapproved new animal drugs, violating sections of the Act. The letter instructs Ambaya Gold Health Products, LLC to take corrective actions and notify the FDA within 15 working days of the steps taken to address the violations. This document is not relevant to insulin contamination issues.

FDA Warning Letter to APG SEVEN, INC

apg-seven-inc-670020-04182024.txt

This document is a warning letter from the FDA to APG SEVEN, INC, concerning their dietary supplement products such as BioMoringa and BioDiabetin. The FDA has determined that claims made on the product labels and websites classify these products as unapproved drugs because they are intended for the cure, mitigation, treatment, or prevention of diseases. The letter cites specific examples of claims that establish the intended use of the products as drugs, such as BioMoringa being advertised as anti-fungal, antiviral, antidepressant, and effective against diabetes, osteoporosis, cancer, and hypertension. Similarly, BioDiabetin is claimed to lower blood sugar and increase insulin production. The FDA states that introducing these products into interstate commerce violates the Federal Food, Drug, and Cosmetic Act because they have not been approved as new drugs. The company is urged to investigate and correct these violations, and to prevent their recurrence. The focus of the document is on regulatory violations related to drug claims and not on contamination issues.

FDA Warning Letter to Bea Lydecker's Naturals

bea-lydeckers-naturals-inc-616439-02092022.txt

This document is a warning letter from the U.S. Food and Drug Administration (FDA) to Bea Lydecker's Naturals, Inc., addressing violations observed during an inspection of their dietary supplement distributing facility. The FDA found that numerous products, including Enzymes Plus, Artho Flex, Herbal Extract, and CBD Oil Procana Spectrum, are being marketed with claims that classify them as unapproved new drugs under section 201(g)(1) of the Federal Food, Drug, and Cosmetic Act. These products are purported to cure, mitigate, treat, or prevent diseases, which requires FDA approval before introduction into interstate commerce. Additionally, several products such as Adult Extra, Digestion, Nerve & Muscle, Artho Flex, and Enzymes Plus are cited as misbranded under section 403 of the Act, due to issues like failing to bear required warning statements and incorrect serving size declarations. The FDA also notes that some products, like Herbal Extract, are promoted to treat COVID-19. Furthermore, certain animal products, including Equine Calmer and Calmer, are considered unapproved new animal drugs. The letter emphasizes that these violations must be corrected to comply with federal regulations. This document does not contain information about insulin contamination.

FDA Warning Letter to Blackhawx Regarding Tobacco Products

blackhawx-606491-03272020.txt

This document is a warning letter from the FDA to Blackhawx regarding the misbranding of electronic nicotine delivery systems (ENDS) products due to the absence of required nicotine warning statements on their website and advertising materials. The FDA states that the ENDS products are misbranded under section 903(a)(7)(B) and section 903(a)(7)(A) of the FD&C Act because the website advertising fails to include the required nicotine warning statement. The letter instructs Blackhawx to correct these violations immediately and ensure all tobacco products comply with the FD&C Act, or face potential consequences such as civil money penalties, criminal prosecution, seizure, and/or injunction. The document does not relate to insulin or contamination issues, it relates to tobacco products.

FDA Warning Letter to Bodyhealth.com, LLC

bodyhealthcom-llc-610728-12092020.txt

This FDA warning letter to Bodyhealth.com, LLC addresses the marketing of unapproved new drugs and misbranded drugs, including 'Healthy-Thin Energize,' 'Body Detox (Oral Spray),' and 'Omega 3 Health.' The FDA found that claims on the company's website indicated these products were intended for use in the treatment or prevention of disease, thus classifying them as drugs under the Federal Food, Drug, and Cosmetic Act. The company was cited for introducing these unapproved drugs into interstate commerce and for misbranding them by failing to provide adequate directions for use. The FDA requested prompt corrective action to address these violations, warning of potential legal action if the issues were not resolved. The letter does not discuss contamination issues related to insulin; instead, it focuses on the unapproved and misbranded status of the listed products.

FDA Warning Letter to Bonagens re Unapproved Drugs

bonagens-609905-11172020.txt

This document is a warning letter from the FDA to Bonagens regarding the marketing of several dietary supplements with unapproved drug claims. The FDA reviewed Bonagens' website and found that products like "Anti-Aging Supports," "Cholesterol & Diabetes Control," and others were being marketed with claims that classify them as drugs under the Federal Food, Drug, and Cosmetic Act. These products are not generally recognized as safe and effective for their claimed uses and are considered new drugs that require FDA approval. The letter states that the products are also misbranded because they lack adequate directions for use, as they are intended for the treatment of diseases that require the supervision of a licensed practitioner. Bonagens is instructed to take prompt action to correct these violations and prevent their recurrence. The document does not relate to insulin contamination; instead, it focuses on violations concerning unapproved drug claims and misbranding of dietary supplements.

FDA Warning Letter to BR Naturals Regarding Supplements

capris-associates-inc-br-naturals-566245-02052019.txt

This document is a warning letter from the FDA to Capris Associates Inc. / BR Naturals regarding the misbranding of several dietary supplements, including Avocado Oil, Black Seed Oil, Moringa Powder, Premium Olive Oil D.O.P., Pumpkin Seed Oil, and Unrefined Coconut Oil. The FDA determined that the company's website and social media platforms made claims that classify these products as drugs, as they were advertised for the treatment, mitigation, or prevention of diseases like Alzheimer's, cancer, diabetes, and heart disease. The FDA stated that these products are not generally recognized as safe and effective for the advertised uses and, therefore, are considered new drugs that require prior approval from the FDA. The letter also mentions that the products are misbranded because they lack adequate directions for their intended use, as they are intended for the treatment of conditions that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. The company is requested to take prompt action to correct these violations and prevent their recurrence. This document does not relate to contamination issues with insulin; instead, it addresses the marketing and sale of unapproved drugs. Therefore, it doesn't provide information related to the query about insulin contamination.

FDA Warning Letter to Cigabuy Regarding E-liquids

cigabuy-608175-05282020.txt

This document is a warning letter from the FDA to Cigabuy regarding the misbranding of e-liquid products due to the absence of a required nicotine warning statement on their website. The FDA has determined that several e-liquid products, such as RY4 Flavor and Chocolate Flavor, are being advertised without the necessary warning about nicotine being an addictive chemical. The letter instructs Cigabuy to correct these violations immediately and to ensure all tobacco products comply with the Federal Food, Drug, and Cosmetic Act (FD&C Act). Failure to comply may result in further action, including civil penalties, seizure, or injunction. The document does not contain any information about insulin or contamination issues related to insulin; it is focused on tobacco products and regulatory compliance regarding nicotine warnings. Therefore, it does not provide any insights into the query about common contamination issues related to insulin.

FDA Warning Letter to CueCig Regarding E-liquid Misbranding

cuecig-592362-10242019.txt

This document is a warning letter from the FDA to CueCig regarding the misbranding of their e-liquid products. The products, including Nic Salts Grape Soda Shake and Vape e-Juice by Airship, Nic Salts 555 Gold Shake and Vape e-Juice by Airship, and Nic Salts Watermelon Ninja e-Juice by Airship, are advertised without the required nicotine warning statement on their website and social media accounts, violating section 903(a)(7)(B) of the FD&C Act and 21 C.F.R. § 1143.3(b). The FDA requests immediate corrective action to address the violation and ensure compliance with the FD&C Act, or the company may face further actions such as civil money penalties, no-tobacco-sale orders, criminal prosecution, seizure, and/or injunction. The company has 15 working days to respond with a plan for maintaining compliance. This document is not relevant to contamination issues related to insulin, as it pertains to tobacco products and advertising standards.

FDA Warning Letter to Day Light Nutrition

day-light-nutrition-653234-08042023.txt

This document is a warning letter from the FDA to Day Light Nutrition regarding their products Above the Weather, Diabetic Support Blend, Joint Well, and ViruZap. The FDA determined that the products are being marketed as drugs without the necessary approval, based on claims made on the company's website and product labels. These claims suggest the products are intended for the cure, mitigation, treatment, or prevention of diseases, violating the Federal Food, Drug, and Cosmetic Act. The warning letter addresses the company's marketing of products as drugs without FDA approval, which is unrelated to contamination issues with insulin.

FDA Warning Letter to Discover Health, LLC

discover-health-llc-dba-discover-cbd-and-strain-snobs-661488-11162023.txt

This document is a warning letter from the FDA to Discover Health, LLC, also known as Discover CBD and Strain Snobs. The letter addresses violations related to the marketing and sale of unapproved new drugs, misbranded drugs, and adulterated foods. The company's products, which contain cannabidiol (CBD), cannabigerol (CBG), hexahydrocannabinol (HHC), and Delta-8 Tetrahydrocannabinol (THC), are being marketed with claims that they can treat various diseases and conditions in both humans and animals. The FDA states that these products are not generally recognized as safe and effective for their intended uses and have not been approved by the agency. The FDA also notes that the company's CBD-infused food products are adulterated because they contain an unsafe food additive. The agency is concerned about the potential health risks associated with the use of CBD and Delta-8 THC, including liver injury, harmful interactions with certain drugs, and adverse effects on the central nervous and cardiopulmonary systems. The FDA requests that Discover Health, LLC address the violations outlined in the warning letter and take steps to prevent their recurrence. The warning letter indicates the company is non-compliant by selling unapproved new drugs. The document does not discuss insulin or contamination issues related to insulin. It focuses on the regulatory status and marketing of CBD and THC products.

FDA Warning Letter to DRF LLC Regarding Unapproved Drugs

drf-llc-612282-04212021.txt

This document is a warning letter from the FDA to DRF LLC regarding the marketing and sale of unapproved new drugs, namely Boston C, Mega-Dose Vitamin C, and Pixie Dust Magnesium. The FDA reviewed the company's websites and determined that the products are being promoted with claims that establish them as drugs under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act because they are intended for use in the cure, mitigation, treatment, or prevention of disease. The FDA states that these products are not generally recognized as safe and effective for the uses claimed, and therefore are considered "new drugs" under section 201(p) of the Act. The letter cites numerous examples of claims made on the company's websites that promote the products for various health conditions, including cancer, immunodeficiency, and cardiovascular disease. The FDA concludes that the introduction or delivery of these misbranded drugs into interstate commerce violates section 301(a) of the Act. The warning letter requests that DRF LLC take corrective action and notify the FDA within 15 working days of the steps taken to address the violations.

FDA/FTC Warning Letter to DrJockers.com Regarding COVID-19 Claims

drjockerscom-llc-605729-04212020.txt

This document is a warning letter from the FDA and FTC to DrJockers.com, LLC regarding the sale of unapproved and misbranded products related to Coronavirus Disease 2019 (COVID-19). The letter states that the company's products, including Super C, Vitamin D/K2, Zinc Charge, and ImmunoStrong Berry Liquid, were being marketed with claims to mitigate, prevent, treat, diagnose, or cure COVID-19, which violates the Federal Food, Drug, and Cosmetic Act. The FDA and FTC requested that DrJockers.com, LLC immediately cease the sale of these products and correct the misleading representations. The company was also warned that failure to comply could result in legal action, including seizure and injunction. The document does not discuss any issues related to insulin or its contamination; it is solely focused on unapproved products marketed for COVID-19 prevention and treatment.

FDA Warning Letter to Duoc Thao Tre Xanh

duoc-thao-tre-xanh-llc-611685-03162021.txt

This FDA warning letter to Duoc Thao Tre Xanh, LLC, addresses the marketing and sale of unapproved drugs, specifically Immune Health, Ganoderma Lucidum Red Reishi Mushroom, Papaya Leaf Extract, and Fucoidan. The FDA reviewed the company's website and found claims that these products are intended for use in the cure, mitigation, treatment, or prevention of diseases, including COVID-19 and cancer, without prior FDA approval. The letter emphasizes that introducing or delivering these products into interstate commerce violates the Food, Drug, and Cosmetic Act. The company is requested to cease the sale of these unapproved products and correct the violations, which include misbranding by not providing adequate directions for use. Failure to comply may result in legal action. The letter highlights the company's marketing of products with claims to treat serious conditions like cancer and COVID-19 without the necessary FDA approvals, posing risks to consumers who may rely on these unproven treatments.

FDA Warning Letter to Eagles Song Health

eagles-song-health-and-wellness-llc-609733-10282020.txt

This document is a warning letter from the FDA to Eagles Song Health and Wellness LLC, addressing violations related to the marketing and sale of unapproved new drugs. The FDA reviewed the company's website and found that products like Greens Hornet Tonic Alchemy, Senior Sage, and Organic Cacao Paste were being marketed with claims that qualify them as drugs under the Federal Food, Drug, and Cosmetic Act, specifically targeting diseases such as diabetes, allergies, and heart conditions. These products have not received the necessary FDA approval for these uses. The company was cited for introducing or delivering these unapproved drugs into interstate commerce and for misbranding the products by failing to provide adequate directions for their intended uses. The FDA has requested a written response within fifteen working days, detailing the steps taken to correct these violations and prevent their recurrence. The warning letter indicates potential legal action if the violations are not promptly addressed. This document does not contain any information about insulin or contamination issues related to insulin.

FDA and FTC Warning Letter to EU Natural Inc.

eu-natural-inc-605871-05202021.txt

This document is a warning letter from the FDA and FTC to EU Natural Inc. regarding their products "CONCEPTION Female Fertility Prenatal" and "CONCEPTION MEN Male Fertility". The FDA determined that the products are being marketed as drugs without the necessary FDA approval, based on claims made on the company's website and social media. These claims suggest the products can be used to treat conditions like infertility, polycystic ovary syndrome, endometriosis, and other diseases. The FDA considers these products 'new drugs' because they are not generally recognized as safe and effective for the claimed uses. The products are also misbranded because they lack adequate directions for use, as they are intended for conditions that require supervision by a licensed practitioner. The FDA requests that EU Natural Inc. respond within 15 working days with a plan to address these violations. The FTC is concerned that the efficacy claims made by EU Natural Inc. may not be supported by scientific evidence. The FTC urges the company to review all product claims and ensure they are substantiated. Violations of the FTC Act could result in legal action, including injunctions, civil penalties, and requirements to provide refunds to consumers. The document does not relate to insulin contamination but rather to unapproved drug claims and advertising standards for dietary supplements.

FDA Warning Letter to Balance of Nature

evig-llc-dba-balance-nature-580888-08202019.txt

This document is a warning letter from the FDA to Evig LLC dba Balance of Nature, addressing serious violations of the Federal Food, Drug, and Cosmetic Act. The letter outlines that the company's Whole Food Fruits, Whole Food Veggies, and Whole Food Fiber & Spice products are considered unapproved new drugs due to claims suggesting they can cure, mitigate, treat, or prevent diseases. The FDA also found that the products are adulterated because they were not manufactured under Current Good Manufacturing Practice (CGMP) requirements. Additionally, the products are misbranded due to labeling issues, including misleading claims and incorrect nutrition information. The warning letter instructs Evig LLC to take prompt action to correct these violations, including establishing written quality control procedures, addressing product complaints, and ensuring compliance with labeling regulations. Failure to correct these violations may result in legal action, including seizure and injunction, and the FDA may assess fees to cover re-inspection-related costs. The document is related to manufacturing standards and FDA regulatory action.

FDA Warning Letter to Evolutionary Biologics Inc

evolutionary-biologics-inc-681586-12302024.txt

This document is a warning letter from the FDA to Evolutionary Biologics Inc. regarding their products EXO RNA™, EVO JEL™, and EVO HYBRID™. The FDA states that these products are unapproved new drugs and unlicensed biological products, violating the Federal Food, Drug, and Cosmetic Act and the Public Health Service Act. The company's claims regarding the intended use of these products, such as tissue repair, inflammation reduction, and regenerative properties, classify them as drugs and biological products requiring premarket review and approval. The FDA also addresses concerns about other products like EXO RX™, EXO ELIXIR™, and EXO PERIO™, requesting the company to explain the basis for their determination regarding whether these products require FDA premarket review. The warning letter instructs the company to respond within fifteen working days, outlining steps to address the violations and prevent recurrence, or face potential legal actions. The document does not provide information about contamination issues related to insulin, as the query requests. Therefore, the information in this document is not relevant to the query.

FDA Warning Letter to FDC Nutrition Inc.

fdc-nutrition-inc-612264-02182021.txt

This document is a warning letter from the FDA to FDC Nutrition Inc. regarding their 'Inositol 100% Pure Free Form' product. The FDA determined that the product is an unapproved new drug because it is intended for use in the cure, mitigation, treatment, or prevention of disease, based on claims made on the company's website. The product is also considered misbranded because it does not bear adequate directions for its intended use, as it is intended for the treatment of diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. The FDA requests prompt action to address these violations, including providing written notification within fifteen working days of the steps taken to correct the violations and prevent their recurrence. The document does not relate to contamination issues with insulin but rather to the marketing and sale of an unapproved and misbranded drug.

FDA Warning Letter to ForYou, Inc.

foryou-inc-607305-10202020.txt

This document is a warning letter from the FDA to ForYou, Inc., addressing significant violations of Current Good Manufacturing Practice (CGMP) regulations and misbranding issues related to their dietary supplements. The FDA inspection revealed that the company failed to establish written procedures for quality control operations, holding and distribution operations, handling product complaints, and managing returned dietary supplements. The letter also notes that several of ForYou, Inc.'s products are considered unapproved new drugs due to therapeutic claims made on their labels and website. The FDA found that the company's Advanced Formula BioAnti-Oxidant, Advanced BioEnzymes, Ancient Sea Mineral Complex, Calcium pHactor, Colostrum, Honey Bee Pollen, Inner Cellular Energy Multi-Vitamin, J-genics, Thin-Ergy A.M., Thin-Ergy BOOST, Tree of Life Olive Leaf Extract, and Youth Factor with DHEA products are misbranded under section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)] because the drug fails to bear adequate directions for its intended use(s). The FDA has requested that ForYou, Inc. take prompt action to correct these violations and prevent their recurrence, or face potential legal action, including seizure and injunction. This document does not contain any information about insulin or contamination issues related to insulin.

FDA Warning Letter to Fresh Nutrition Inc

fresh-nutrition-inc-612984-05272021.txt

This document is a warning letter from the FDA to Fresh Nutrition Inc. The FDA found serious violations of the Federal Food, Drug, and Cosmetic Act related to the company's marketing of several products, including Berberine, Echinacea, European Elderberry, Milk Thistle, Lion's Mane Mushroom, Turmeric Curcumin, Fish Oil, and Green Lipped Mussels. These products were found to be unapproved new drugs and misbranded drugs because they were being marketed with claims to treat or prevent diseases without FDA approval or proper labeling. The FDA has asked Fresh Nutrition Inc. to correct these violations and prevent their recurrence. The document does not discuss insulin or contamination issues; instead, it focuses on unapproved new drugs and misbranded drugs.

FDA Warning Letter to Galt Pharmaceuticals Regarding Doral

galt-pharmaceuticals-llc-593156-09132019.txt

This document is a warning letter issued by the FDA to Galt Pharmaceuticals regarding the misbranding of their drug Doral (quazepam) through misleading promotional materials. The email advertisement made false claims about the drug's safety and efficacy, omitted important risk information, and presented misleading comparisons to other sleep aids. The FDA requests that Galt Pharmaceuticals cease misbranding Doral and issue corrective messages. The document focuses on regulatory violations related to promotional practices rather than contamination issues. Therefore, it does not address the query about common contamination issues related to insulin.

FDA Warning Letter to Enzyme Process International

global-vitality-inc-dba-enzyme-process-international-585738-04162020.txt

This document is a warning letter from the FDA to Global Vitality, Inc. dba Enzyme Process International, addressing serious violations of the Federal Food, Drug, and Cosmetic Act and applicable regulations. The violations include the marketing of unapproved new drugs, misbranded drugs, and dietary supplement CGMP violations. The FDA conducted an inspection of the company's manufacturing facility and reviewed product labels and the company's website, identifying numerous violations. The company's products, including Liverchol, Celery Seed, ColoNorm G, Agaricus Blazei Mycelia, Zymepro, B-Plus w/Glandulars, Thyroid Cytotrophin, and Alkaplex Green, are cited for making drug claims without FDA approval and for being misbranded due to inadequate directions for use. The warning letter does not directly relate to insulin contamination but rather to manufacturing and labeling deficiencies for a range of dietary supplements and drugs.

FDA & FTC Warning Letter: Holistic Healer Supplement

holistic-healer-wellness-center-inc-614538-09072021.txt

This warning letter, issued by the FDA and FTC, addresses Holistic Healer & Wellness Center, Inc. regarding their 'Diabalance Diabetes Supplement.' The FDA has determined that the supplement is being marketed as a drug without the necessary approval, based on claims made on the company's website, such as aiding people with diabetes, lowering blood pressure, and balancing blood sugar levels. The FTC is concerned that the company is advertising that the supplement can treat or cure diabetes without sufficient scientific evidence. The company has been asked to cease making such claims and provide evidence to support them. The letter also states that failure to address the concerns may result in legal action, including seizure and injunction by the FDA, and civil penalties by the FTC. The document pertains to unsubstantiated claims about a dietary supplement for diabetes, rather than insulin contamination issues.

FDA Warning Letter to ICA Health, LLC

ica-health-llcfuture-formulations-llc-614383-09202021.txt

This document is a warning letter from the FDA to ICA Health, LLC/Future Formulations, LLC, concerning the marketing of products such as Dr. Wilson's Good Sugar, Dr. Wilson's Super Immune Space Sprinkles, Dr. Wilson's Cortisol Stress Reset, Dr. Wilson's BFF, and Dr. Wilson's Nat-Stim. The FDA has determined that these products are unapproved drugs under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act because they are intended for use in the cure, mitigation, treatment, or prevention of disease. The warning letter was issued because the claims made on the company's websites (www.icahealth.com, www.drwilsons.com, and www.adrenalfatigue.org) establish that these products are intended for use as drugs. The company is advised to review the Act and FDA regulations and take prompt action to correct the violations. The letter does not relate to insulin or contamination issues; it concerns the marketing of unapproved drugs based on the claims made about their therapeutic benefits.

FDA Warning Letter to Eliquidplanet.com

jabja-inc-dba-eliquidplanetcom-607632-05122020.txt

This document is a warning letter from the FDA to Jabja Inc. d/b/a Eliquidplanet.com regarding the misbranding of their e-liquid product, Galaxy Maxx Sugar Cloud. The FDA found that the company's website failed to include the required nicotine warning statement in the advertising of this product, violating the Federal Food, Drug, and Cosmetic Act (FD&C Act). The warning letter specifies that the absence of the warning statement makes the product misbranded under sections 903(a)(7)(B) and 903(a)(7)(A) of the FD&C Act. The FDA emphasizes that failure to comply with the FD&C Act may result in further action, including civil money penalties, no-tobacco-sale orders, criminal prosecution, seizure, and/or injunction. The company is requested to provide a written response within 15 working days, detailing corrective actions and a plan for maintaining compliance. The document does not relate to insulin, but rather to e-liquid tobacco products and the required nicotine warning statement.

FDA Warning Letter to JC Ayur Life LLC

jc-ayur-life-llc-609701-10292020.txt

This document is a warning letter from the FDA to JC Ayur Life LLC regarding their product 'Heritage of Ayurveda Dia-Tonic Incudil Herbal Dietary Supplement'. The FDA determined that the company was making unapproved drug claims on their website and social media, violating the Federal Food, Drug, and Cosmetic Act. The claims suggested the product could be used to treat or prevent diseases such as cancer, diabetes, and other conditions. The FDA stated that because the product is not generally recognized as safe and effective for these uses, it is considered a 'new drug' and requires prior approval. The letter also noted that the product is misbranded because it does not bear adequate directions for its intended uses, as it is intended for conditions that require the supervision of a licensed practitioner. The company was instructed to take prompt action to correct these violations, including ceasing the marketing of their product for unapproved drug uses, or face potential legal action. The document does not relate to insulin contamination issues, but rather to unapproved drug claims for a dietary supplement.

FDA Warning Letter to JLM Nutritionals, Inc.

jlm-nutritionals-inc-dba-jlm-nutrition-super-naturals-health-612754-05262021.txt

This document is a warning letter from the U.S. Food and Drug Administration (FDA) to JLM Nutritionals, Inc. regarding their websites and product pages. The FDA found that products like Super Naturals IBSolution, Premium Probiotic, Sleep Solution, Joint Solution, and Ultra Omega Fish Oil are being marketed with claims that classify them as drugs under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act. These products are claimed to treat conditions like Irritable Bowel Syndrome (IBS), reduce inflammation, improve sleep, and relieve joint pain. The FDA's warning is based on claims made on the company's websites, Amazon pages, and Facebook pages, which suggest that the products are intended for use in the cure, mitigation, treatment, or prevention of disease. The document highlights specific statements and testimonials used in the marketing of these products. The warning letter does not relate to contamination issues but rather to the unapproved drug claims made by JLM Nutritionals, Inc.

FDA Warning Letter to Kingdom Harvest

kingdom-harvest-625058-05042022.txt

This document is a warning letter issued by the FDA to Kingdom Harvest regarding the marketing and sale of unapproved drug products, adulterated foods, and unapproved new animal drugs. The products in question contain cannabidiol (CBD) or Delta-8 tetrahydrocannabinol (THC) and are marketed for both human and animal use. The FDA states that these products are in violation of the Federal Food, Drug, and Cosmetic Act (FD&C Act) because they are unapproved new drugs, misbranded, and adulterated. The warning letter highlights concerns about the safety and efficacy of these products, particularly those marketed for food-producing animals and those making claims to mitigate, prevent, treat, diagnose, or cure COVID-19. The FDA also notes that CBD and Delta-8 THC have not been approved for use in conventional foods and raise concerns about potential harm from these substances. The document does not discuss contamination issues related to insulin.

FDA Warning Letter to MD Smoke Electronic Cigarette

md-smoke-electronic-cigarette-605490-08202019.txt

This document is a warning letter from the FDA to MD Smoke Electronic Cigarette regarding the misbranding of e-liquid products due to the absence of required nicotine warning statements on their website. The FDA has determined that the e-liquid products are misbranded under the Federal Food, Drug, and Cosmetic Act (FD&C Act) because they fail to include the necessary nicotine warning. The letter specifies that advertising for e-liquid products must bear the warning: WARNING: This product contains nicotine. Nicotine is an addictive chemical. The company is requested to take immediate corrective actions to comply with the FD&C Act and to provide a written response within 15 working days detailing the steps taken to address the violation. Failure to comply may result in further action by the FDA, including civil money penalties, seizure, and/or injunction. The document does not relate to insulin contamination issues, but rather to regulatory compliance for tobacco products, specifically e-liquids, and the required nicotine warnings.

FDA Warning Letter to Nephron SC Inc.

nephron-sc-inc-610867-09222020.txt

This document is a warning letter from the FDA to Nephron SC Inc. regarding the misbranding of Budesonide Inhalation Suspension. The FDA's Office of Prescription Drug Promotion (OPDP) found that Nephron was promoting Budesonide for a new use (treatment of COVID-19 symptoms) without approval and without adequate directions for use. The emails also failed to include risk information about the drug, making them false or misleading. The FDA requested that Nephron immediately cease misbranding Budesonide and provide a plan to correct the misleading information. The warning letter addresses the promotion of a drug for an unapproved use and the omission of risk information, which is not related to insulin contamination. The document does not discuss any contamination issues.

FDA Warning Letter to Nutrition Coalition Inc

nutrition-coalition-inc-566090-02052019.txt

This document is a warning letter from the U.S. Food and Drug Administration (FDA) to Nutrition Coalition Inc. The FDA reviewed the company's websites and found that several products, including Alpha-Lipoid Acid, Colostrum Alpha Whey III (Liquid), Colloidal Silver, and others, were marketed with claims that classify them as unapproved drugs. These claims suggest the products are intended for the cure, mitigation, treatment, or prevention of diseases, which violates the Federal Food, Drug, and Cosmetic Act. The FDA also noted that some products lack adequate directions for safe use by a layperson, making them misbranded. The warning letter instructs Nutrition Coalition Inc. to take prompt corrective action, including notifying the FDA of the steps taken to address the violations and prevent their recurrence. Failure to comply may result in enforcement actions such as seizure and injunction. The letter does not relate to insulin contamination issues but rather to the marketing and regulatory compliance of dietary supplements with respect to unapproved drug claims.

FDA/FTC Warning Letter to Nuturna International LLC

nuturna-international-llc-614577-09072021.txt

This document is a warning letter from the FDA and FTC to Nuturna International LLC regarding their "Diabetic Support Formula" product. The FDA determined that Nuturna is marketing the product as a drug without proper approval, based on claims and testimonials suggesting it can treat diabetes. The product is also considered misbranded due to the lack of adequate directions for use. The FTC is concerned about unsubstantiated claims that the product can prevent, treat, or cure diabetes, demanding that Nuturna cease and desist from making such claims without scientific evidence. The company was marketing an unapproved drug with claims to help diabetics without FDA approval and without scientific evidence. The warning letters do not mention any contamination issues related to insulin.

FDA Warning Letter to Omega Wonders LLC

omega-wonders-llc-613279-05262021.txt

This document is a warning letter from the FDA to Omega Wonders LLC regarding their Cardia 7 Heart Health OMEGA 7 and Advanced Tear Health OMEGA 7 dietary supplements. The FDA found that the company's websites made claims that these products are intended for use in the cure, mitigation, treatment, or prevention of disease, thus classifying them as drugs under the Federal Food, Drug, and Cosmetic Act. The products are considered misbranded because they lack adequate directions for use by a layperson. The FDA also notes that the products have not been recognized as safe and effective for their intended uses and were introduced into interstate commerce without prior approval. The letter instructs Omega Wonders LLC to address these violations within 15 working days to avoid legal action. The document does not relate to insulin contamination issues but rather to the misbranding of dietary supplements and their unapproved drug claims.

FDA Warning Letter to Organa International Corp.

organa-international-corp-613018-10132021.txt

This document is a warning letter from the U.S. Food and Drug Administration (FDA) to Organa International Corp. regarding significant violations of the Federal Food, Drug, and Cosmetic Act. The FDA reviewed Organa's website and social media and found that the company was marketing several products, including Copper, Rhodium, Ruthenium, Zinc, and Essiac Tea, as unapproved new drugs and misbranded drugs. The FDA's warning letter highlights numerous violations, including making unapproved health claims, failing to provide adequate directions for use, and misbranding dietary supplements. The letter also notes that Organa's products are not generally recognized as safe and effective for their intended uses and have not been approved by the FDA. The document does not relate to insulin contamination issues, but rather to the marketing of unapproved and misbranded drugs and dietary supplements. The FDA is requesting corrective action to address the marketing of unapproved new drugs and misbranded dietary supplements.

FDA Warning Letter to Ostar Beauty Sci-Tech

ostar-beauty-sci-tech-co-ltd-667871-12042023.txt

This document is a warning letter from the FDA to Ostar Beauty Sci-Tech Co Ltd. The FDA has found that Ostar Beauty is marketing several medical devices in the United States without the required marketing clearance or approval, violating the Federal Food, Drug, and Cosmetic Act. These devices include items like injection insulin guns, derma pens, LED masks, and other personal care devices. The FDA states that these products are adulterated and misbranded because the company does not have premarket approval or an investigational device exemption. Additionally, Ostar Beauty has not fulfilled annual registration and listing requirements with the FDA. The letter instructs Ostar Beauty to respond within fifteen business days, outlining the steps they will take to correct these violations and prevent future occurrences. The FDA warns that failure to comply may result in the refusal of entry of these devices into the United States. The document does not contain information about contamination issues related to insulin but rather FDA violations for marketing unapproved medical devices.

FDA and FTC Warning Letter to Paradigm RE LLC

paradigm-re-llc-612014-12072020.txt

This document is a warning letter from the FDA and FTC to Paradigm RE LLC regarding the sale of unapproved and misbranded products, specifically 'Thymosin Alpha 1', which is claimed to treat or prevent COVID-19. The letter states that the company's claims lack scientific evidence and violate the FD&C Act and the FTC Act. The company is required to cease the sale of these products and respond to the FDA and FTC within 48 hours with corrective actions. Failure to comply may result in legal action, including seizure and injunction. The document does not discuss contamination issues related to insulin, but rather focuses on the unapproved sale of a product marketed for COVID-19 treatment. The FDA and FTC are concerned about the misleading claims and lack of scientific evidence supporting the use of 'Thymosin Alpha 1' for COVID-19.

FDA Warning Letter to Prime Vitality, Inc.

prime-vitality-inc-dba-prime-peptides-695156-12102024.txt

This document is a warning letter from the FDA to Prime Vitality, Inc. (dba Prime Peptides) regarding the sale of unapproved new drugs, specifically Semaglutide and Retatrutide. The FDA reviewed Prime Vitality's website and social media and found that the company was marketing these products for human use, with claims related to weight loss, blood sugar control, and cardiovascular benefits. The FDA states that these products are not generally recognized as safe and effective for their intended uses and, therefore, are considered new drugs that require an approved application before being introduced into interstate commerce. The company is in violation of the Federal Food, Drug, and Cosmetic Act (FD&C Act). The warning letter instructs Prime Vitality to take corrective action and notify the FDA within fifteen working days of the steps taken to address the violations. The document is related to the query because it involves drugs intended to help control blood sugar levels, and highlights the sale of unapproved drugs.

CPAP Manufacturing Issues Report

Executive Summary

Several common issues plague the manufacturing and marketing of **CPAP** and **CPAP-related** devices, primarily revolving around regulatory compliance and adherence to quality standards. A recurring theme is the failure to obtain necessary premarket approval or clearance from the FDA before introducing devices into commercial distribution. This includes both the **CPAP** devices themselves and accessories like sanitizers and cleaning devices. Many companies market their products with claims of disinfection and sterilization, often using technologies like ozone or UV light, without providing sufficient evidence to support these claims or addressing the potential risks associated with these technologies. Violations of current good manufacturing practice requirements are also prevalent. These include failures in establishing and maintaining adequate procedures for **corrective and preventive actions (CAPA)**, complaint handling, process validation, design control, risk analysis, and control of nonconforming products. Maintaining accurate device master records (DMRs) and device history records (DHRs) is another area where deficiencies are frequently observed. The lack of robust quality control systems raises concerns about the safety and effectiveness of these devices. The industry trend of marketing devices for new or expanded intended uses without proper FDA clearance or approval is a significant concern. Companies are often found to be marketing their devices as treatments for conditions or with features that have not been adequately evaluated or supported by clinical evidence. This practice can pose serious risks to public health and safety. Another trend is the failure to comply with labeling requirements, such as including a unique device identifier (UDI) on the label and submitting required information to the Global Unique Device Identification Database (GUDID). These omissions hinder traceability and post-market surveillance efforts. The FDA consistently emphasizes the need for prompt corrective action to address these violations and prevent their recurrence, underscoring the importance of regulatory compliance in the medical device industry.

CPAP Manufacturing Issues Report

Tags Summary

Regulatory compliance and **FDA warning letters** are the most prevalent topics, suggesting heightened scrutiny. **Device defects** and **manufacturing** show similar engagement levels, indicating concern with production quality. **CPAP** is the least frequent, possibly reflecting a narrower scope within the broader discussion.

Tag Frequency



Document Relevancy



Questions And Answers

1. What testing or quality control procedures for CPAP devices are discussed in this document?



2. What is the FDA's assessment of the company's response to the CPAP manufacturing issues, according to this document?



3. What specific regulations related to CPAP manufacturing are referenced in this document?



4. What defects or failures in CPAP devices are mentioned in this document?



5. What are the potential health risks associated with the CPAP manufacturing issues outlined in this document?



6. What corrective actions related to CPAP manufacturing have been requested by the FDA, according to this document?

7. What manufacturing processes related to CPAP devices are discussed in this document?



Top Matches

FDA Warning Letter to CPAPNEA Medical Supply

cpapnea-medical-supply-592737-01222020.txt

This document is a warning letter from the FDA to CPAPNEA Medical Supply regarding violations related to the manufacturing and marketing of the Optipillows EPAP mask. The FDA conducted an inspection of the firm and determined that the device is adulterated and misbranded due to the absence of an approved premarket approval application and failure to notify the agency of the intent to introduce the device into commercial distribution. The letter outlines several violations of current good manufacturing practice requirements, including failures in establishing procedures for corrective and preventive action, complaint handling, acceptance activities, purchasing controls, quality audits, and device history records. The firm also failed to establish a procedure for internal systems that provide for timely and effective identification, communication, and evaluation of events that may be subject to MDR requirements. The FDA expresses concern over the firm's marketing of the Optipillows EPAP mask as a treatment for obstructive sleep apnea and as a substitute for CPAP devices, which raises serious public health and safety concerns. The letter emphasizes that the firm has not provided any evidence supporting the use of its device to treat obstructive sleep apnea and that the FDA is unaware of any evidence supporting the use of EPAP masks for this purpose. The FDA requests prompt action to correct the violations and prevent their recurrence. The information in this document is highly relevant to the query regarding common issues with CPAP manufacture because it outlines specific manufacturing deficiencies and regulatory violations observed by the FDA in the production of a CPAP-related device.

FDA Warning Letter to Adventure Innovations LLC Regarding CPAP Cleaner

adventure-innovations-llc-676842-08072024.txt

This document is a warning letter from the FDA to Adventure Innovations LLC regarding the marketing and sale of their Sani Bot D3 device. The Sani Bot D3 is intended for cleaning CPAP devices and accessories using ultrasonic transducer technology. The FDA states that the Sani Bot D3 is being marketed without the necessary premarket approval or clearance, violating the Federal Food, Drug, and Cosmetic Act (FD&C Act). The FDA argues that the Sani Bot D3 is a medical device accessory because it is intended to support the performance of CPAP therapy devices by cleaning them and preventing disease. The letter also addresses the company's disagreement with the FDA's assessment that their product is a medical device. The FDA requests that Adventure Innovations LLC cease activities that result in the misbranding or adulteration of the Sani Bot D3 and take prompt action to address the violations. The company is required to respond in writing within fifteen business days, outlining the steps taken to address the violations and prevent their recurrence. The FDA's primary concern is that Adventure Innovations LLC is marketing a medical device accessory without the required FDA clearances or approvals.

FDA Warning Letter to Fresenius Kabi AG

fresenius-kabi-ag-671249-01042024.txt

This document is a warning letter from the FDA to Fresenius Kabi AG regarding violations of the Federal Food, Drug, and Cosmetic Act. The violations pertain to the manufacture of the Ivenix Infusion System, including issues with corrective and preventive actions, design control, design validation, and medical device reporting. The FDA found that the company's responses to previous observations were inadequate, as they lacked evidence to ensure that corrective actions would prevent future violations. The warning letter addresses the company's failure to establish adequate procedures for CAPA, design control, and risk analysis. It also cites the company's failure to report medical device malfunctions and corrections/removals in a timely manner. The FDA is concerned that these violations may lead to serious health risks. The information in this document is relevant to the query because it discusses manufacturing issues and regulatory compliance related to medical devices, specifically infusion pumps.

FDA Warning Letter to LEEL Tech Regarding CPAP Cleaners

leel-tech-677297-08072024.txt

This document is a warning letter from the FDA to LEEL Tech regarding the sale of CLYN, LEEL, and SOLID CPAP cleaners in the United States without the necessary marketing clearance or approval. The FDA has determined that these products are adulterated and misbranded under the Federal Food, Drug, and Cosmetic Act because LEEL Tech does not have an approved application for premarket approval or an investigational device exemption for these devices. The company's website claims that these devices use activated oxygen (ozone) to disinfect CPAP machines and accessories. The FDA sent a letter to LEEL Tech on May 10, 2023, stating that the CPAP cleaners appear to meet the definition of a device under the FD&C Act and that they do not appear to be Class I exempt medical devices. LEEL Tech responded by stating that they are an "agent for CPAP cleaner machines" and planned to continue selling their remaining inventory. The FDA deemed this response inadequate because it does not address the lack of clearance or approval for the devices. The FDA requests that LEEL Tech cease any activities that result in the misbranding or adulteration of the devices and provide a written response within fifteen business days detailing the steps taken to address the violations and prevent future occurrences. The information in this document is important to the query because it outlines the FDA's concerns regarding the manufacturing and sale of CPAP cleaners without proper approval, highlighting potential regulatory and safety issues.

FDA Warning Letter to Natures Pillows, Inc.

natures-pillows-inc-and-top-dog-direct-llc-676849-08072024.txt

This document is a warning letter from the FDA to Natures Pillows, Inc. and Top Dog Direct, LLC regarding the marketing of their Clean Zone CPAP Sanitizer without proper clearance or approval. The FDA has determined that the device is adulterated and misbranded because the company does not have an approved application for premarket approval or an approved application for an investigational device exemption. The company claims the device uses activated oxygen to disinfect CPAP devices and accessories, killing 99% of germs and bacteria. The FDA argues that CPAP accessories are semi-critical devices that indirectly contact the user's respiratory tract, and ozone treatment presents risks that need to be addressed through special controls. The FDA has requested that the company cease activities that result in the misbranding or adulteration of the device and take prompt action to address the violations. The warning letter indicates the FDA's concerns about regulatory compliance and the potential risks associated with the unapproved CPAP sanitizing device.

FDA Warning Letter to Sea-Long Medical Systems

sea-long-medical-systems-llc-647320-04042023.txt

This FDA warning letter to Sea-Long Medical Systems, LLC, addresses significant violations of current good manufacturing practice requirements of the Quality System regulation. The firm failed to establish and maintain adequate procedures for complaint handling, process validation, design changes, corrective and preventive action (CAPA), control of nonconforming product, finished device acceptance, and acceptance of incoming product. The company also did not maintain device master records (DMRs) or device history records (DHRs), and failed to establish procedures for quality audits and management review. The FDA also notes that the company is marketing its treatment hoods for new intended uses, such as non-invasive ventilation and COVID-19 treatment, without the necessary clearances or approvals. Additionally, the devices are misbranded for failing to include a unique device identifier (UDI) on the label and failing to submit required information to the Global Unique Device Identification Database (GUDID). The FDA considers the firm's responses to the inspectional observations inadequate, as procedural updates were mentioned without providing supporting documentation or evidence. The company needs to take prompt action to address these violations, which relate to the manufacturing of treatment hoods and not specifically CPAP devices. However, the violations highlight common issues in medical device manufacturing and regulatory compliance, including quality control, validation, and adherence to labeling requirements.

FDA Warning Letter to Shenzhen Moyeah Technology

shenzhen-moyeah-intelligent-life-technology-co-677092-08082024.txt

This document is a warning letter from the FDA to Shenzhen Moyeah Intelligent Life Technology Co. regarding the sale of CPAP cleaners and sanitizers in the United States without the required marketing clearance or approval. The FDA has determined that these devices are adulterated and misbranded under the Federal Food, Drug, and Cosmetic Act. The company's products are described as using ozone, UV light, or a combination of both to disinfect and sterilize CPAP devices and accessories, claiming a 99.99% sterilization rate. The FDA has requested that the company cease the commercial distribution of these devices and respond in writing within fifteen business days with specific steps taken to address the violations and prevent future occurrences. The warning letter also mentions previous communication with the company, which has gone unanswered. The document is relevant to the query as it discusses manufacturing issues related to CPAP devices, specifically concerning regulatory compliance and the lack of FDA approval for the company's CPAP cleaning and sanitizing products.

FDA Warning Letter to Ostar Beauty Sci-Tech

ostar-beauty-sci-tech-co-ltd-667871-12042023.txt

This document is a warning letter from the FDA to Ostar Beauty Sci-Tech Co Ltd. The FDA has found that the firm is marketing several medical devices in the United States without the required marketing clearance or approval, violating the Federal Food, Drug, and Cosmetic Act. These devices include items like injection guns, derma pens, LED masks, and other personal care devices. The FDA has determined that these devices are adulterated and misbranded because the firm does not have premarket approval (PMA) or an approved application for an investigational device exemption. Additionally, the firm did not notify the agency of its intent to introduce these devices into commercial distribution. The letter also notes that the firm has not fulfilled annual registration and listing requirements for fiscal year 2023, making the devices misbranded. As a result, the FDA is taking steps to refuse entry of these devices into the United States until the violations are addressed. The company must respond to the warning letter within fifteen business days, detailing the steps they will take to correct the violations and prevent future occurrences. This document does not contain information about CPAP devices or manufacturing.

Hepatitis C Elimination Report

Executive Summary

The elimination of **Hepatitis C (HCV)** is a global public health priority, with the World Health Organization (WHO) setting ambitious targets for incidence reduction. Achieving these goals requires multifaceted strategies, including enhanced surveillance, targeted testing, improved linkage to care, widespread access to treatment, and effective prevention measures. Several key populations, such as people who inject drugs (PWID), incarcerated individuals, men who have sex with men (MSM), and pregnant women, require focused attention due to higher prevalence rates and unique barriers to care. During the COVID-19 pandemic, HCV elimination efforts faced significant disruptions, including decreased testing rates and strained healthcare resources. However, innovative approaches such as telehealth, virtual models of care, and mobile services helped maintain access to screening and treatment for vulnerable populations. The importance of **data-driven** decision-making and surveillance systems became even more apparent, enabling the tracking of progress and identification of gaps in service delivery. Collaborative problem-solving and partnerships between healthcare providers, community organizations, and peer workers proved essential in adapting to the challenges posed by the pandemic. Direct-acting antiviral (DAA) therapies have revolutionized HCV treatment, offering high cure rates and improved tolerability. However, barriers to accessing these treatments persist, particularly among marginalized populations. These barriers include restrictive insurance policies, stigma, lack of awareness, and difficulties in navigating the healthcare system. Peer-based interventions and community-based models of care have emerged as effective strategies for engaging vulnerable individuals, dispelling myths about HCV, and supporting them throughout the care pathway. Addressing social determinants of health, such as housing instability and opioid use disorder, is also crucial for improving treatment uptake and adherence. Surveillance systems play a critical role in monitoring HCV trends and identifying high-risk populations. The use of electronic laboratory reporting (ELR) data, including negative test results, can enhance case finding and improve estimates of acute HCV burden. Correctional facilities present a unique opportunity for HCV screening and treatment, given the high prevalence of the virus among incarcerated individuals. Integrating HCV testing and treatment into routine healthcare settings, such as urgent care units and HIV clinics, can also improve access to care. Addressing disparities in access to care based on insurance type, race/ethnicity, and geographic location is essential for achieving equitable HCV elimination. Prevention strategies, such as harm reduction interventions for PWID and education about safe injection practices, are vital for reducing HCV transmission. Contact tracing, although challenging due to the long asymptomatic phase of HCV, can be a valuable tool for identifying and informing individuals who may have been exposed to the virus. Addressing stigma and discrimination associated with HCV is crucial for creating a supportive environment that encourages testing and treatment. Efforts to raise awareness about HCV among healthcare providers and the general public are also essential for promoting early diagnosis and linkage to care. Ultimately, a comprehensive and integrated approach that addresses the complex interplay of social, behavioral, and clinical factors is necessary to achieve Hepatitis C elimination.

Hepatitis C Elimination Report

Tags Summary

Hepatitis C and **HCV** are the most discussed topics, indicating a strong focus on the disease itself. **Public Health** and **Diagnosis** also show significant prevalence. **Policy** appears less frequently, potentially highlighting an area of less focus compared to direct disease management and awareness. **Elimination** and **Treatment** have same values.

Tag Frequency



Document Relevancy



Questions And Answers

1. What are the treatment options for Hepatitis C discussed in the context of elimination in this document?



2. What are the cost implications of Hepatitis C elimination strategies discussed in this document?



3. How does this document address the issue of diagnosis and linkage to care in the context of Hepatitis C elimination?



4. What are the ethical considerations surrounding Hepatitis C elimination strategies discussed in this document?



5. What strategies for Hepatitis C elimination are discussed in this document?



6. What role does surveillance play in Hepatitis C elimination as described in this document?



7. What are the barriers to Hepatitis C elimination identified in this document?



8. What specific populations are mentioned in relation to Hepatitis C elimination efforts in this document?



9. What are the prevention strategies for Hepatitis C discussed in relation to elimination efforts in this document?



Top Matches

Hepatitis C Elimination During a Global Pandemic Response

Hepatitis C Elimination During a Global Pandemic.pdf

This case study illustrates San Francisco's approach to local HCV elimination efforts during the COVID-19 pandemic, highlighting strategies that enabled the city to rebuild HCV-related services. The study describes End Hep C SF's transition to a virtual model, the use of telehealth, and the adaptation of services for vulnerable populations like PWID and PEH. It emphasizes the importance of maintaining HCV treatment access, screening, and linkage to care, while addressing barriers created by the pandemic. The study also touches on resource constraints and the need for collaborative problem-solving. The document also discusses the use of data dashboards and surveillance to track progress. The information in this document is important to the query as it provides insights into real-world strategies and challenges in Hepatitis C elimination efforts during a major public health crisis, focusing on maintaining and adapting services to continue progress toward elimination goals.

Hepatitis C Elimination During a Global Pandemic: Resilience

Hepatitis C Elimination During a Global Pandemi.pdf

This case study examines San Francisco's response to local Hepatitis C virus (HCV) elimination efforts during the COVID-19 pandemic, highlighting the adaptations and resilience of the End Hep C SF initiative. The study describes how the initiative transitioned to a virtual model, maintained regular meetings, and leveraged partnerships to continue its work. It also discusses the use of data dashboards to track progress and the importance of offering HCV screening and treatment alongside COVID-19-related services. The study identifies challenges such as decreased testing rates and the need for clear safety guidelines. It also emphasizes the importance of addressing the needs of vulnerable populations, including people who inject drugs and people experiencing homelessness. The work of End Hep C SF demonstrates the importance of continuous communication and common agenda to continue HCV elimination strategies through telehealth and mobile services, offering HCV screening and linkage to care in tandem with COVID-19–related initiatives, being flexible and inventive, such as administering HCV treatment to residents of shelter-in-place hotels; establishing a data dashboard to track HCV testing and treatment.

COVID-19 Impact on HCV Elimination Among PWID

Modeling the impact of the COVID-19 pandemic on achieving HCV elimination amongst young and unstably housed people who inject drugs in San Francisco.pdf

This document models the impact of the COVID-19 pandemic on achieving Hepatitis C virus (HCV) elimination among young and unstably housed people who inject drugs (PWID) in San Francisco. The study assesses progress towards the World Health Organization's (WHO) HCV elimination goal of an 80% reduction in incidence by 2030. The document uses a dynamic HCV transmission model parameterized and calibrated using bio-behavioral survey data from San Francisco. The model simulates various intervention scenarios, including increasing testing and treatment rates, expanding access to medication for opioid use disorder (MOUD), and improving housing stability among PWID. The document identifies several barriers to Hepatitis C elimination, including the impact of the COVID-19 pandemic on decreasing testing and treatment rates, unstable housing among PWID, and reduced access to prevention and treatment services. The study highlights the importance of surveillance systems for tracking testing and treatment estimates by subgroups to ensure that no group is left behind in HCV elimination efforts. The document emphasizes the importance of addressing diagnosis and linkage to care in the context of Hepatitis C elimination, noting a significant gap in linkage to care among young PWID diagnosed with chronic HCV infection. The document presents evidence for the value of sustained investments in PWID health to safeguard progress and achieve elimination by 2030, showing that a well-defined strategy that also enhances access to housing and MOUD is particularly important to ensure elimination is achieved while ensuring equitable treatment and service availability for those most in need.

Hepatitis C Testing and Linkage to Care Projects

HCV_Demo_Eval_Report_ADA.pdf

This document is an evaluation report on Hepatitis C testing and linkage to care demonstration projects in California from 2016-2018. It discusses the background of Hepatitis C in the United States, particularly in California, where it is a leading cause of liver disease. The report outlines the interventions and grantees involved in the projects, which aimed to increase the number of people with Hepatitis C infection who are screened, diagnosed, linked to care, treated, and cured. The evaluation aims to describe the extent to which funded sites provided HCV testing and linkage to care services, enacted policy or program changes, and addressed barriers to successful outreach, testing, and treatment. The document also presents findings on surveillance, testing, linkage to care, and treatment outcomes, as well as lessons learned and best practices for providing outreach, testing, linkage, and care to vulnerable individuals. The report is relevant to the query as it provides insights into strategies for Hepatitis C elimination, barriers to elimination, specific populations involved, the role of surveillance, treatment options, and diagnosis and linkage to care in the context of elimination efforts.

Hepatitis C Prevalence in Incarcerated Settings 2013-2021

Hepatitis C prevalence in incarcerated settings between 2013-2021.pdf

This systematic review and meta-analysis aimed to determine the prevalence of Hepatitis C Virus (HCV) antibodies (Ab) and RNA in incarcerated settings between January 2013 and August 2021. The study included 92 unique sources reporting data for 36 countries. It found that HCV in incarcerated settings remains a significant problem, with higher prevalence than in the general population. The review highlights the importance of screening for HCV (Ab and RNA) in incarcerated settings to inform reliable and recent figures for treatment planning, aligning with the 2030 WHO targets for elimination. Elimination of HCV, including micro-elimination, is discussed in the context of incarcerated individuals, emphasizing the importance of data collection and mapping HCV RNA prevalence for targeted treatment efforts.

Hepatitis C: Prevention, Symptoms, and Treatment

hepcgeneralfactsheet.pdf

The document discusses Hepatitis C, its transmission, symptoms, and prevention. It emphasizes the importance of testing, especially for those with risk factors such as pregnant women, people who inject drugs, have HIV, or were born to infected mothers. The document outlines how Hepatitis C spreads through sharing drug-injection equipment, birth, healthcare exposures, sex with an infected person, unregulated tattoos or body piercings, sharing personal items, and blood transfusions. It also details prevention methods like avoiding sharing needles and not getting tattoos in informal settings. The document highlights that Hepatitis C can be cured with available treatments in 8 to 12 weeks. The document emphasizes the importance of testing and prevention strategies for Hepatitis C.

Peer-Facilitated Treatment Access for Hepatitis C Elimination Project

Peer-facilitated treatment access for hepatitis C.pdf

This commentary explores the lessons learned during the implementation of a peer-facilitated hepatitis C virus (HCV) testing and treatment access project. The project aims to facilitate access to on-the-spot HCV testing, treatment, and care in priority settings through partnership between a peer worker (PW) and a clinical nurse. The project has been able to highlight the benefits of incorporating trustworthy, efficient, and convenient peer-centered health services to engage and support vulnerable populations through HCV testing and treatment, particularly individuals who have historically been disconnected from the health care system. The project focuses on micro-elimination of HCV, with peer workers playing a key role in dispelling myths about HCV testing and treatment, addressing misconceptions about treatments, and supporting clients through the care pathway. The long-term aim of the project is service-based micro-elimination of HCV. The document also addresses barriers to HCV care, including personal and systemic factors, and the importance of lived experience in overcoming these barriers. The project's adaptability takes into account a client's broader life experiences and potential points of connection, engagement, and access with the health system.

Contact Tracing for Hepatitis C Viral Elimination

Contact tracing for hepatitis C The case for novel screening strategies as we strive for viral elimination.pdf

This paper discusses contact tracing as a novel screening strategy for hepatitis C virus (HCV) elimination, particularly among people who inject drugs (PWID). The paper highlights the limitations of contact tracing for HCV, including the long asymptomatic phase of HCV, patient reluctance to seek testing, and stigma. It emphasizes the importance of frequent screening of high-risk populations to diagnose recent HCV infections. The paper also mentions the use of direct-acting antivirals (DAAs) as treatment options and emphasizes the importance of rapid diagnosis and linkage to care. Contact tracing is being re-evaluated as a tool for HCV elimination, especially with the availability of effective treatment. Contact tracing can help identify and inform those who may have been exposed to HCV, offering them testing and treatment. The document highlights the benefits and limitations of contact tracing and its potential role in achieving viral elimination.

Hepatitis C Virus Treatment as Prevention in USA

Hepatitis C virus treatment as prevention in an extended.pdf

This study examines Hepatitis C virus (HCV) treatment as prevention in an extended network of people who inject drugs (PWID) in the USA using a network-based modeling approach. It simulates the transmission of HCV and HIV through injection networks, comparing the effectiveness of various treatment-as-prevention strategies. The study explores different levels of treatment coverage and targets, including random treatment and targeting individuals with the most injection partners. The results suggest that treatment-as-prevention strategies can substantially reduce HCV prevalence, especially when combined with expanded treatment coverage and harm reduction strategies. The study highlights the potential of network-based interventions to achieve HCV elimination among PWID in the USA, with the ultimate goal of informing resource allocation to improve treatment and prevention.

The Role of Peer-Based Approaches in Hepatitis C

Beyond the willing & the waiting The role of peer-based approaches in hepatitis C diagnosis & treatment.pdf

This commentary examines the role, value, and importance of peer-based programmatic approaches for ensuring the effective roll-out of new Hepatitis C (HCV) treatments among those most affected – that is, people who inject drugs (PWID). It discusses recent approaches to HCV treatment in Australia, including universal access to new direct-acting antiviral (DAA) regimens. Key components include expanding existing peer-education initiatives, supporting the development of the PWID peer workforce, and promoting linkages and partnerships between peer-based and HCV treatment service providers. Barriers include PWID being hidden and disconnected from the health system, stigma, discrimination, and criminalisation. The document highlights the need to expand access to HCV testing and prevention among PWID and discusses community-based models of HCV care to recognize and address barriers to testing and treatment. The document advocates for a broad health and human rights-based approach to address stigma and discrimination associated with hepatitis C.

Facilitating Hepatitis C Treatment Access in a Community

Facilitating access to direct-acting antivirals in a community-based point-of-diagnosis model for hepatitis C treatment.pdf

The document describes a study on facilitating access to direct-acting antivirals (DAAs) for hepatitis C treatment through a community-based model called the No One Waits (NOW) study. This study targets socially marginalized populations, including people experiencing homelessness and injecting drugs, in San Francisco. The intervention involves a partnership with a specialty pharmacy team to overcome insurance-related barriers and provide same-day treatment initiation. The study highlights the importance of addressing systemic barriers to treatment access for marginalized populations to achieve hepatitis C elimination. The study leverages a sustained partnership with a specialty pharmacy team to transition participants to insurance-covered treatment quickly and overcome barriers. The study-provided 2-week starter pack facilitated same-day treatment at the point of diagnosis. This is important to the query because it describes strategies, barriers, populations, and treatment options for Hepatitis C elimination.

Hepatitis C in California: Prevalence and Prevention

Infographic-Hepatitis-C-Trends-in-California-2016.pdf

This document discusses the prevalence and transmission of Hepatitis C in California. It highlights that Hepatitis C is a frequently reported communicable disease, primarily transmitted through sharing needles and injection equipment. About 400,000 Californians have chronic Hepatitis C, with baby boomers accounting for almost half of the reported cases. The number of cases among young people has doubled in the last five years. It advises that people who have injected drugs and baby boomers should get tested. Prevention strategies include access to sterile syringes and treatment for opioid use disorders. New treatments can cure Hepatitis C in as little as two months. The document is relevant to the query because it discusses Hepatitis C, prevention strategies, diagnosis, and specific populations affected in California.

Understanding Hepatitis C: Symptoms, Diagnosis, and Treatment

NIHnIDDK HCV webpage.pdf

This document provides information about Hepatitis C, including its causes, symptoms, diagnosis, treatment, and prevention. It discusses acute and chronic hepatitis C, how it spreads, and who is more likely to get it. The document also covers screening recommendations, complications, and available treatments, including antiviral medications. The document is relevant to Hepatitis C elimination because it provides information on diagnosis, treatment, and prevention. It also mentions screening efforts and treatment, which help doctors identify and cure more people with the disease, potentially making Hepatitis C less common in the United States in the future.

Hepatitis C Virus in Pennsylvania Prisons: Limitations of Screening

4 Limitations of 1945–1965 Birth Cohort Screening in Correctional Settings..pdf

This research article examines the epidemiology of Hepatitis C virus (HCV) in Pennsylvania state prisons between 2004 and 2012, focusing on the limitations of 1945-1965 birth cohort screening in correctional settings. The study used observational data to determine anti-HCV prevalence and assess the burden of anti-HCV in different birth cohorts. It found that HCV prevalence was high in the prison population, particularly among those born between 1945 and 1965. The study recommends universal anti-HCV screening in correctional facilities, followed by testing and treatment. The document also highlights the importance of risk reduction education and counseling. Cost-sharing arrangements between correctional authorities and public health departments should be explored to facilitate widespread HCV treatment in prisons.

Efficacy and Safety of Sofosbuvir for Hepatitis C

Efficacy and safety of sofosbuvir in the treatment of hep C among patients on hemodialysis.pdf

This document is a systematic review and meta-analysis that assesses the efficacy and safety of sofosbuvir-based regimens for the treatment of Hepatitis C virus (HCV) infection among patients requiring maintenance hemodialysis. The study analyzed data from multiple studies to determine the effectiveness of sofosbuvir in this specific population. The overall pooled estimate of the efficacy of sofosbuvir-based regimens was found to be 95%. The most frequent adverse event was fatigue, followed by anemia and nausea or vomiting. The document concludes that sofosbuvir-based regimens are effective and safe for treating HCV infection in patients requiring hemodialysis.

Hepatitis C Mortality Trends in San Francisco

Hepatitis C mortality trends in San Francisco.pdf

This study analyzes Hepatitis C virus (HCV)-related mortality trends in San Francisco from 1999 to 2019 and assesses progress toward HCV elimination targets. It uses vital registry data to estimate overall and demographic-specific HCV-related mortality, comparing local trends to state and national trends. The study examines the impact of direct-acting antiviral (DAA) therapies on HCV-related mortality. The analysis includes assessing trends in various demographic subgroups, such as age groups, sex, and race/ethnicity. The goal is to evaluate San Francisco's progress toward achieving a 65% reduction in HCV-related mortality by 2030, as set by the CDC. The study highlights the importance of prevention, testing, and linkage to treatment services, especially for communities most affected by HCV. The document is relevant to the query as it analyzes HCV-related mortality trends and assesses progress toward HCV elimination targets, providing insights into strategies and outcomes in San Francisco.

Hepatitis C Reinfection in People Who Inject Drugs

Hepatitis C Reinfection in People Who Inject Drugs in Resource-Limited Countries.pdf

This document is a systematic review focusing on Hepatitis C reinfection among people who inject drugs (PWID) in low- and middle-income countries (LMICs). It highlights the World Health Organization's (WHO) strategic plan for HCV elimination and the effectiveness of direct-acting antiviral (DAA) therapies. The study identifies the lack of clinical data in resource-limited settings as a significant challenge. It emphasizes the need for dedicated research to understand the HCV epidemic among PWID in LMICs and suggests that policies should ensure access to HCV testing and treatment without restrictions for PWID. The review uses genotyping and deep sequencing to study HCV transmission factors. The document concludes that there is a need for comprehensive public health strategies, including widespread testing, faster linkage to care, treatment for all, and increased access to harm reduction interventions to effectively engage PWID in resource-limited countries and further understand the HCV epidemic.

Examining Global Policy on Hepatitis C Elimination

Towards eliminating viral hepatitis Examining the productive capacity and constitutive effects of global policy on hepatitis C elimination.pdf

This document analyzes the World Health Organization's global strategy to eliminate viral hepatitis, with a focus on hepatitis C. It examines the governance and conceptual frameworks of this strategy, including how 'elimination' is defined and pursued through targets, management, and surveillance. The document also touches on the role of direct-acting antiviral (DAA) medicines in treatment and prevention. The analysis considers the implications of global policies for local contexts and specific populations, such as people who inject drugs. The document emphasizes the importance of understanding how the disease is made visible and governable through quantification and data-driven approaches.

Hepatitis C Virus Infection Among Women Giving Birth

10 Hepatitis C Virus Infection Among Women Giving Birth - Tennessee and United States, 2009-2014..pdf

This document is a report on Hepatitis C Virus (HCV) infection among women giving birth in Tennessee and the United States from 2009 to 2014. It highlights the increasing rates of maternal HCV infection, particularly among specific populations. The study used U.S. birth certificate data to analyze trends and geographic variations in HCV infection rates among women giving birth. The document also points out that the recent increase in maternal HCV infection disproportionately affects rural and white populations, as well as those in or near Appalachian regions. The report suggests that primary prevention and testing strategies for HCV infection could be targeted to these populations and areas at high risk. Ensuring women of childbearing age have access to HCV testing and treatment is mentioned as a way to mitigate risk and prevent transmission.

Chronic Hepatitis C in California: A Technical Note

2018-Chronic-HCV-Surveillance-Report-Technical-Notes (1) (1).pdf

This document is a technical note on chronic Hepatitis C in California, focusing on data sources, definitions, and limitations of surveillance data. It defines chronic Hepatitis C infection according to the Council of State and Territorial Epidemiologists (CSTE) criteria and explains how cases are reported to the California Department of Public Health (CDPH). The report details the methodology for calculating rates of newly reported cases, including adjustments for age, gender, and race/ethnicity. Special attention is given to incarcerated populations and the challenges in accurately capturing Hepatitis C cases within correctional facilities. The document acknowledges limitations in surveillance data, such as unreported cases, migration of infected individuals, and missing race/ethnicity information. The report is a surveillance report and informs public health policy. The document provides a detailed overview of how chronic Hepatitis C cases are defined, reported, and tracked in California, highlighting the role of surveillance in understanding the disease's prevalence and distribution.

Prevalence of Hepatitis C Virus in Men Who Have Sex

3 MSM high risk.pdf

The study investigates the prevalence of hepatitis C virus (HCV) among men who have sex with men (MSM) at a community health center in Boston. It examines risk factors associated with HCV infection in this population. The study population included 218 MSM who were screened for HCV infection during routine clinic visits. The study found that prevalence of HCV infection was 11.5%. The study also found that HCV-infected men were more likely to have a history of rectal or urethral gonorrhea and to have used crack cocaine in the past six months. The study concludes that prevention and screening should target MSM engaging in high-risk sex and that sexually transmitted infection risk reduction interventions should be targeted at MSM with HCV. The information relevant to the query includes the focus on HCV among MSM, risk factors, and the emphasis on prevention and screening.

Spectrum of Undiagnosed Hepatitis C in a US Clinic

7 The Spectrum of Undiagnosed Hepatitis C Virus.pdf

This document discusses Hepatitis C virus (HCV) infection among HIV-infected individuals in a US HIV clinic. It focuses on the importance of routine HCV antibody testing for HCV-seronegative patients to detect incident HCV infections. The study evaluates the implementation of annual HCV antibody re-testing in a Rhode Island HIV clinic. The document suggests that repeated HCV screening is cost-effective and can provide widespread surveillance data. The study identifies a significant number of undiagnosed HCV infections among HIV-infected individuals and emphasizes the benefits of early diagnosis and treatment of acute HCV to prevent further spread. The document highlights the need for improved screening practices and awareness among providers to identify and link patients to care, particularly in high-risk populations such as men who have sex with men (MSM).

Barriers to HCV Care Among Young People Who Inject Drugs

barriers among young people.pdf

This paper investigates barriers to Hepatitis C Virus (HCV) care among young people who inject drugs (PWID) in Boston, Massachusetts. The study identifies several key barriers, including stigma and beliefs about who deserves treatment, dissatisfaction with healthcare providers, difficulties in referral and care coordination, disincentives related to treatment costs and adherence challenges, and individual perceptions of the need for treatment. The research involved in-depth interviews with young PWID living with HCV to understand their experiences and perspectives on navigating the HCV care continuum. It highlights the need for patient-centered approaches and addressing stigma to improve HCV treatment uptake and adherence among this vulnerable population. The document emphasizes the importance of addressing the social determinants of health in order to improve the continuum of Hepatitis C care for young people who inject drugs.

Curing Hepatitis C in People Who Inject Drugs

Curing People Who Inject Drugs of Hepatitis C in Non-Specialty Care Settings.pdf

This document is an abstract that discusses Hepatitis C treatment outcomes for people who inject drugs (PWID) in non-specialty care settings. The study was conducted by the California Department of Public Health (CDPH) in three local health jurisdictions. The funded sites used electronic health records (EHR) to identify clients and track their treatment outcomes, including sustained virologic response (SVR). The study found that seventy-five percent of PWID who initiated treatment were known to achieve SVR. The document suggests that Hepatitis C can be effectively treated and cured among both PWID and people without a known injection drug use history in non-specialty care settings. The document is most relevant to treatment and diagnosis of Hepatitis C, particularly within the PWID population.

Decreasing Hepatitis C Incidence in British Columbia, Canada

Decreasing Hepatitis C Incidence Among a Population With Repeated Tests.pdf

This study examines Hepatitis C virus (HCV) incidence among a population with repeated tests in British Columbia, Canada, from 1993 to 2011. The study estimates HCV incidence among individuals who repeatedly underwent anti-HCV testing. The study found that HCV incidence rates decreased sharply in the 1990s and more gradually in the 2000s. The study also found that men had a higher incidence than did women across all years, although the gap narrowed over time. The study mentions addictions treatment, harm reduction, and prevention education as novel initiatives to remove barriers in health infrastructure need to be intensified for those who inject drugs, particularly men and younger persons. The study also highlights the importance of monitoring HCV incidence in core groups for planning and evaluating prevention efforts, treatment, and resource allocation, and the need to link individuals to population-level impact.

Hepatitis C Antiviral Awareness Among People Who Inject Drugs

Determinants of hepatitis C antiviral effectiveness awareness among people who inject drugs in the direct-acting antiviral era.pdf

This study assesses the awareness of hepatitis C antiviral effectiveness and treatment among people who inject drugs (PWID) in Scotland. It highlights that PWID are at greatest risk of hepatitis C virus (HCV) infection. The study found poor awareness of the high cure rates associated with direct-acting antivirals (DAAs) among PWID in Scotland, despite relatively high rates of HCV testing. Increased effort is needed to ensure population groups with high risk of HCV infection are fully informed of the highly effective antiviral medications now available to treat this chronic disease. The study suggests that Scotland's prioritization strategy does not confine the prescription of DAA therapy to those with advanced liver disease. The study emphasizes the need for educational interventions and strategies to improve HCV treatment knowledge and engagement with care among PWID to achieve WHO elimination goals.

Hepatitis C and Injection Drug Use Information

FactSheet-PWID.pdf

This document primarily focuses on Hepatitis C in the context of injection drug use. It details how the virus spreads among people who inject drugs, emphasizing the risks associated with sharing needles and equipment. The document outlines symptoms of Hepatitis C, stressing that many infected individuals may not show symptoms. It advises those who have ever injected drugs to get tested for Hepatitis C and describes the types of tests available. The document also provides prevention strategies, such as using sterile equipment and cleaning injection sites. It mentions available treatments for Hepatitis C and highlights the importance of consulting a doctor for treatment options. The document focuses on the prevention and treatment of Hepatitis C, particularly within the population of injection drug users.

Barriers to HCV Care Continuum Among Young People

HCV stigma.pdf

This study explores the barriers to Hepatitis C virus (HCV) care among young people who inject drugs (PWID) in Boston, Massachusetts. It identifies themes emerging from in-depth interviews with PWID, focusing on their knowledge, experiences, and perceptions related to HCV treatment. The study highlights social determinants of engagement in care, including stigma, insurance coverage, and provider interactions, as well as factors related to illness level and healthcare service utilization. The document emphasizes the importance of addressing barriers such as stigma, lack of insurance, and provider-related issues to improve HCV treatment readiness and willingness among young PWID, ultimately aiming to enhance engagement in care and reduce viral circulation in this population.

Hepatitis C Cascade of Care in the DAA Era

Hepatitis C Cascade of Care in the Direct-Acting Antivirals Era.pdf

This document is a meta-analysis examining the Hepatitis C virus (HCV) care cascade in the direct-acting antiviral era. It assesses outcomes across various strategies and venues, reporting proportions attained at each step of the HCV care cascade after the availability of direct-acting antivirals (DAAs). The study included studies from North America, Europe, and Australia from January 2014 through March 2021. The document identifies persistent gaps in achieving desired outcomes across the HCV care cascade despite effective therapies. It notes that certain populations, such as those with HIV, substance use disorders, homelessness, and incarceration, face multilevel barriers to completing the HCV care cascade. The analysis highlights the need for continued efforts to improve care cascades, especially for marginalized individuals, to achieve the WHO's goal of curing HCV infection and reducing its incidence. This document is relevant to the query because it analyzes the current state of the HCV care cascade and identifies key barriers to elimination.

Hepatitis C and Opioid Use in Young Adults

HepCYoungAdults_infographic.pdf

This document discusses the rise in hepatitis C and heroin overdoses among young adults in California. It identifies sharing injection equipment as a primary mode of hepatitis C transmission and suggests medication-assisted drug treatment, such as maintenance buprenorphine, as a method to reduce hepatitis C rates. The document also promotes getting sterile syringes and testing for hepatitis C. The document focuses on young adults in California and emphasizes the importance of addressing both opioid use and hepatitis C infections. It encourages those who inject drugs to access medication-assisted drug treatment and to get tested for hepatitis C. The document suggests that medication-assisted drug treatment can reduce hepatitis C rates. Prevention strategies involve obtaining sterile syringes. Getting tested for hepatitis C and accessing treatment are encouraged.

Hepatitis C and Opioid Use in Young Adults

HepCYoungAdults_infographic (1).pdf

This document discusses the rise of Hepatitis C rates among young adults in California, particularly those who inject drugs. It highlights the connection between opioid use and Hepatitis C transmission through shared injection equipment. The document emphasizes the role of medication-assisted drug treatment in preventing both opioid overdoses and Hepatitis C infections, noting a 50% reduction in Hepatitis C rates with such treatment. Additionally, it promotes prevention strategies such as providing sterile syringes and encouraging testing for Hepatitis C, especially for individuals who inject drugs. The information is important to the query because it highlights strategies to reduce the spread of Hepatitis C.

Integrated Community-Based Hepatitis C Treatment for People Who Inject Drugs

Initial outcomes of integrated community-based hepatitis C treatment Queensland Injectors_ Health Network.pdf

This study examines the outcomes of a community-based program providing direct-acting antiviral (DAA) therapy for Hepatitis C virus (HCV)-infected people who inject drugs (PWID) through the Queensland Injectors' Health Network (QuIHN). The program integrates harm reduction and treatment services, including opioid substitution therapy and other treatments. The study reports on treatment completion, sustained virological response (SVR), and treatment adherence among participants. The study found that a significant proportion of participants completed treatment, achieved SVR, and adhered to the prescribed treatment regimen. The findings suggest that integrated, community-based approaches can be effective in engaging PWID in HCV treatment and achieving positive outcomes. The integration of harm reduction, counseling, and medical services within the QuIHN framework appears to facilitate treatment engagement and adherence, ultimately contributing to improved SVR rates among this population.

Screening for Hepatitis C in Urgent Care Units

Screening for hepatitis C in urgent and emergency units.pdf

This systematic review identifies studies that performed screening for hepatitis C and assessed the virus prevalence in urgent and emergency unit users. The review used databases like LILACS and MEDLINE. It identified that screening in urgent and emergency units is effective in identifying new cases, especially when associated with age factor. The association of three strategies is recommended: screening location, age group, and risk factors. The study highlights the importance of screening for hepatitis C in urgent and emergency units to identify infected individuals, especially considering the difficulties in identifying them otherwise. The review also mentions that making the diagnosis is a necessary prerequisite to offer treatments and proper screening supports the cascade of treatment.

Enhancing Hepatitis C Case Finding and Linkage to Care

Shining the (Sun) Light on Hepatitis C_ Prospects for Negative Reporting to Enhance Acute Hepatitis C Case Finding and Hepatitis C Linkage to Care in California.pdf

This document discusses Hepatitis C surveillance and linkage to care efforts in California. It focuses on enhancing acute Hepatitis C case finding and improving linkage to care by utilizing negative electronic lab report (ELR) data. The California Department of Public Health (CDPH) assessed the potential to identify acute and resolved HCV infection by analyzing available negative HCV electronic lab reports. Barriers to surveillance and linkage to care efforts exist because most cases are asymptomatic, and negative test results are not readily available to identify recent seroconversion, treatment status, and viral suppression. The document highlights the importance of using negative ELR data to improve estimates of acute HCV burden and facilitate timely interventions. This is important to the query because it highlights the role of data and surveillance in Hepatitis C elimination efforts.

Sofosbuvir and Ribavirin for Hepatitis C in HIV

Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection.pdf

This study evaluates the effectiveness of sofosbuvir and ribavirin in treating Hepatitis C virus (HCV) in patients coinfected with human immunodeficiency virus (HIV). The study was an open-label, nonrandomized, uncontrolled phase 3 trial conducted at 34 treatment centers in the United States and Puerto Rico. The results showed that patients with HIV who were coinfected with HCV genotype 1, 2, or 3 who received the oral, interferon-free combination of sofosbuvir and ribavirin for 12 or 24 weeks had high rates of sustained virologic response. The study focuses on treatment outcomes and does not address prevention strategies, barriers to elimination, or ethical considerations related to HCV elimination. The treatment options for Hepatitis C are discussed in the context of elimination.

Hepatitis C Virus Prevalence in the Western Pacific

Systematic Review of Hepatitis C Virus Prevalence in the WHO Western Pacific Region.pdf

This review aims to identify hepatitis C virus (HCV) prevalence estimates among the general population and six key populations (people who inject drugs, men who have sex with men, sex workers, prisoners/detainees, Indigenous people, and migrants) in the World Health Organization Western Pacific Region (WHO WPR). Original research articles published between 2016 and 2020 were identified from bibliographic databases. Publications were retrieved, replicas removed, and abstracts screened. Data on HCV exposure and active infection were extracted and aggregated and forest plots generated for each population by country. Countries require detailed knowledge of HCV in diverse populations to evaluate the impact of efforts to support WHO HCV elimination goals. Results provide baseline estimates from which to monitor and evaluate progress and by which to benchmark future elimination efforts. The study highlights the diversity of HCV infection among specific sub-populations in the WHO WPR, with a high prevalence of exposure to HCV among people who inject drugs and specific sub-populations where injection drug use is prevalent.

Peer Support in Hepatitis C Treatment Intervention

Tensions in relation How peer support is experienced and received in a hepatitis C treatment intervention.pdf

This article explores the experiences of peer support in Hepatitis C (HCV) treatment among marginalized populations, focusing on people who inject drugs (PWID). It discusses how peer support can enhance HCV treatment plans and increase provision in community settings, especially with the development of direct-acting antiviral therapies (DAAs). The study identifies organizational structures and boundaries as potential constraints to the efficacy of peer involvement. It emphasizes the importance of increasing HCV diagnosis and treatment in primary care and drug treatment settings. The research highlights the role of peer support in lowering organizational costs. The document addresses the ethical considerations surrounding peer involvement and the use of peers in the delivery of health care services.

Mobile App for Hepatitis C Care Knowledge Assessment

Understanding Users' Engagement in a Provider-Created Mobile.pdf

This study evaluates the initial rollout of an HCV educational app designed for patients and healthcare staff, focusing on user engagement and knowledge retention. The app covers five learning modules: testing for Hep C, testing for Hep C positive patients, treatments available, what to expect during treatment, and what to expect after treatment. The study analyzes app usage data from November 2019 to November 2022, examining user demographics, engagement metrics, and module usage patterns. It aims to address the lack of HCV educational resources and improve patient and healthcare staff knowledge about HCV treatment and management. The study highlights the need for improved viral hepatitis education and addresses barriers to HCV testing and treatment gaps. The app aims to provide on-demand education, enabling patients to access crucial HCV management and treatment information.

Hepatitis C in Young People in California

HCVinYouthInfographic.pdf

This document presents data on hepatitis C among young people aged 15-29 in eight California counties in 2018. It highlights that injection drug use is a commonly reported risk factor, with 73% of females and 69% of males who use drugs having injected them. A significant portion, 27%, had a history of incarceration. Only 2% of those with HCV received antiviral treatment. Many were unaware of their risk, with only one in three thinking they were at risk before diagnosis. Among those who inject drugs, 83% witnessed an overdose, and while 63% had access to naloxone while injecting, 44% needed it during an overdose but didn't have it. The document suggests providing sterile syringes, HCV testing, referrals to care, and naloxone and overdose prevention training to help people at risk for HCV. The document emphasizes the importance of addressing injection drug use and incarceration history and increasing awareness of HCV risk to facilitate diagnosis and treatment among young people in California.

Peer Support in Hepatitis C Treatment Intervention

Tensions in relation How peer support is experienced and received in a Hep C Intervention.pdf

The article explores the experience of peer support in Hepatitis C (HCV) treatment interventions, focusing on marginalized populations, particularly people who inject drugs (PWID). It discusses how peer support is crucial in HCV treatment by expanding possibilities for meaningful peer involvement in community settings, facilitated by direct-acting antiviral therapies (DAAs). The study reports findings from a qualitative component of a complex intervention aimed at increasing HCV diagnosis and treatment in primary care and drug treatment settings in the UK. The study identifies organizational structures and boundaries as constraints to peer involvement. The research emphasizes the need to carefully implement peer programs within wider recovery and harm reduction frameworks, highlighting the importance of addressing organizational policies and client-peer relations to ensure successful interventions. The study contributes insights into the role of peer support in HCV treatment, focusing on the experiences and perceptions of those involved, and addressing challenges in integrating peer support within existing healthcare systems.

Feasibility Study: Intervention to Reduce Hepatitis C Transmission

An uncontrolled, feasibility study of a group intervention to reduce hepatitis C transmission risk behaviours and increase transmission knowledge among women who inject drugs..pdf

This document presents a study evaluating the feasibility and effectiveness of a three-session psychosocial group intervention (REDUCE) to reduce Hepatitis C (HCV) transmission risk behaviors among women who inject drugs in five European cities/towns. The intervention aimed to increase knowledge about HCV transmission, improve skills for safer injecting practices, and motivate participants to change their risk behaviors. The study assessed outcomes such as HCV transmission knowledge, injecting and drug risk behaviors, condom use, and depressive symptoms at baseline and one-month post-intervention. The intervention included education, role-play exercises, and discussions. The study found that the intervention was feasible and acceptable, and it significantly increased women's knowledge of HCV transmission. There were also reductions in certain drug administration and preparation risk behaviors. The document highlights the importance of addressing the specific needs of women who inject drugs in interventions to reduce HCV transmission.

Insurance Disparities in Hepatitis C Treatment Access

denials HCV.pdf

This study investigates disparities in access to direct-acting antiviral (DAA) treatments for Hepatitis C virus (HCV) infection based on insurance type. The study found that patients with Medicaid insurance were more likely to have their DAA prescriptions denied compared to those with Medicare or commercial insurance. The most common reasons for denial were insufficient information to assess medical need and lack of medical necessity. The study highlights the impact of insurance coverage on access to HCV treatment and the potential for restrictive preapproval policies to create disparities in care. The information in the document important to the query is the identification of insurance-related barriers to Hepatitis C treatment access.

Healthcare-associated hepatitis B and C transmission in Europe

Healthcare-associated hepatitis B and C transmission to patients in the EUEEA and UK.pdf

This systematic review examines healthcare-associated transmission events of Hepatitis B and C in the EU/EEA and the UK between 2006 and 2021. The study identifies failures in infection prevention control (IPC) precautions as a primary cause of outbreaks in healthcare settings, including dialysis units, nursing homes, and CT/MRI scanning units. The review emphasizes the importance of strengthening surveillance systems and standardizing reporting practices to improve the understanding and control of nosocomial hepatitis transmission. It also points out the need for better adherence to universal precautions in all settings and regular audits. The document does not specifically address Hepatitis C elimination strategies, but it provides insights into the transmission dynamics and risk factors associated with healthcare-associated Hepatitis C infections, highlighting the need for improved infection control practices and surveillance to reduce transmission in healthcare settings, which is relevant to Hepatitis C elimination efforts.

Global Incidence of HIV and Hepatitis C Among PWID

Incidence of HIV and hepatitis C virus among people who inject drugs, and associations with age and sex or gender.pdf

The document is a global systematic review and meta-analysis focused on HIV and Hepatitis C virus (HCV) incidence among people who inject drugs (PWID). It examines the incidence rates in various geographical regions and among different subgroups of PWID, such as young individuals and women. The study aims to understand the global levels of HIV and HCV transmission among PWID by pooling data from multiple studies. The review highlights the importance of monitoring HIV and HCV incidence to track progress towards targets set by UNAIDS and WHO. It also underscores the need for intensified prevention efforts and gender-appropriate prevention services to address the higher risks of HIV and HCV acquisition among specific subgroups. The study provides insights into the global epidemiology of HIV and HCV among PWID but does not directly address specific elimination strategies, barriers, cost implications, or ethical considerations related to Hepatitis C elimination.

Hepatitis C Knowledge and Treatment Willingness Among PWID

Knowledge of hepatitis C and treatment willingness amongst people.pdf

This study investigates Hepatitis C Virus (HCV) knowledge and treatment willingness among people who inject drugs (PWID) in Vancouver, Canada, during the era of direct-acting antivirals (DAAs). The study aims to identify factors associated with greater HCV knowledge and willingness to undergo treatment to inform future education and treatment efforts. The research involved a cohort of PWID who were assessed for HCV knowledge and treatment willingness using questionnaires. The study considered various sociodemographic characteristics, drug use behaviors, and healthcare access variables. The primary outcomes were composite scores for knowledge and treatment willingness. The study found a high level of HCV knowledge among the PWID sample. Greater healthcare exposure was associated with higher HCV knowledge scores, while residence in the Downtown Eastside (DTES) and daily crack cocaine smoking were associated with less willingness to initiate HCV treatment. The findings suggest that addressing socioeconomic and structural barriers, as well as concerns regarding treatment side effects, is important for improving HCV treatment uptake among PWID. The study also highlights the need for targeted educational interventions to address knowledge gaps regarding interferon-sparing DAA regimens.

Risk of Hepatitis C Transmission through Acupuncture

Risk of Hepatitis C Virus Transmission through Acupuncture.pdf

This document is a systematic review and meta-analysis assessing the association between acupuncture and Hepatitis C virus (HCV) transmission. It analyzes data from 28 studies with 194,826 participants and finds that acupuncture users show significantly higher HCV transmission rates than controls. The study suggests that unsafe medical procedures, including acupuncture, should be performed with caution. The document concludes that the evidence from this meta-analysis shows that acupuncture potentially increases the HCV transmission rate and highlights the need for safer acupuncture practices to prevent HCV transmission. The study identifies that acupuncture users showed significantly higher HCV transmission rates than controls. It also suggests that safer acupuncture practices using disposable needles and close monitoring of acupuncturists worldwide could be a public health priority to prevent HCV transmission.

Hepatitis C Virus Testing and Diagnostic Delays

Hepatitis C Virus Testing and Diagnostic Delays in Rural Northern California.pdf

This document discusses Hepatitis C virus (HCV) testing and diagnostic delays in rural Northern California. Butte County Public Health Department (BCPHD) receives approximately 330 newly reported chronic HCV cases annually. Between July 2014 and June 2015, only 49% of patients with HCV antibody (Ab) positive tests had confirmatory Nucleic Amplification test (NAT) results reported. Lack of confirmatory testing can result in delayed diagnosis, missed opportunities for HCV clinical management and interruption of transmission. In September 2016, BCPHD analyzed HCV surveillance data and identified that a significant proportion of facilities and providers with the lowest rates of HCV confirmatory testing utilized local hospital laboratories. Medical records were reviewed for patients who had a positive HCV Ab test result reported to BCPHD between July 2015 and September 2016 without NAT results reported within 30 days. BCPHD worked with three laboratories to implement a reflex testing policy to ensure that when a patient receives a positive HCV Ab result, the patient automatically receives confirmatory NAT. After three major facilities in Butte County adopted reflex testing, there was a 96% decrease in the number of patients with positive HCV Ab results without confirmatory NAT reported to BCPHD each month. The document is relevant to the query because it addresses strategies to improve timely diagnosis of HCV infection through reflex testing policies.

Chronic Hepatitis C in California: 2018 Technical Notes

2018-Chronic-HCV-Surveillance-Report-Technical-Notes.pdf

This document is a technical report on chronic Hepatitis C in California as of 2018. It details data sources, definitions, and limitations related to Hepatitis C surveillance. The report uses data from the California Department of Public Health (CDPH) and local health jurisdictions (LHJs). It defines chronic Hepatitis C infection based on the Council of State and Territorial Epidemiologists (CSTE) case definition. The document also addresses the rates of newly reported cases, stratified by age, gender, and race/ethnicity, and includes specific data on incarcerated persons with chronic Hepatitis C. The report highlights the use of electronic laboratory reporting (ELR) and discusses potential errors in data matching and deduplication. The document is related to the query because it provides information on Hepatitis C surveillance and data collection efforts, which are foundational to understanding the scope of the epidemic and planning elimination strategies. The document also mentions treatment options for Hepatitis C, which is a key component of elimination efforts.

Increases in Acute Hepatitis C Virus Infection and Opioids

6 Increases in Acute Hepatitis C Virus Infection Related to a Growing Opioid Epidemic and Associated Injection Drug Use, United States, 2004 to 2014.pdf

This research article examines the relationship between the opioid epidemic and the increase in acute Hepatitis C virus (HCV) infections in the United States from 2004 to 2014. The study uses national surveillance data to assess trends in HCV infection rates and their correlation with injection drug use (IDU), particularly opioid injection. It identifies significant increases in acute HCV infection, especially among young people and those reporting injection of heroin and prescription opioid analgesics. The findings suggest that the opioid epidemic is contributing to the rise in HCV infections across the country. The study also highlights the need for coordinated responses to address both the opioid crisis and the associated increase in HCV infections. Surveillance data is used to track the increase in HCV infections.

Estimate of the Prevalence of Hepatitis C in USA

Edlin_et_al-2015-Hepatology.pdf

This document primarily focuses on estimating the prevalence of Hepatitis C in the United States, particularly among populations excluded from the National Health and Nutrition Examination Survey (NHANES). It highlights the underestimation of Hepatitis C cases due to the exclusion of certain high-risk groups such as incarcerated individuals, homeless individuals, and Native Americans living on reservations from the NHANES sampling frame. The study uses data from various sources to provide a more accurate estimate of the national burden of Hepatitis C. The document underscores the importance of accurate prevalence estimates for establishing disease burdens, guiding policy, targeting interventions, and allocating resources. The document emphasizes the need for better assessment and monitoring of the health needs of socially marginalized populations.

Hepatitis C Infection and Treatment Among Injecting Drug Users

Hepatitis C Infection and Treatment among Injecting Drug Users Attending General Practice.pdf

This document is a systematic review and meta-analysis investigating hepatitis C infection and treatment among injecting drug users (IDUs) attending general practice. It looks at the prevalence of HCV among IDUs, diagnostic actions, antiviral treatments, and cure rates in a general practice setting. The document notes that the treatment of HCV has improved with the introduction of direct-acting antivirals (DAAs), which have shorter treatment durations and fewer side effects compared to previous treatments like interferon and ribavirin. However, barriers to successful treatment in IDUs include chaotic lifestyles, homelessness, alcohol and illicit drug abuse, social isolation, poor medication compliance, and social stigma. The study aims to provide an overview of the available data regarding Hepatitis C treatment and diagnosis among IDUs in general practice. The key focus is on the treatment options and the challenges in achieving successful outcomes in this population.

Hepatitis C Virus Infection and Hospital-Related Outcomes

Hepatitis C Virus Infection and Hospital-Related Outcomes.pdf

This systematic review investigates the impact of Hepatitis C Virus (HCV) infection on hospital-related outcomes, including hospitalizations, length of stay, and mortality. The review analyzes 57 studies to determine the relationship between HCV infection and these outcomes. It also explores the potential impact of direct-acting antivirals (DAAs) on these outcomes. The review finds that HCV infection is associated with increased hospitalizations, length of stay, and readmissions. It also suggests that DAAs may modify the relationship between HCV infection and in-hospital mortality. The study highlights that inpatient services account for two-thirds of the economic burden of HCV on hospital systems. The review aims to understand the effect of DAAs on hospital-related outcomes, including medical advice, readmissions, and in-hospital mortality. The purpose of this review was to comprehensively assess the literature to better understand the impact of HCV on hospital-related outcomes.

Syphilis and Hepatitis C Co-Infection Among Women

Increase in Syphilis and Hepatitis C Virus Co-Infection Among Women, California, 2012-2016..pdf

This document is an abstract from the 2018 Annual Conference discussing an increase in syphilis and Hepatitis C virus co-infection among women in California from 2012-2016. The study assessed trends in syphilis/HCV coinfection among women and determined if high-risk sexual or drug use behaviors are associated with coinfection. Data from the California Department of Public Health was used to match cases of probable and confirmed chronic HCV infection with cases of early syphilis infection. The study found a steady increase in syphilis/HCV coinfection among women in California. Treatment is needed to prevent ongoing transmission of syphilis and HCV among people who inject drugs and who exchange sex for drugs. Strategies to increase identification and treatment of both syphilis and HCV among women, such as offering integrated testing in syringe exchange and drug treatment programs, should be considered.

Hepatitis C Prevalence Among Homeless Adults in Los Angeles

8 Prevalence, Distribution, and Correlates of Hepatitis C Virus Infection Among Homeless Adults in Los Angeles.pdf

This study documents the prevalence, distribution, and correlates of Hepatitis C virus (HCV) infection among urban homeless adults in Los Angeles. The study found a high rate of hidden HCV infection among this population, with nearly half of those infected being unaware of their status. The research highlights the need for interventions that include HCV education, counseling, and treatment services. The study also found that injection drug use was the strongest independent predictor of HCV infection in this sample, with higher rates among multiple-drug injectors. Other factors associated with HCV infection included older age, less education, and prison history. The document emphasizes the importance of increased testing and counseling as part of HCV reduction efforts within the community. The document indicates that there is an unmet need for treatment and that clinicians should screen homeless adults for HCV, especially those with a history of injection drug use, prison stay, or unspecified hepatitis.

Chronic Hepatitis C Cases and Rates in California

Chronic-Hepatitis-C-Infections-in-California-Surveillance-Report-2018-Data-Tables.pdf

This document presents data on chronic Hepatitis C cases and rates of newly reported cases in California from 2014 to 2018. The data is stratified by various demographic factors, including gender, age, and race/ethnicity. It also includes information on cases in state prisons. The document does not delve into specific strategies, barriers, or ethical considerations related to Hepatitis C elimination. It primarily serves as a statistical overview of the disease's prevalence during the specified period. The document focuses on the number of cases reported to the California Department of Public Health, broken down by different demographics such as age, gender and race in California and California state prisons.

Chronic Hepatitis C Cases in California State Prisons

Chronic-Hepatitis-C-Infections-in-California-Surveillance-Report-2018-Data-Tables (1).pdf

This document presents data on chronic Hepatitis C cases and rates in California state prisons from 2014 to 2018. The data is stratified by age and race/ethnicity. It includes the number of cases and rates per 100,000 population for different age groups (Young Adults & Adolescents (Age 15-39), Age 15-19, Age 20-29, Age 30-39, Age 40-49, Age 50-59, Age 60+) and racial/ethnic groups (American Indian/Alaska Native, Asian/Pacific Islander, African American/Black, Hispanic/Latino, White, Other, Multiple, and Unknown). The document does not offer strategies for hepatitis C elimination, but it provides data on cases in state prisons, which is useful for anyone interested in elimination strategies. The document includes data on the total number of cases, rates per 100,000 population, and the change in rates from 2014 to 2018. This information is pertinent to understand the burden of Hepatitis C in California state prisons.

Risk Perception and Harm Reduction for Hepatitis C in California

Ohringer_et_al-2021-BMC_Public_Health.pdf

This study investigates disparities in risk perception, awareness, access, and utilization of harm reduction services among young people (15-29 years old) with newly reported hepatitis C infections in California in 2018. It aims to describe the demographics, risk behaviors, and utilization of harm reduction services among this population to support targeted HCV prevention and treatment strategies. The study used surveillance data from the California Department of Public Health to identify newly reported HCV cases and conducted interviews with patients to assess their risk perception, awareness, and access to preventive services. The findings highlight racial disparities in risk perception and access to harm reduction services, particularly among people who inject drugs (PWID). The study emphasizes the need for expanded HCV education, prevention, testing, and linkage to care in settings serving at-risk populations, including PWID and racial/ethnic minorities. The document is relevant to the query because it focuses on Hepatitis C among young people in California, and touches on aspects of prevention and treatment, while highlighting the importance of harm reduction services for at-risk populations. However, it does not specifically address elimination strategies.

Hepatitis B and C among Healthcare Workers in Africa

Hepatitis B and C virus infection among.pdf

This study is a systematic review and meta-analysis that aimed to determine the pooled prevalence of hepatitis B and C infections among healthcare workers in Africa. The review included 44 studies with a total of 17,510 healthcare workers. The pooled prevalence of hepatitis B virus infection among healthcare workers in Africa was estimated to be 6.81%, while the pooled prevalence of hepatitis C virus infection was 5.58%. The study found that one in fifteen and more than one in twenty healthcare workers are infected by HBV and HCV, respectively. The high burden of HBV and HCV infections remains a significant problem among healthcare workers in Africa. The document does not address Hepatitis C elimination strategies, but it provides important context for the prevalence of Hepatitis C in healthcare workers in Africa, which is relevant to understanding the scope of the problem that elimination efforts would need to address.

Risk Perception and Harm Reduction for Young HCV Cases

Ohringer_et_al-2021-BMC_Public_Health (1).pdf

This research article focuses on the disparities in risk perception, awareness, access, and utilization of harm reduction services among young people (ages 15-29) with newly reported Hepatitis C infections in California in 2018. It highlights that newly reported Hepatitis C virus (HCV) infections increased by 50% between 2014 and 2016, especially among those who inject drugs. The study involved enhanced surveillance by local health jurisdictions, collecting data via structured questionnaires to assess demographics, HCV risk, and service utilization. The findings indicate significant racial and ethnic disparities in pre-diagnosis HCV risk perception and access to harm reduction services. The study also notes that correctional institutions provide critical opportunities for conducting HCV prevention, education, testing, and treatment. The document emphasizes the need for expanded education, prevention, testing, and linkages to care, particularly for young people who inject drugs and non-PWID at risk for HCV infection.

HCV Risk Behaviors Among Prison Inmates

9 Prevalence of HCV Risk Behaviors Among Prison Inmates Tattooing and Injection Drug Use.pdf

The study explores the prevalence of Hepatitis C virus (HCV) risk behaviors among prison inmates, focusing on tattooing and injection drug use in Puerto Rico prisons. The study used a cross-sectional anonymous survey of sentenced inmates from 26 penal institutions in 2004. The research investigates the association between HCV infection and risk factors such as injection drug use and tattooing within correctional facilities. The study suggests that preventive interventions are required to reduce the risk of HCV transmission through unsafe tattooing and injection practices. The document addresses the importance of culturally sensitive drug treatment and education programs, including needle and syringe exchange, and voluntary HCV and HIV testing. It highlights the need for additional research to understand the dynamics of the epidemic in prisons and identify public health interventions to reduce the potential for HCV transmission from tattoos performed in this context. The study provides several additional implications for public health practices within penal institutions, and suggests that prisoner populations should be included in surveillance programs.

Meta-analysis: Risk of Hepatitis C Infection with Invasive Procedures

Meta-analysis risk of hepatitis C virus infection associated with hospital-based invasive procedures.pdf

This meta-analysis aims to understand and quantify the role of hospital-based invasive procedures on Hepatitis C virus (HCV) transmission. The study identifies healthcare settings, where invasive procedures are frequently performed, as potentially important in the transmission dynamics of blood-borne pathogens when infection control precautions are suboptimal. The study included 71 studies and found that various invasive procedures were significantly associated with HCV infection. The risk of HCV infection differed according to procedure groups, with transplantation and wound care being associated with the highest risk, while dental procedures and endoscopy were associated with the lowest risk. The study also found that the per-procedure risk tended to be higher in countries with high HCV prevalence. The document refers to WHO targets for global HCV elimination and notes that countries such as Egypt and Pakistan have engaged in elimination programs.

Chronic Hepatitis C in California: 2018 Technical Notes

2018-Chronic-HCV-Surveillance-Report-Technical-Notes (1).pdf

This document is a technical note on chronic Hepatitis C in California for 2018. It provides data sources and definitions used for reporting cases, including case definitions based on the Council of State and Territorial Epidemiologists (CSTE) criteria. The report details how newly reported cases are defined and counted, and it describes the methodology for calculating rates of newly reported cases by demographic groups and local health jurisdictions. The document also addresses data limitations, such as underreporting, missing race/ethnicity information, and the challenges of deduplication. It mentions the availability of direct-acting antivirals but does not provide details on treatment strategies. The document provides information on surveillance data and reporting practices for chronic Hepatitis C cases in California, including the definition of cases, data sources, and limitations affecting the accuracy of prevalence estimates.

Hepatitis C Knowledge Among Pregnant Women with Opioid

1 Hepatitis C Virus Knowledge Among Pregnant Women with Opioid Use Disorder..pdf

This study evaluates Hepatitis C virus (HCV) knowledge and awareness among pregnant women with opioid use disorder (OUD). A one-time survey was distributed to assess their knowledge of risk factors for HCV infection, transmission prevention strategies, hepatotoxic risk reduction, and perinatal/neonatal implications. The study found that many pregnant women with OUD have a low level of knowledge regarding HCV-related content areas, including the impact of HCV infection during pregnancy, perinatal transmission, breastfeeding, and the need for pediatric follow-up. Healthcare providers have a unique opportunity to provide HCV education and counseling during pregnancy. The document emphasizes the need to improve knowledge and awareness of HCV among pregnant women with OUD to improve prevention and treatment outcomes.

HIV and Hepatitis C Testing in Pregnancy

5 Current considerations of HIV and HCV testing and the risks of vertical transmission during pregnancy..pdf

This document discusses the current considerations of HIV and Hepatitis C virus (HCV) testing and the risks of vertical transmission during pregnancy. It emphasizes the importance of testing pregnant women for HIV and HCV to reduce the risk of vertical transmission to infants. The document notes that the risk of vertical transmission of HIV can be as high as 25%, and the odds of vertical HCV transmission are significantly higher for HIV-HCV co-infected mothers. The document highlights that approximately 30% of pregnant women are not tested for HIV during pregnancy, and another 15% to 20% receive no or minimal prenatal care, increasing the risk for potential newborn transmission. The American Congress of Obstetricians and Gynecologists (ACOG) reaffirms its recommendation for routine HIV screening for all pregnant women when they first present for prenatal care. The document also mentions that Hepatitis C is the leading cause of liver transplants. The information relevant to the query is the discussion around testing and prevention of vertical transmission of Hepatitis C.

Liver Disease Knowledge and Acceptability Among People Who Inject Drugs

Hepatitis C virus testing, for people who are homeless in Sydney, Australia The LiveRLife homelessness study.pdf

This study aimed to assess factors associated with baseline knowledge of HCV and liver disease, acceptability of transient elastography (TE) assessment, and willingness and intent to receive HCV treatment among people who inject drugs (PWID) participating in a liver health promotion campaign. The LiverLife campaign involved three phases: campaign resource development, campaign resource testing, and campaign implementation. Participants were enrolled in an observational cohort study with recruitment at four clinics in Australia between May and October 2014. The study found that liver disease and HCV knowledge was moderate, and acceptability of TE by PWID was high. The study did not specifically address elimination strategies but focused on knowledge, attitudes, and willingness to receive treatment among PWID.

Injecting Risk Behaviours Among People in an Australian Prison

Longitudinal injecting risk behaviours among people with a history of IDU in Australian Prison setting.pdf

This study investigates injecting risk behaviors among people with a history of injecting drug use in an Australian prison setting. It aims to identify factors associated with changes in injecting drug use patterns before, during, and after incarceration. The study highlights the need for improved HCV prevention strategies in prisons, including improved needle/syringe access and scale-up of HCV therapy. The study does not explicitly discuss specific strategies for Hepatitis C elimination, barriers to elimination, cost implications, the role of surveillance, or ethical considerations. It focuses on PWID in prison and the need for prevention strategies and scaling up of HCV therapy to reduce transmission.

Prevalence of Hepatitis B and C in Indian Prisons

Prevalence of Hepatitis B and C Among Prison Inmates in India.pdf

This study is a systematic review and meta-analysis that estimates the pooled prevalence of hepatitis B and C among prison inmates in India. The review included cross-sectional studies published until June 2020. Data was obtained from databases like PubMed, Embase, and Google Scholar. The study found a high prevalence of hepatitis B and C in prisoners, which is a cause for concern. Specifically, the study indicates that prisoners are a vulnerable population for hepatitis B and C infections. The analysis also considered factors such as injection drug use and unprotected sexual intercourse among prisoners. The study does not directly address strategies for hepatitis C elimination but rather focuses on the prevalence of the disease within the prison population in India. It highlights the need for appropriate and effective interventions to reduce the transmission of hepatitis B and C in prisons.

Monitoring Disparities in HIV, STIs, and Viral Hepatitis

Using Sexual Orientation and Gender Identity to Monitor Disparities in HIV, Sexually Transmitted Infections, and Viral Hepatitis..pdf

This document discusses the importance of using sexual orientation and gender identity (SOGI) data to monitor disparities in HIV, sexually transmitted infections (STIs), and viral hepatitis, including Hepatitis C. It highlights that HIV, syphilis, and gonorrhea incidence are higher among male individuals, while Hepatitis B and C are more common among male individuals. The document emphasizes the need for jurisdictions to include SOGI data with infectious disease reporting to reduce disparities. The study uses data from a federally qualified health center in Los Angeles to examine the association between incidence proportions and SOGI among people living with HIV and HIV-negative patients. The document also mentions efforts to improve SOGI data collection to monitor infectious disease disparities. The document is related to Hepatitis C because it studies the incidence of Hepatitis C among different gender and sexual orientation groups.

Sexual Transmission of Hepatitis C Virus in MSM

7 Lack of evidence of sexual transmission of hepatitis C virus in a prospective cohort study of men who have sex with men..pdf

This study investigates the prevalence and incidence of Hepatitis C Virus (HCV) infection among men who have sex with men (MSM) participating in the Omega Cohort Study. The study found an association between injection drug use and HCV infection. The study involved consenting men who attended a follow-up visit to the ongoing Omega Cohort Study and tested for HCV. The seroconverter was an active injection drug user who reported needle sharing. The study also suggests that preventive counseling during follow-up may have reduced HCV incidence among IDUs. The study provides insights into HCV prevalence and risk factors among MSM, which can inform targeted prevention and intervention efforts.

Monitoring Hepatitis C Care Cascade in California, 2014-2015

Abstract_ Using Electronic Laboratory Data to Monitor the Hepatitis C Care Cascade in California, 2014-2015 (2016 CSTE Annual Conference).pdf

This document presents an analysis of the Hepatitis C care cascade in California from 2014-2015 using electronic laboratory data. It describes how clinicians use nucleic acid testing (NAT) to diagnose current hepatitis C virus (HCV) infection, inform HCV treatment decisions, and monitor treatment response. The analysis uses positive HCV NATs to examine the HCV care cascade in California. The study found that one-third of individuals with a positive anti-HCV received any positive NAT (HCV diagnostic testing), and non-incarcerated young adults were less likely than their older counterparts to receive any positive NAT after a positive anti-HCV test. The document suggests a need for improved diagnostic testing among all age groups, including non-incarcerated young adults in California. The document is relevant to the query as it discusses the diagnosis of Hepatitis C, but it does not provide information about elimination strategies.

Patient Costs and Outcomes Associated with Hepatitis

OVHPData_HepHospitalizations.pdf

This document discusses the patient costs, characteristics, and outcomes associated with hospitalizations related to hepatitis B and hepatitis C in California from 2002-2011. It highlights that hepatitis B virus (HBV) and hepatitis C virus (HCV) are the most prevalent bloodborne infections in the United States. The study collected data from California hospitals and analyzed patient discharge data to determine the proportion of hepatitis-related hospitalizations attributable to patients with a history of HBV or HCV infection. The document reports on demographics, HBV and HCV complications, charges and length of hospitalization, and changes in hospitalizations for severe complications from 2002 to 2011. The study also notes that HBV and HCV infections were major burdens on California's healthcare system during 2002-2011, with over 125,000 HBV-infected and HCV-infected patients, over 400,000 hepatitis-related hospitalizations, and over $26 billion in charges. It is noted that the burden is expected to grow, especially among persons with chronic HCV infection in the 1945-1965 birth cohort. This document includes information on the diagnosis of Hepatitis C.

Chronic Hepatitis C Epidemiology in California

HCVSurvRpt_Figures_2018.pptx

This document is a slide set notes from the California Department of Public Health, STD Control Branch, focusing on chronic Hepatitis C infections in California, with cases newly reported through 2018. The data presented describes cumulative cases of chronic hepatitis C newly reported to CDPH from 1994-2018. The document highlights findings for the most recent five-year period (2014-2018) to minimize the chance that an increase in case reports is due to the initiation of statewide electronic laboratory reporting (ELR) and auto processing of ELR hepatitis C data in October and December 2013, respectively. The data presented in these slides does not measure prevalence or incidence of chronic hepatitis C virus infections in California. The document provides information on the rates and numbers of newly reported cases, including those in state prisons, and analyzes the data by resolution status, age group, and race/ethnicity. It also discusses changes in case definitions and reporting practices over time. The document is relevant to understanding the epidemiology of Hepatitis C in California, particularly in state prisons, but does not explicitly discuss strategies for Hepatitis C elimination.

Prevalence of Hepatitis C and B in LGBT Populations

The prevalence of hepatitis C and hepatitis B in lesbian, gay, bisexual and transgender populations.pdf

This systematic review and meta-analysis investigates the prevalence of hepatitis C and hepatitis B in lesbian, gay, bisexual, and transgender (LGBT) populations. The study analyzes data from multiple databases between April 2000 and July 2021 to estimate the pooled prevalence of HBV and HCV infections worldwide. The research highlights that transgender people face numerous health, social, and medical risks, including sexually transmitted and blood-borne diseases such as hepatitis C and B. These populations also encounter problems such as lack of proper access to health services, social stigma, discrimination, and mental health challenges, which contribute to risky behaviors. The study concludes that the prevalence of HBV and HCV infections is higher in transgender people compared to the general population, emphasizing the need for targeted interventions and healthcare policies. The document provides an overview of the prevalence of hepatitis C in LGBT populations.

Alcohol Consumption by Patients Considering HCV Treatment

An empirical study of alcohol consumption by patients considering HCV treatment.pdf

This study investigates alcohol consumption patterns among patients with Hepatitis C virus (HCV) undergoing treatment. It examines the relationship between alcohol use and HCV, focusing on patients attending university and VA liver clinics. The study aims to compare alcohol consumption patterns among patients with and without alcohol use disorders, considering current and lifetime alcohol use histories. The research does not directly address strategies for Hepatitis C elimination but highlights the impact of alcohol on HCV treatment outcomes. The study enrolled 309 patients and divided them into three groups based on alcohol use histories: current, former, and never users. The document concludes that the study's findings indicate that patients who have achieved sustained abstinence from alcohol, whether or not they have a past alcohol use disorder history, have behavioral treatment-related risks that are similar to those of patients without a history of alcohol use, indicating that they deserve equal consideration for HCV treatment. The document emphasizes the importance of clinicians paying attention to alcohol consumption in patients with HCV due to the known interactive effects of alcohol and HCV in damaging the liver.

Psychometric Evaluation of Hepatitis C Virus Patient-Reported Outcomes

Psychometric evaluation of the hepatitis C virus patient-reported outcomes.pdf

This document describes a study focused on the psychometric evaluation of the Hepatitis C Virus Patient-Reported Outcomes (HCV-PRO) instrument. The study aims to assess the validity, responsiveness, and identification of the minimally important difference (MID) of the HCV-PRO in a phase 2 clinical trial. The HCV-PRO is designed to measure function and well-being in adults with chronic HCV infections. The study involved patients receiving direct-acting antivirals (DAAs) or peg-interferon/ribavirin. The document discusses the development process of the HCV-PRO, including item generation, expert reviews, and patient interviews. It also presents results on the instrument's reliability, validity, and responsiveness to changes in health status. The document focuses on the development and validation of a tool to measure the impact of HCV treatment on patient-reported outcomes, rather than strategies for Hepatitis C elimination.

Quality of Life in HIV/HCV Co-infected Patients

Assessment of factors associated with the quality of life of patients living with HIVHCV co-infection.pdf

This study investigates the factors affecting the quality of life (QoL) in patients co-infected with HIV and Hepatitis C (HCV). It examines the sociodemographic, HIV-related, and psychological symptoms associated with QoL in these patients. The study population consisted of 248 HIV/HCV co-infected individuals. The research identifies that co-infected patients reported significantly lower QoL in various domains. Factors such as psychological distress, employment status, and education were found to be associated with QoL. The study highlights the importance of addressing psychological symptoms and providing effective management to improve the overall well-being of individuals co-infected with HIV and HCV. The findings emphasize the need for tailored interventions to improve the QoL in this population, particularly focusing on mental health and social support.

Chronic Hepatitis B in California: 2016 Technical Notes

2016-Chronic-Viral-Hep-B-Surv-Technical-Notes.pdf

This document is a technical note from the California Department of Public Health (CDPH) concerning chronic Hepatitis B in California for the year 2016. It details the data sources and definitions used for surveillance of chronic Hepatitis B infections, including case definitions, reporting criteria, and data limitations. The report describes how data on chronic Hepatitis B infections are collected from various sources, including local health jurisdictions (LHJs), laboratories, and healthcare providers. It also explains how duplicate case reports are handled to ensure accurate counts. The document further defines key terms such as "newly reported cases," describes how rates are calculated, and discusses the reporting of cases by local health jurisdictions, age, gender, and race/ethnicity. Data limitations that affect the accuracy of chronic Hepatitis B surveillance data are also mentioned, including issues with underreporting, missing information, and variations in data collection methods.

Factors Associated with Hepatitis C Among HIV-Infected Women

2 the Women_s Interagency HIV Study.pdf

This study investigates factors associated with prevalent Hepatitis C virus (HCV) infection among HIV-infected women with no reported history of injection drug use (IDU). The research was conducted within the Women's Interagency HIV Study (WIHS) from October 1994 to November 2002. Clinical and demographic factors were assessed using multivariate logistic regression models, controlling for blood transfusion and IDU history. The study found that among women without a history of IDU, sex with an IDU male was independently associated with HCV positivity. The study suggests that sexual transmission may be an important mode of HCV transmission for high-risk women. The study does not address any strategies for Hepatitis C elimination, barriers to elimination, cost implications, the role of surveillance, treatment options, prevention strategies, diagnosis and linkage to care, or ethical considerations related to Hepatitis C elimination.

Desired Social Distance From People Who Have Hepatitis C

Desired Social Distance From People Who Have Hepatitis C Virus00000000.pdf

This research paper explores the desired social distance from people who have Hepatitis C virus (HCV) among staff working in healthcare, dentistry, drug treatment, and tattoo/body piercing settings. The study assesses staff comfort with varying levels of intimacy with people who have HCV and examines how contact and knowledge of HCV affect the desire for social distance. Data were collected from a sample of 82 individuals in the Pacific Northwest region of the United States. The study found that staff desire social distance from persons with HCV, but contact of certain types reduces this desire. The findings have implications for people employed in these fields and highlight the need to dispel myths and reduce fear among staff serving persons with HCV. The study does not focus on strategies, barriers, populations, costs, surveillance, treatment options, prevention strategies, diagnosis/linkage to care, or ethical considerations related to Hepatitis C elimination.

Development and Evaluation of the Hepatitis C Virus Instrument

Development and initial psychometric evaluation of the hepatitis C virus-patient-reported outcomes (HCV-PRO) instrument.pdf

The article focuses on the development and initial psychometric evaluation of the hepatitis C virus patient-reported outcomes (HCV-PRO) instrument. The study aimed to develop a new patient self-report tool to assess patients' function and well-being, reflecting both HCV disease and treatment burdens. Methods involved qualitative phases, including literature review and patient interviews, with initial psychometric testing in adult HCV patients. The study provides initial evidence that the HCV-PRO can yield reliable and valid measurements of the effects of HCV and its treatment on the well-being and function of HCV-infected patients. The document does not discuss strategies, barriers, populations, costs, surveillance, treatment options, prevention strategies, diagnosis, or ethical considerations related to Hepatitis C elimination. The article primarily concentrates on creating and validating a tool for measuring the impact of HCV on patients' lives.

Harm Reduction: Effects of Alcohol Reduction on Health

Harm reduction-a systematic review on effects of alcohol reduction on.pdf

This document is a systematic review focusing on the effects of alcohol reduction on physical and mental health symptoms. It examines a range of studies to assess how reducing alcohol intake can improve various health outcomes. The review covers topics such as alcohol-related injuries, liver disease, cardiovascular health, and mental health. It also touches on the socioeconomic benefits of alcohol reduction, such as reduced healthcare costs and improved workforce productivity. The document mentions individuals with heightened vulnerability, such as those with hepatitis C virus infection, as benefiting from alcohol reduction. However, the document primarily concerns itself with alcohol-related health outcomes and does not contain information related to Hepatitis C elimination.

Chronic Hepatitis B Infections in California, 2016

HBVSurvRpt_Graphs.pdf

The document is a slide set regarding chronic Hepatitis B infections in California. The data presented describes cumulative cases of chronic Hepatitis B newly reported to CDPH from 1989-2016. Findings from 2012-2016 are highlighted. The data presented in these slides do not measure prevalence or incidence of chronic Hepatitis B virus infections in California due to the asymptomatic nature of these infections, varied levels of completeness of surveillance reporting, and because it remains unknown how many of the cases described are currently living. Percentages, rather than rates, were used to describe newly reported cases by race/ethnicity, since race/ethnicity information was not reported for approximately 60 percent of chronic hepatitis B cases in 2016. Information regarding identification of Asian/Pacific Islander (API) individuals within specific API groups was available for approximately 17 percent of hepatitis B cases reported as API. The document presents data on the rates of newly reported cases by gender, age, race/ethnicity, and local health jurisdiction.

Chronic Hepatitis B in California 2016 Executive Summary

2016-Chronic-Viral-Hep-B-Surveillance-Exec-Summary.pdf

This document is an executive summary focusing on chronic Hepatitis B in California in 2016. It provides an overview of the burden of Hepatitis B infections, noting that in 2016, 9,778 new cases were reported. The document highlights demographic characteristics, such as the overrepresentation of Asian/Pacific Islander (API) persons among chronic Hepatitis B cases, and geographic distribution, with high rates in Los Angeles, San Francisco, and Sacramento counties. It also discusses trends in infection rates among different age groups and genders. The summary aims to inform efforts to reduce Hepatitis B transmission and limit the progression of viral hepatitis-related liver disease. The document does not contain any information about Hepatitis C elimination.

Medical Device Failures Report

Executive Summary

A pervasive issue in the **manufacture of medical devices** is the marketing and distribution of unapproved new drugs and devices, often with misleading claims about their efficacy, particularly in treating conditions like COVID-19. This includes instances where products are sold directly to consumers for at-home use without the requisite FDA approvals, clearances, or authorizations. These actions violate the Federal Food, Drug, and Cosmetic Act (FD&C Act) and the Public Health Service Act (PHS Act), leading to products being deemed adulterated and misbranded. Violations of Current Good Manufacturing Practice (CGMP) regulations are also common, encompassing a range of failures such as inadequate facility design, insufficient environmental monitoring, unreliable laboratory records, and a failure of the quality control unit to adequately exercise its authority. Other CGMP violations include failures in aseptic processing, such as poor aseptic behavior by operators, use of non-integral cleanroom materials, and inadequate cleanroom design, leading to a high risk of contamination of sterile drug products. Failures in process validation, stability testing, and complaint handling are also observed, alongside inadequate investigation of out-of-specification (OOS) results, poor facility maintenance, and insufficient cleaning procedures. **Data integrity issues** are a recurring theme, with instances of falsified laboratory data, failure to maintain accurate device history records, and inadequate controls over computer systems. These failures compromise the reliability and integrity of study data, impacting the safety and efficacy of medical devices. Many firms also demonstrate inadequate handling of medical device reports (MDRs) and deficiencies in MDR procedures, along with failure to report adverse events and device malfunctions in a timely manner. **Quality control failures** are evident in instances of inadequate testing of components, failure to validate manufacturing processes, and lack of proper cleaning and maintenance of equipment. In some cases, manufacturers have been found to have substituted ingredients, such as methanol for ethanol in hand sanitizers, leading to adulteration and potential harm to consumers. These failures underscore the importance of robust quality control systems and adherence to manufacturing standards to ensure the safety and efficacy of medical devices. This is further exacerbated by a lack of premarket notification or approval for significant device modifications, which could significantly affect the safety or effectiveness of the devices. Across the industry, these failures often stem from inadequate oversight and control over manufacturing processes, a lack of comprehensive investigations into discrepancies, and insufficient corrective actions to address the root causes of the violations. Regulatory actions for non-compliance include seizure, injunction, and civil money penalties. Addressing these failures requires comprehensive risk assessments, detailed remediation plans, and improved practices, often with the assistance of third-party consultants, to ensure ongoing CGMP compliance and prevent future violations. A trend shows a repeat of similar CGMP deviations, indicating that executive management oversight and control over the manufacture of drugs is inadequate.

Medical Device Failures Report

Tags Summary

Regulatory violations are the most prevalent issue, substantially exceeding other categories. **FDA compliance** and **manufacturing failures** also represent significant concerns. **Device defects** are notable, while issues specifically related to **inpatient** and **home medical devices** are much less frequent. **CPAP** related issues appear to be an anomaly due to their extremely low occurrence.

Tag Frequency



Document Relevancy



Questions And Answers

1. How did the company's response to the FDA address the identified manufacturing failures?



2. What impact did the manufacturing failures described in this document have on the safety or efficacy of the medical devices?



3. What specific manufacturing process failures are described in this document?



4. What corrective actions did the company take to address the manufacturing failures outlined in this document?



5. What specific types of medical devices are associated with the manufacturing failures described in this document?



6. What were the consequences of the manufacturing failures described in this document, such as recalls, adverse events, or regulatory penalties?



7. What internal investigations or audits were conducted by the company to identify the root causes of the manufacturing failures described in this document?



8. What role did quality control or quality assurance systems play in the manufacturing failures described in this document?



9. What sections of the FD&C Act or related regulations were violated due to manufacturing failures, as detailed in this document?



Top Matches

FDA Warning Letter to Five Leaf Pet Botanicals

five-leaf-pet-botanicals-inc-661290-06222023.txt

This warning letter from the FDA to Five Leaf Pet Botanicals, Inc. addresses the marketing of unapproved new animal drug products, including 'Canine Heart Tonic', 'Hawthorne Tincture', 'Hepara-Cleanse', and 'Rena-Cleanse'. These products are being sold for the treatment of diseases in animals without the required FDA approval, violating sections of the Federal Food Drug and Cosmetic Act (FD&C Act). The FDA reviewed the company's websites and found claims that the products are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in animals. The letter states that the products are unsafe and adulterated, and the company is required to take prompt action to correct the violations and prevent their recurrence. The company's marketing of unapproved animal drugs violates the FD&C Act.

FDA/FTC Warning Letter to Genesis 2 Church

genesis-2-church-606459-04082020.txt

This document is a warning letter issued by the FDA and FTC to Genesis 2 Church regarding the sale and marketing of Miracle Mineral Solution (MMS) as a treatment for COVID-19. The letter states that MMS is an unapproved new drug and a misbranded drug in violation of the Federal Food, Drug, and Cosmetic Act (FD&C Act). It also addresses the misleading claims made by the church regarding the product's safety and effectiveness in treating COVID-19. The FDA and FTC request that Genesis 2 Church take immediate action to cease the sale of MMS and correct the violations cited in the letter. Failure to do so may result in legal action, including seizure and injunction. The letter also mentions that the church will be added to a published list of firms that have received warning letters from the FDA concerning the sale of COVID-19-related products. The document emphasizes the FDA's concern about the dangerous and potentially life-threatening side effects of MMS and advises consumers not to purchase or use products that have not been approved, cleared, or authorized by the FDA. The warning highlights the regulatory agencies' efforts to protect consumers from unproven and potentially harmful treatments during the COVID-19 pandemic.

FDA Warning Letter to Zerocig dba Aristo

zerocig-dba-aristo-electronic-cigars-634686-06032022.txt

This warning letter from the FDA to Zerocig dba Aristo Electronic Cigars addresses violations of the Federal Food, Drug, and Cosmetic Act (FD&C Act) regarding the manufacturing and sale of e-liquid products without the required marketing authorization. The FDA determined that the e-liquid products are new tobacco products that were not commercially marketed in the United States as of February 15, 2007. These products are adulterated and misbranded because they do not have an FDA marketing authorization order in effect. The letter emphasizes that marketing new tobacco products without premarket authorization is unlawful and subject to enforcement action. The company is urged to review its websites and other advertising to ensure compliance with the FD&C Act and FDA regulations. Failure to address the violations may lead to regulatory action, including civil money penalties, seizure, and/or injunction. The company must provide a written response within 15 working days detailing actions taken to address the violations and ensure compliance. The document is related to regulatory violations.

FDA Warning Letter to 1st Phorm LLC

1st-phorm-llc-613715-07292021.txt

This document is a warning letter from the FDA to 1st Phorm LLC regarding violations of the Federal Food, Drug, and Cosmetic Act (the Act). The FDA found that the company's Whole Heart Cardiovascular Health Formula and Full-Mega Omega-3 Fish Oil products are unapproved new drugs and misbranded drugs because they are intended for use in the cure, mitigation, treatment, or prevention of disease without prior FDA approval. Additionally, the company's MegaWatt V2, Thyro-Drive, 1-Db Overdrive Fastpack, 1-Db Goddess, and 1-Db Overdrive & Thyro-Drive products are adulterated dietary supplements because they contain hordenine, a new dietary ingredient for which the company has not provided adequate safety information. The warning letter notifies the company of the violations and provides an opportunity to address them. The FDA requests a written response within 15 working days outlining the steps taken to address the violations and prevent their recurrence. Failure to adequately address the matter may result in legal action, including seizure and injunction. The document is relevant to the query because it describes failures related to unapproved new drugs and adulterated dietary supplements.

FDA Warning Letter to 21st Century LaserMed

21st-century-lasermed-pain-institute-dba-create-wellness-clinics-607654-07212020.txt

This document is a warning letter issued by the FDA and FTC to 21st Century LaserMed Pain Institute d/b/a Create Wellness Clinics. The letter addresses the company's marketing and sale of unapproved and misbranded products, including stem cell products, exosome products, immune support bundles, and COVID-19 test kits, all claimed to mitigate, prevent, treat, diagnose, or cure COVID-19. The FDA and FTC found that the company's products violate the Federal Food, Drug, and Cosmetic Act (FD&C Act) and the Public Health Service Act (PHS Act) because they are being marketed without proper approval, licensure, or authorization. The letter details specific claims made by the company on its websites and YouTube channel that mislead consumers about the safety and efficacy of these products. The company is directed to take immediate action to cease the sale of these products and correct the violations. Failure to do so may result in legal action, including seizure and injunction. The document is relevant to the query because it outlines failures in the marketing and sale of medical-related products, specifically concerning regulatory compliance and unapproved claims related to COVID-19.

FDA Warning Letter to 21st Century Scientific

21st-century-scientific-inc-566834-05132019.txt

This warning letter addresses several violations related to the manufacturing and reporting of medical devices by 21st Century Scientific Inc. The FDA inspection revealed that the company's Bounder powered wheelchairs and associated seating systems were being marketed with modifications that added functionality without proper notification or clearance. These modifications, such as power recline and tilt systems, could significantly affect the safety or effectiveness of the devices. Additionally, the company failed to adequately report adverse events and maintain written MDR procedures, leading to further violations of FDA regulations. The key issues include the failure to submit a new 510(k) premarket notification for significant device modifications, inadequate handling of medical device reports (MDRs), and deficiencies in the firm's MDR procedures. The FDA's concerns revolve around the potential risks to users due to the unapproved modifications and the lack of proper reporting and investigation of adverse events. The company's response to the FDA's findings was deemed inadequate, as it lacked evidence of systemic corrective actions and necessary documentation. The document is about manufacturing failures of medical devices.

FDA Warning Letter Regarding Unapproved and Misbranded Drugs

247rxpillin-615313-08312021.txt

This document is a warning letter from the FDA to 247RX-PILL, an online vendor, regarding the sale of unapproved and misbranded drugs, including opioids like tramadol and benzodiazepines like clonazepam. The FDA observed that 247RX-PILL introduces these drugs into interstate commerce, violating sections of the Federal Food, Drug, and Cosmetic Act (FD&C Act). The FDA emphasizes the risks associated with purchasing unapproved drugs, which may be contaminated, counterfeit, or contain incorrect ingredients. The letter requests that 247RX-PILL cease offering these drugs for sale and respond with corrective actions. The document highlights the FDA's concerns about the easy availability of opioids and benzodiazepines via the internet and the potential harm to U.S. consumers. The document is relevant to the query because it involves regulatory violations related to drug sales, safety concerns, and potential harm to consumers.

FDA Warning Letter to 4E Global on Hand Sanitizers

4e-global-sapi-de-cv-608940-10232020.txt

This warning letter from the FDA to 4E Global, S.A.P.I. de C.V. addresses significant violations related to the manufacture of hand sanitizers. FDA testing revealed that the company's blumen Advanced Instant Hand Sanitizer Clear Ethyl Alcohol 70% and blumen Clear Advanced Hand Sanitizer Extra Soft products were adulterated due to the substitution of ethanol with methanol. This substitution violates section 501(d)(2) of the FD&C Act. The agency also found that the quality assurance within the facility was not functioning according to Current Good Manufacturing Practice (CGMP) requirements, violating section 501(a)(2)(B) of the FD&C Act. The products are also considered unapproved new drugs and are misbranded under several sections of the FD&C Act, including 505(a), 502(j), 502(a), 502(e), 502(f)(2), and 502(ee). The company agreed to recall the affected products and is engaging a CGMP consultant to address the violations. The FDA has placed all drugs and drug products manufactured by the firm on Import Alert 66-78. The key issue is the substitution of ethanol with methanol in hand sanitizers, leading to adulteration, misbranding, and violations of CGMP requirements.

FDA Warning Letter on Unapproved COVID-19 Treatments

4nrxmd-606115-05132020.txt

This document is a warning letter from the FDA to 4nrx.md regarding the unlawful sale of unapproved and misbranded drugs related to Coronavirus Disease 2019 (COVID-19) to United States consumers over the Internet. The FDA reviewed the website www.4nrx.md and found that it offers drug products for sale in the United States intended to mitigate, prevent, treat, diagnose, or cure COVID-19, which are unapproved new drugs sold in violation of section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) and misbranded drugs under section 502 of the FD&C Act. The website lists lopinavir + ritonavir, hydroxychloroquine sulfate, and ribavirin under the heading “Coronavirus Treatments.” The FDA notes that while there are FDA-approved versions of these drugs, the versions offered by www.4nrx.md do not have approved drug applications. The letter also states that no drug has yet been approved by the FDA for use in the prevention, diagnosis, treatment, mitigation, or cure of COVID-19. The FDA requests that 4nrx.md take immediate action to cease the sale of such unapproved and unauthorized products and correct the violations cited in the letter. The company is responsible for ensuring that the products it sells comply with the FD&C Act and FDA's implementing regulations. The letter advises the company to review its websites, product labels, and other labeling and promotional materials to ensure that it is not misleadingly representing its products as safe and effective for a COVID-19-related use for which they have not been approved by FDA and that it does not make claims that misbrand the products in violation of the FD&C Act. The document is related to the query because it discusses failures in the context of selling drugs for the treatment of a disease.

FDA Warning Letter to Viatrexx on CGMP Violations

8046255-canada-inc-dba-viatrexx-596178-06112020.txt

This warning letter from the FDA to 8046255 Canada Inc. DBA Viatrexx outlines significant violations of current good manufacturing practice (CGMP) regulations for finished pharmaceuticals. The FDA inspected the drug manufacturing facility and found that the methods, facilities, and controls for manufacturing, processing, packing, or holding do not conform to CGMP, leading to adulterated drug products. The company also manufactured and distributed unapproved new drugs, specifically injectable homeopathic products, which pose risks of serious harm to users. The violations include failures in aseptic manufacturing processes, such as inadequate validation, use of unsuitable filters, poor aseptic techniques, and failure to ensure proper sterilization processes. The company's corrective actions were deemed insufficient, and the FDA required a comprehensive risk assessment, detailed remediation plan, and improved practices. The company violated sections of the FD&C Act and now faces potential import restrictions and withholding of new drug application approvals. The key issue is the failure to adhere to CGMP regulations in the manufacturing of sterile injectable homeopathic drug products, posing significant risks to patient safety.

FDA Warning Letter to AAA Cosmetica on Hand Sanitizer

aaa-cosmetica-sa-de-cv-609083-02032021.txt

This document is a warning letter from the FDA to AAA Cosmetica, SA de CV, a human drug manufacturer, regarding significant violations related to the manufacture of bio aaa ADVANCE HAND SANITIZER. The FDA's laboratory testing revealed that the hand sanitizer, labeled to contain 70% ethanol, was adulterated with methanol, a toxic substance. This substitution violates several sections of the Federal Food, Drug, and Cosmetic (FD&C) Act, rendering the product adulterated, an unapproved new drug, and misbranded. The FDA also found that the company's quality assurance systems were not functioning according to Current Good Manufacturing Practice (CGMP) requirements. The company initiated a voluntary recall of the product and proposed corrective actions, but the FDA found these actions incomplete and insufficient to address the underlying issues. The FDA recommended engaging a consultant to evaluate the company's operations and assist in meeting CGMP requirements. The letter also details unapproved new drug and misbranding violations, as the product did not conform to the relevant tentative final monograph (TFM) and contained undeclared methanol. The consequences of these violations included the product's detention at the border and its placement on Import Alert 66-78. The document emphasizes the need for the company to conduct a thorough investigation, implement comprehensive corrective actions, and ensure ongoing compliance with CGMP regulations to resume manufacturing drugs for the U.S. market. The FDA's concerns center on the substitution of ethanol with methanol, inadequate quality control, and misbranding of the hand sanitizer, which pose significant safety risks to consumers.

FDA Warning Letter to Abbott on i-STAT cTnI

abbott-point-care-canada-limited-640946-11082022.txt

This document is a warning letter from the FDA to Abbott Point of Care Canada Limited regarding violations of the Federal Food, Drug, and Cosmetic Act (FD&C Act) related to the i-STAT cTnI Test. The FDA conducted an inspection and determined that the company made significant design changes to the i-STAT cTnI cartridge without proper premarket notification or approval. These changes included alterations to materials and processes, which could impact the accuracy and safety of the device. The FDA also found that the company's quality control procedures were inadequate, particularly in assessing the cumulative effect of design changes and maintaining original design records. The letter outlines specific violations of the FD&C Act and the Quality System regulation, and requests prompt corrective action from the company. The FDA emphasizes that failure to address these violations may result in further regulatory action. The document emphasizes the importance of adhering to FDA regulations and ensuring the safety and efficacy of medical devices, particularly regarding design changes and quality control processes.

FDA Warning Letter to Abington Memorial Hospital

abington-memorial-hospital-irc-576854-06242019.txt

This warning letter from the FDA to Abington Memorial Hospital outlines several violations of 21 CFR Part 56 related to the operation of the hospital's Institutional Review Board (IRB). The FDA conducted an inspection and found that the IRB failed to review proposed research at convened meetings with a majority of members present, including at least one member whose primary concern is in non-scientific areas. Additionally, the IRB failed to prepare and maintain adequate documentation of its activities, including discrepancies in meeting minutes and insufficient documentation of study approvals. The letter requests the hospital to provide written documentation of the actions they will take to correct these violations and prevent recurrence. The FDA emphasizes that failure to address these issues could result in regulatory action. The violations relate to the IRB's oversight of clinical studies, particularly those involving biologics and significant risk devices, highlighting the importance of proper review and documentation to ensure patient safety and regulatory compliance.

FDA Warning Letter to Abiomed on Impella Devices

abiomed-inc-663150-09192023.txt

This document is a warning letter from the FDA to Abiomed Inc. regarding violations of the Federal Food, Drug, and Cosmetic Act (FD&C Act) and related regulations. The violations stem from issues with the manufacture and reporting of medical device failures, specifically concerning the Impella series of heart pumps and the Impella Connect System. The FDA found that Abiomed failed to adequately address nonconforming products, verify corrective actions, and report adverse events and device malfunctions in a timely manner. The warning letter details specific instances of manufacturing failures, such as purge sidearm leaks, yellow luer failures, and software bugs, and their potential impact on patient safety. It also highlights the company's failure to conduct thorough health hazard evaluations and initiate recalls when necessary. The FDA found that Abiomed's quality control and assurance systems were inadequate, leading to the distribution of adulterated and misbranded devices. The company's responses to the FDA's concerns were often deemed insufficient, as they failed to fully address the systemic issues and provide adequate documentation of corrective actions. The document is relevant to the query because it details common manufacturing failures in medical devices, their impact on patient safety and regulatory compliance, and the corrective actions required to address them. The Impella Connect System lacked premarket approval, and the company failed to report medical device events and corrections/removals.

Warning Letter on Manufacturing Violations at Abraxis Bioscience

abraxis-bioscience-llc-633713-10312022.txt

This warning letter addresses significant violations of Current Good Manufacturing Practice (CGMP) regulations at Abraxis Bioscience, LLC, specifically regarding the manufacturing of the drug product Abraxane. The FDA inspection revealed failures in thoroughly investigating discrepancies, implementing corrective actions, and maintaining control over aseptic processing operations. Multiple media fill failures occurred, indicating serious non-sterility risks. Investigations into these failures were inadequate, lacking rigor in determining root causes and the scope of impact. The company's responses, including batch rejections and suspension of operations, were deemed insufficient due to recurring contamination incidents. The FDA requested a comprehensive risk assessment, remediation plan, and independent assessment of the company's deviation investigation system. The company was also asked to conduct a retrospective evaluation of investigations and failure modes related to the aseptic processing operation. The FDA recommends engaging a consultant to assist in meeting CGMP requirements. The key issue is the failure to maintain a state of control in aseptic operations, leading to recurring contamination and potential risks to product sterility.

FDA Warning Letter to Absara Cosmetics

absara-cosmetics-sapi-de-cv-612455-02182021.txt

This document is a warning letter from the FDA to Absara Cosmetics regarding the adulteration of their FRAGRANCE FREE VLANC + PLUR HAND SANITIZER. FDA testing revealed that the product, labeled to contain 70% alcohol, only contained 58%. The FDA has determined that the hand sanitizer drug product is adulterated under section 501(c) of the FD&C Act because the active ingredient, ethanol, is present at levels lower than declared on the label. Furthermore, it is adulterated under section 501(a)(2)(B) due to quality assurance failures. The company's investigation into the subpotency was deemed inadequate, and their test methods lacked validation. The letter requests a detailed investigation, lists of materials and batches, batch records, and test methods. The FDA recommends engaging a CGMP consultant and notes that all drugs from the firm are on Import Alert 66-78. The key manufacturing failure highlighted in this document is the subpotency of the hand sanitizer, indicating a failure in quality control and adherence to CGMP requirements.

FDA Warning Letter to Absolute Vapor Lounge

absolute-vapor-lounge-llc-623339-12162021.txt

This document is a warning letter from the FDA to Absolute Vapor Lounge, LLC, concerning violations of the Federal Food, Drug, and Cosmetic Act (FD&C Act) related to their e-liquid products. The FDA determined that the company manufactures and distributes e-liquid products without the required premarket authorization, making them adulterated and misbranded. The letter specifies that these products are new tobacco products that were not commercially marketed in the United States as of February 15, 2007, and lack the necessary FDA marketing authorization. The FDA also determined that the company failed to submit reports under section 905(j) of the FD&C Act. The letter instructs Absolute Vapor Lounge, LLC to respond within 15 working days, detailing actions taken to address the violations and ensure compliance with the FD&C Act. The company faces potential regulatory action, including civil money penalties, seizure, and/or injunction if the violations are not addressed. The warning letter emphasizes the company's responsibility to comply with all applicable provisions of the FD&C Act and FDA regulations. The document is related to the query because it discusses regulatory violations.

FDA Warning Letter to Accu Bio-Chem Laboratories

accu-bio-chem-laboratories-619450-02242022.txt

This warning letter from the FDA to Accu Bio-Chem Laboratories details significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. The FDA inspected the contract testing laboratory and found failures in investigating out-of-specification (OOS) results, not establishing and documenting the accuracy of test methods, and not having appropriate controls over computer systems. The firm's responses to the FDA's findings were deemed inadequate, as they did not provide a retrospective review of OOS results or a comprehensive assessment of data systems. The FDA recommended engaging a consultant to assist in meeting CGMP requirements and warned that failure to address the violations could result in regulatory or legal action. The violations are related to testing OTC drug products and ensuring the quality and reliability of testing procedures. The key information related to the query is the specific manufacturing process failures, the lack of thorough investigations, and the violations of CGMP regulations, all highlighting failures in the quality control processes.

Accupack Midwest Inc. FDA Warning Letter

accupack-midwest-inc-680228-08152024.txt

This warning letter from the FDA to Accupack Midwest, Inc. addresses significant violations of Current Good Manufacturing Practice (CGMP) regulations. The FDA inspected the drug manufacturing facility and found failures in laboratory controls, particularly regarding water quality, and the lack of written procedures for production and process control, including process validation. The firm manufactures over-the-counter (OTC) drug products, including sunscreens, anti-itch creams, and analgesics. The company's response included a commitment to cease drug production temporarily and a plan to engage a consultant to evaluate operations and assist in meeting CGMP requirements. The FDA requires a comprehensive remediation plan, purified water system validation report, and a detailed risk assessment addressing the potential effects of the water system failures on drug product quality. The violations cited in this letter relate to sections of the FD&C Act and 21 CFR parts 210 and 211, specifically concerning CGMP regulations. The key information related to the query is the identification of manufacturing failures related to laboratory controls, water quality, and process validation, impacting the quality and safety of OTC drug products.

FDA Warning Letter to AcelRx Pharmaceuticals

acelrx-pharmaceuticals-inc-613257-02112021.txt

This document is a warning letter from the FDA to AcelRx Pharmaceuticals, Inc. regarding false or misleading claims and representations about the risks and efficacy of DSUVIA (sufentanil) sublingual tablet in their promotional materials, specifically an "SDS Banner Ad" and a tabletop display. The promotional communications misbrand DSUVIA within the meaning of the Federal Food, Drug, and Cosmetic Act (FD&C Act) and make its distribution violative. The FDA highlights that the promotional materials oversimplify the administration process, omit material information about the maximum daily dosage, and fail to adequately present risk information. The letter requests AcelRx to cease any violations of the FD&C Act and submit a written response within 15 days addressing the concerns and providing a plan for corrective action. The document is relevant to the query because it discusses failures in promotional materials for a medical device, which constitutes a type of manufacturing failure from a regulatory perspective.

Adept Medical Ltd. FDA Warning Letter Analysis

adept-medical-ltd-692226-10112024.txt

This warning letter from the FDA to Adept Medical Ltd. outlines several violations of the Federal Food, Drug, and Cosmetic Act (FD&C Act) concerning the manufacture of NeoZoline Ventilation Tubes. The FDA inspection revealed failures in establishing and maintaining adequate procedures for acceptance activities, process validation, corrective and preventive actions, control of nonconforming products, and control over suppliers. Adept Medical's responses to the FDA's observations were deemed inadequate, lacking sufficient evidence and retrospective analysis to ensure product safety and effectiveness. The firm's manufacturing processes for the NeoZoline Ventilation Tubes did not conform to current good manufacturing practice requirements. Specifically, the company failed to validate its ultrasonic cleaning process, adequately control nonconforming products, and ensure supplier compliance. The FDA also noted that the company modified the NeoZoline Ventilation Tubes without notifying the agency, necessitating a new 510(k) submission. These failures have led to the devices being deemed adulterated and misbranded under the FD&C Act, resulting in potential regulatory penalties and the need for corrective actions to ensure compliance and prevent future violations.

FDA Warning Letter to Advanced Pharmaceutical Technology

advanced-pharmaceutical-technology-692576-03142025.txt

This document is a warning letter from the FDA to Advanced Pharmaceutical Technology, citing significant violations of Current Good Manufacturing Practice (CGMP) requirements for combination products. The FDA inspection revealed failures in preventing microbiological contamination, inadequate testing of controlled-release dosage forms, lack of validated production processes, and an inadequate quality control unit. The company's responses to the FDA's findings were deemed insufficient. The FDA recommends engaging a consultant to assist with CGMP compliance and warns of potential regulatory actions if the violations are not addressed. The document highlights the importance of adhering to CGMP standards and ensuring the quality and safety of drug products. The most important information in this document relative to the query is the discussion of manufacturing failures related to preventing microbiological contamination of sterile drug products, inadequate validation of drug manufacturing processes, and failures in quality control.

FDA Warning Letter to Adventure Innovations LLC

adventure-innovations-llc-676842-08072024.txt

This document is a warning letter from the FDA to Adventure Innovations LLC regarding the Sani Bot D3 device. The FDA has determined that the device is being marketed without the required premarket approval or clearance, violating the Federal Food, Drug, and Cosmetic Act (FD&C Act). The Sani Bot D3 is intended for use in cleaning Continuous Positive Airway Pressure (CPAP) therapy devices and accessories. The FDA argues that the Sani Bot D3 meets the definition of a medical device accessory and that the company's claims about preventing congestion and sickness further classify it as a device under the FD&C Act. The company's initial response disagreeing with the FDA's assessment was deemed inadequate. The FDA requests that Adventure Innovations LLC cease activities that result in the misbranding or adulteration of the Sani Bot D3 and take prompt action to address the violations. The warning letter highlights the company's failure to obtain premarket approval or clearance for the device, which is a critical aspect of medical device manufacturing and regulatory compliance.

FDA Warning Letter to Aerosol and Liquid Packaging

aerosol-and-liquid-packaging-inc-676746-07242024.txt

This warning letter from the FDA to Aerosol and Liquid Packaging, Inc. outlines significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. The violations include failures in identity testing of components, inadequate process validation, insufficient cleaning and maintenance of equipment, and an inadequate quality unit. The firm also violated sections of the FD&C Act by marketing an unapproved new drug. The company's responses to the FDA's observations were deemed inadequate, as they failed to provide sufficient details of corrective actions, retrospective evaluations of potential impacts, and robust plans for ensuring consistent quality and compliance. The FDA recommends engaging a consultant to evaluate the firm's operations and assist in meeting CGMP requirements. The letter also warns of potential regulatory or legal action if the violations are not promptly and adequately addressed. The FDA may re-inspect the facility to verify that corrective actions have been completed. The information most relevant to the query is the discussion of specific manufacturing failures and the FDA's concerns about the company's quality control and assurance systems.

FDA Warning Letter to AG Essence, Inc.

ag-essence-inc-678344-06142024.txt

This warning letter, issued by the FDA to AG Essence, Inc. on June 14, 2024, addresses violations related to the manufacturing and marketing of Banda-SiL Silver Wound Care Gel and Banda-Sil Silver Liquid Gel Spray. The FDA had previously communicated with the firm about these products, with inspections in 2019 leading to a Regulatory Meeting in 2020, where the FDA informed the firm that its products require premarket review. Despite these communications, the firm continued to market the products without the necessary marketing authorization. The violations include failure to obtain premarket approval, lack of unique device identifiers (UDI) on product labels, failure to submit information to the Global Unique Device Identification Database (GUDID), and failure to fulfill annual device registration and listing requirements. These violations contravene sections of the Federal Food, Drug, and Cosmetic Act. The FDA requests that AG Essence, Inc. cease activities that result in the misbranding or adulteration of the products and take prompt action to address the identified violations. The company's failure to comply may result in regulatory action, including seizure, injunction, and civil money penalties. The warning letter emphasizes the importance of premarket review due to the potential risks associated with wound dressings containing antimicrobials like silver, including adverse tissue reactions, immunological reactions, and the spread of antimicrobial resistance. The firm's products are in violation of UDI requirements, GUDID reporting requirements, and device registration and listing requirements.

FDA Warning Letter to Age Management Institute

age-management-institute-santa-barbara-625261-04182022.txt

This FDA warning letter to Age Management Institute Santa Barbara outlines significant violations of the Federal Food, Drug, and Cosmetic Act (FDCA) related to the manufacturing of sterile drug products. The FDA's inspection revealed insanitary conditions, including the lack of a certified ISO 5 area, visibly dirty equipment, and the use of expired components. These violations led to the adulteration of drug products under section 501(a)(2)(A) of the FDCA. The company responded by voluntarily ceasing production of drug products for IV therapy. The FDA recommends a comprehensive assessment of operations and the engagement of a third-party consultant if the company decides to resume production. The company violated sections 501(a)(2)(A) and 301(k) of the FDCA, and the FDA issued a warning letter as a consequence.

FDA Warning Letter to Aidaccess.org

aidaccessorg-575658-03082019.txt

This document is a warning letter from the FDA to Aidaccess.org, addressing the sale of misbranded and unapproved new drugs, specifically mifepristone and misoprostol, in violation of the Federal Food, Drug, and Cosmetic Act (FD&C Act). The FDA emphasizes the inherent risks to consumers who purchase these products, as they lack the safety and effectiveness assurances of FDA-approved drugs and may be contaminated or counterfeit. The letter highlights that Aidaccess.org's actions bypass important safety measures and regulations, including the Risk Evaluation and Mitigation Strategy (REMS) program for mifepristone. The FDA requests that Aidaccess.org immediately cease the sale of these violative drugs and correct all other violations of the FD&C Act, or face potential regulatory action. The letter identifies violations of sections 301(a), 301(d), 505(a), 502(f)(l), and 502(f)(2) of the FD&C Act. The key concern is the distribution of unapproved drugs that do not adhere to FDA's safety and quality control standards.

FDA Warning Letter to Aire-Master of America

aire-master-america-inc-622546-05232022.txt

This document is a warning letter from the FDA to Aire-Master of America, Inc., outlining significant violations of Current Good Manufacturing Practice (CGMP) regulations. The FDA inspected the drug manufacturing facility and found that the company's methods, facilities, and controls did not conform to CGMP, leading to adulterated drug products. The letter also states that Aire-Master Foaming Hand Sanitizer products are unapproved new drugs and are misbranded. The FDA details specific violations, including failures in laboratory controls, inadequate investigations into complaints, insufficient testing for microorganisms, improper cleaning and maintenance of equipment, and a lack of identity testing for incoming components. The company's corrective actions were deemed inadequate, and the FDA requested comprehensive assessments and remediation plans to address the deficiencies. The FDA's warning letter highlights numerous failures in the manufacturing processes of drug products, indicating a lack of adherence to quality standards and regulatory requirements. The FDA emphasizes the need for thorough investigations, corrective actions, and preventive measures to ensure the safety, identity, strength, quality, and purity of all products.

Aizu Olympus Warning Letter on Manufacturing Failures

aizu-olympus-co-ltd-643172-11022022.txt

This warning letter addresses manufacturing deficiencies at Aizu Olympus Co., Ltd., specifically regarding their sterile and non-sterile Endoscopes and Automated Endoscope Reprocessors. The FDA inspection revealed failures in design validation, process validation, and maintenance of accurate device history records (DHR). The firm did not validate the entire device design to ensure it conformed to user needs, bonding/gluing processes lacked proper validation, and curing times for adhesives were not documented on all DHRs. The company's response included plans to re-validate designs, update procedures, conduct health hazard evaluations, and review DHRs, but the FDA deemed these actions ongoing and their adequacy yet to be determined. The violations also extend to medical device reporting (MDR) procedures. The company failed to develop, maintain, and implement written MDR procedures as required. The FDA has requested a comprehensive response within fifteen business days, detailing the corrective actions taken and plans to prevent future violations. The company needs to provide updates on corrective actions, as they are completed, to demonstrate compliance and avoid further regulatory actions. The FDA is concerned about failures in design validation, process validation, and maintaining accurate device history records.

FDA Warning Letter to AkivaMed Inc.

akivamed-inc-609211-07232020.txt

This document is a warning letter issued by the FDA to AkivaMed Inc. regarding the sale of their "COVID-19 Antibody Rapid Test Kit". The FDA reviewed AkivaMed's website and found that the test kit was being offered for sale directly to consumers for at-home use without the necessary marketing approval, clearance, or authorization. This makes the product adulterated and misbranded under the Federal Food, Drug, and Cosmetic Act. The FDA is taking urgent measures to protect consumers from unapproved products claiming to mitigate, prevent, treat, diagnose, or cure COVID-19. AkivaMed is requested to cease the sale of the unapproved product immediately and correct the violations, the company has 48 hours to respond to the FDA with corrective actions. The warning letter also mentions that failure to correct these violations may result in legal action, including seizure and injunction. The FDA has advised consumers not to purchase or use unapproved products for COVID-19, and AkivaMed will be added to a published list of firms that have received warning letters for selling COVID-19 related products in violation of the Act. The document is related to the query because it describes failures in the manufacture and distribution of a medical device, specifically the lack of FDA approval for a COVID-19 antibody test kit.

FDA Warning Letter to Akorn re: CGMP Violations

akorn-inc-558914-02042019.txt

This warning letter issued by the FDA to Akorn, Inc. details significant violations of current good manufacturing practice (CGMP) regulations at their drug manufacturing facility. The FDA's inspection revealed failures in aseptic processing, including poor aseptic behavior by operators, use of non-integral cleanroom materials, and inadequate cleanroom design. These issues led to a high risk of contamination of sterile drug products. The company's environmental monitoring and cleaning programs were also found to be deficient, with instances of skipped sanitization steps and inadequate personnel monitoring practices. The firm also failed to adequately test the stability of its drug products, specifically acetylcysteine injection 200 mg/mL. The FDA deemed Akorn's initial responses inadequate and requested a comprehensive risk assessment, a detailed corrective action and preventative action (CAPA) plan, and significant improvements in aseptic processing operation design and control. The FDA also raised concerns about data integrity and requested a comprehensive investigation into inaccuracies in data, records, and reporting. The FDA is concerned about failures in manufacturing of medical devices.

FDA Warning Letter to Akorn Inc. June 2019

akorn-inc-568173-06132019.txt

This document is a warning letter from the FDA to Akorn Inc. regarding significant violations of current good manufacturing practice (CGMP) regulations for finished pharmaceuticals. The FDA inspected Akorn's drug manufacturing facility and observed violations including inadequate investigations into out-of-specification (OOS) laboratory results and manufacturing deviations, failures to exercise appropriate controls over computer systems, poor aseptic behavior, and failures to prepare batch production and control records with complete information. The letter details specific instances of these violations, such as OOS osmolality results for ketorolac tromethamine ophthalmic solution, metal shavings on aseptic filling equipment during filling of lidocaine hydrochloride 2% jelly, and unjustified invalidation of OOS results during testing of hydroxyamphetamine hydrobromide API. The FDA also found that data could be deleted and altered from laboratory instruments, and standalone laboratory instruments were not backed up. The FDA requests a comprehensive investigation into the extent of inaccuracies in data records and reporting, a current risk assessment of the potential effects of the observed failures on the quality of Akorn's drugs, and a management strategy that includes a detailed CAPA plan. The FDA also reminds Akorn of their responsibility to correct deficiencies found during quality assurance program audits. Akorn was issued a previous warning letter for similar CGMP violations, demonstrating that management oversight and control over the manufacture of drugs are inadequate. The violations include failures in manufacturing sterile drugs, data integrity issues, and deviations from CGMP regulations, impacting the quality and safety of medical devices.

FDA Warning Letter: Albek de Mexico Hand Sanitizer

albek-de-mexico-sa-de-cv-609202-03112021.txt

This document is a warning letter from the FDA to Albek de Mexico S.A. de C.V. regarding the adulteration and misbranding of their NEXT ADVANCED ANTIBACTERIAL HAND SANITIZER. FDA laboratory testing revealed that the product, labeled to contain 70% ethanol, was found to contain significant amounts of methanol, a toxic substance. The product is also deemed an unapproved new drug and misbranded under several sections of the FD&C Act because it does not conform to FDA's requirements and contains undeclared methanol. The FDA recommended a recall of the product and requested a comprehensive review of the company's manufacturing and laboratory practices. The company's failure to adhere to CGMP requirements led to the adulteration of the hand sanitizer with methanol, posing serious health risks to consumers.

FDA Warning Letter to Amazon Regarding Unapproved Drugs

amazoncom-inc-629452-08042022.txt

This document is a warning letter from the FDA to Amazon regarding the distribution of unapproved new drugs for mole and skin tag removal. The FDA purchased "Deisana Skin Tag Remover, Mole Remover and Repair Gel Set" and "Skincell Mole Skin Tag Corrector Serum" through Amazon's website and found them to be in violation of the Federal Food, Drug, and Cosmetic Act (FD&C Act). These products are considered unapproved new drugs because they are not generally recognized as safe and effective for their intended uses and lack prior approval from the FDA. The letter states that the introduction or delivery of these products into interstate commerce is prohibited under sections 505(a) and 301(d) of the FD&C Act. The FDA expresses concerns about the safety of such products, as self-diagnosis and treatment of moles could lead to delayed cancer diagnosis and even cancer progression. The letter instructs Amazon to investigate the causes of the violations and prevent their recurrence, and requests a written response detailing the steps taken to address the violations and prevent future occurrences. The key issue is Amazon's distribution of unapproved drugs for mole and skin tag removal, violating FDA regulations and posing potential health risks to consumers.

FDA Warning Letter to Amazon Regarding Unapproved Drugs

amazoncom-inc-631751-10282022.txt

This document is a warning letter from the FDA to Amazon regarding the distribution of "Artri Ajo King," "Artri King Reforzado con Ortiga y Omega 3," and "Ortiga Mas Ajo Rey" products. These products are marketed as dietary supplements but contain the undeclared drug ingredient diclofenac. The FDA found that these products violate the Federal Food, Drug, and Cosmetic Act (FD&C Act) because they are unapproved new drugs and are misbranded. The presence of undeclared diclofenac poses significant health risks to consumers, including cardiovascular events and gastrointestinal damage. The warning letter cites violations of sections 301(a), 301(d), 505(a), and 502(a) of the FD&C Act. Amazon is expected to investigate the causes of these violations and prevent their recurrence. Failure to address the issues may result in legal action, including seizure or injunction. The key issue is the distribution of products containing undeclared diclofenac, which makes them unapproved new drugs and misbranded under the FD&C Act.

FDA Warning Letter to Amazon Regarding Unapproved Drugs

amazoncom-inc-649056-08182023.txt

This document is a warning letter from the FDA to Amazon.com, Inc. regarding the distribution of unapproved new drugs intended to treat molluscum contagiosum, which violates sections 301(d) and 505(a) of the FD&C Act. The FDA purchased several products, including "Naturasil Molluscum Treatment Kit," "Conzerol 2 Step Treatment for Molluscum Contagiosum," "ZymaDerm for Molluscum," and "HealthyDerm Molluscum Contagiosum Treatment," through Amazon's website. These products are considered unapproved new drugs because they are not generally recognized as safe and effective for their intended uses. The FDA is concerned that individuals may delay proper diagnosis and treatment of potentially serious health conditions by using these unapproved products. Amazon is requested to respond within fifteen working days, detailing the steps taken to address the violations and prevent their recurrence. The document is relevant to the query because it discusses the distribution of unapproved drugs, which can be considered a failure in the manufacturing and regulatory compliance of medical or health-related products.

FDA Warning Letter to Amazon Regarding Unapproved Drugs

amazoncom-inc-662503-12202023.txt

This document is a warning letter from the FDA to Amazon regarding the distribution of products containing undeclared and potentially harmful active pharmaceutical ingredients (APIs). The FDA purchased several products from Amazon's website, including "MANNERS Energy Boost," "Round 2," "WeFun," "Genergy," "Big Guys Male Energy Supplement," "Mens Maximum Energy Supplement," and "X Max Triple Shot Energy Honey," and laboratory analysis revealed the presence of APIs like tadalafil and sildenafil, which are not declared on the product labels. The FDA asserts that these products are unapproved new drugs and misbranded under the Federal Food, Drug, and Cosmetic Act (FD&C Act). The undeclared APIs pose health risks, as they can interact with other medications and cause dangerous drops in blood pressure. Amazon is requested to provide a written response detailing the steps taken to address these violations and prevent their recurrence. The focus of the document is on Amazon's distribution of products that violate the FD&C Act due to undeclared APIs.

FDA Warning Letter to Amazon Regarding Unapproved Drugs

amazoncom-inc-695821-03032025.txt

This warning letter, issued by the FDA to Amazon.com, addresses the distribution of unapproved new drugs, specifically injectable lipolytic drug products, in violation of the Federal Food, Drug, and Cosmetic Act (FD&C Act). The FDA purchased “LemonBottle Ampoule Solution,” “L-Carnitine Body Serum Ampoule,” and “Matrigen PPC Ampoule” through Amazon's website, noting that these products are unapproved and pose significant public health risks due to their injectable nature, bypassing the body's natural defenses against toxins. The letter states that Amazon is responsible for introducing these products into interstate commerce without the required FDA approval, thus violating sections 301(d) and 505(a) of the FD&C Act. The FDA requests a written response from Amazon within fifteen working days, detailing the steps taken to address these violations and prevent their recurrence. The FDA emphasizes that failure to comply may result in legal action, including seizure and/or injunction. The focus of the document is on regulatory violations related to drug products rather than medical device manufacturing failures. Therefore, while the query concerns medical device manufacturing failures, this document is about unapproved drugs sold through Amazon's platform.

FDA Warning Letter to AMCO Regarding AED Batteries

amco-international-manufacturing-design-inc-681557-06252024.txt

This warning letter, issued by the FDA to AMCO International Manufacturing & Design, Inc., addresses the firm's failure to obtain premarket approval for replacement batteries used in Automated External Defibrillators (AEDs). The FDA determined that the company continued to manufacture and distribute these devices after the February 3, 2022, compliance date, thus violating section 501(f)(1)(A) of the Federal Food, Drug, and Cosmetic Act. The letter specifies that the firm needs to cease activities resulting in the adulteration of necessary AED accessories and must respond within fifteen business days with a plan to address and prevent future violations. Potential regulatory actions for non-compliance include seizure, injunction, and civil money penalties. The letter also indicates that the company manufactures batteries for various AED models, including Cardiac Science Powerheart, Philips HeartStart, and Physio-Control LifePak devices. The key issue is the company's failure to meet the premarket approval requirements for these AED accessories, which are critical for the proper functioning and safety of the AEDs.

FDA Warning Letter on Manufacturing Violations

american-cleaning-solutions-632881-09062022.txt

This warning letter from the FDA to American Cleaning Solutions details significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. The FDA inspected the drug manufacturing facility and found failures in cleaning and maintenance of equipment, production and process control, component testing, and quality control. The firm lacked adequate cleaning procedures, failed to validate manufacturing processes, and did not adequately test incoming components. The quality unit also failed to ensure CGMP compliance. The company's hand sanitizer drug products were found to be adulterated due to the substitution of isopropanol with ethanol. The FDA also noted that similar CGMP observations were cited in a previous inspection, indicating repeated failures. The company committed to ceasing production of drugs, but the FDA found their response inadequate and questioned their commitment based on past experiences. The FDA emphasizes the importance of investigating the causes of the violations and preventing their recurrence, warning that failure to address the issues may result in regulatory or legal action. The most important detail regarding the query is the document describes failures in the manufacture of hand sanitizers.

FDA Warning Letter to American Contract Systems, Inc.

american-contract-systems-inc-595573-11092019.txt

This document is a warning letter from the FDA to American Contract Systems, Inc. following an inspection of their medical device manufacturing operations. The FDA found significant violations of the Federal Food, Drug, and Cosmetic Act and its Quality System regulation, including failures in sterilization validation, monitoring and control of process parameters, review and evaluation of process changes, validation of computer software, and maintenance of device master records. The firm's sterilization operations were not adequately validated, and process parameters were not properly monitored or controlled. Changes to software and processes were not adequately reviewed or revalidated. Device master records were also inadequately maintained. These failures led to potential safety concerns, such as foreign matter found in sterilized bags and delayed surgeries. The FDA requests a comprehensive response from the firm detailing corrective actions and plans to prevent future violations. The document highlights the importance of adhering to quality standards and regulatory requirements in medical device manufacturing, with the FDA emphasizing the need for thorough validation, monitoring, and documentation processes to ensure device safety and efficacy.

FDA Warning Letter on Preclinical Services Violations

american-preclinical-services-562382-02122019.txt

This warning letter discusses objectionable conditions observed during an FDA inspection of American Preclinical Services. The inspection revealed violations of Title 21 CFR Part 58, concerning Good Laboratory Practice (GLP) for Nonclinical Laboratory Studies. These violations include failures of the study director and the Quality Assurance Unit (QAU) to fulfill their responsibilities, inadequate animal identification and water analysis, and improper labeling of reagents and specimens. The study director failed to take corrective action for animal deaths, ensure protocol adherence, and properly transfer data. The QAU failed to identify issues like incorrect ventilator settings and lack of review of clinical pathology data. The company's corrective actions, such as training sessions and SOP updates, were deemed inadequate by the FDA, which requested further documentation and clarification. The FDA is concerned about the reliability and integrity of study data, which could impact the safety and efficacy of medical devices. The FDA requests documentation of corrective actions, impact assessments, and staff training records to address these failures. The violations described in this document pertain directly to failures in the manufacture of medical devices.

FDA Warning Letter on Manufacturing Failures

amman-pharmaceutical-industries-668867-02142024.txt

This warning letter from the FDA to Amman Pharmaceutical Industries details significant violations of Current Good Manufacturing Practice (CGMP) regulations. The violations include inadequate facility design for aseptic processing, insufficient environmental monitoring, unreliable laboratory records, and a failure of the quality control unit to adequately exercise its authority. The FDA found fundamental design flaws compromising the ability to maintain aseptic conditions, along with poor aseptic technique and cleanroom behavior. The company's responses to the FDA's findings were deemed inadequate, with concerns raised about retrospective reviews and data integrity. The FDA has placed the firm on Import Alert 66-40 and may withhold approval of new applications. The company has committed to recalling all drug products and suspending production for the U.S. market. The document is relevant to the query because it describes in detail manufacturing failures related to sterile drug products, which fall under the umbrella of medical devices, and the regulatory consequences of those failures.

FDA Warning Letter to Amnio Technology, LLC

amnio-technology-llc-646460-10012024.txt

This warning letter from the FDA to Amnio Technology, LLC addresses significant deviations from current good manufacturing practice (CGMP) requirements and violations of the Federal Food, Drug, and Cosmetic Act (FD&C Act) and the Public Health Service Act (PHS Act) concerning their amniotic membrane and amniotic fluid-derived products, PalinGen® Flow® and PalinGen® Inov Flo®. The FDA inspection revealed failures in process validation, stability testing, and complaint handling. The company distributed these products without proper validation, assigned expiration dates without adequate stability data, and failed to report a consumer complaint involving a communicable disease to the FDA within the required timeframe. The company's responses to the FDA's observations were deemed inadequate, as they did not provide sufficient data to demonstrate consistent product specifications or address the impact of the deficiencies on distributed products. The FDA also raised concerns about the lack of an approved biologics license application (BLA) for these products, which are required for lawful marketing. The letter emphasizes that failure to adequately address these issues may lead to regulatory action, including seizure and/or injunction. The warning letter highlights the company's failure to adhere to CGMP requirements, impacting the quality and safety of their products. The FDA is concerned about the manufacturing failures and the lack of compliance with regulatory standards.

FDA Warning Letter to Amplicon Land, LLC

amplicon-land-llc-607975-06072021.txt

This document is a warning letter from the FDA to Amplicon Land, LLC, regarding the sale of the "QuikPacII COVID-19 IgG/IgM Test" without the necessary FDA approvals. The test is being offered for sale in the United States for the diagnosis of COVID-19, which classifies it as a medical device under the Federal Food, Drug, and Cosmetic Act. The FDA has determined that the product is adulterated and misbranded because the company does not have an approved application for premarket approval or an investigational device exemption, nor did they notify the agency of their intent to introduce the device into commercial distribution. The letter requests that the company cease the sale of the unauthorized products and take immediate action to correct the violations. The document is related to the query because it discusses failures in compliance with manufacturing regulations for a medical device.

FDA Warning Letter to Anderson Compounding Pharmacy

anderson-compounding-pharmacy-inc-dba-anderson-compounding-pharmacy-598303-01132020.txt

This document is a warning letter from the FDA to Anderson Compounding Pharmacy, Inc. The letter addresses serious deficiencies in the pharmacy's practices for producing sterile drug products, which put patients at risk. FDA investigators observed insanitary conditions in the ISO 5 classified aseptic processing areas, including difficult to clean and visibly dirty surfaces, non-microbial contamination, unsealed ceiling tiles, and failure to perform adequate smoke studies. The pharmacy voluntarily ceased sterile compounding of human and veterinary drugs and initiated a recall of all drug products intended to be sterile due to a lack of sterility assurance. The FDA acknowledged these actions but recommended a comprehensive assessment of operations, including facility design, procedures, personnel, processes, maintenance, materials, and systems, with the assistance of a third-party consultant if the pharmacy decides to resume production of sterile drugs. The FDA found that the pharmacy's drug products were adulterated under section 501(a)(2)(A) of the FDCA and that the pharmacy violated section 301(k) of the FDCA. The FDA requires the pharmacy to take prompt action to correct the violations and notify the FDA prior to resuming operations, or face potential legal action. The violations involve manufacturing failures that led to potential contamination of sterile drug products, posing a risk to patient safety and violating FDA regulations.

FDA Warning Letter on Clinical Investigation Violations

angela-d-ritter-md-681999-06072024.txt

This document is a Warning Letter from the FDA to Dr. Angela D. Ritter regarding objectionable conditions observed during an inspection of her clinical site. The inspection revealed failures to adhere to statutory requirements in the Federal Food, Drug, and Cosmetic Act (FD&C Act) and applicable regulations, specifically concerning an expanded access protocol for an investigational drug. The FDA identified several violations, including failure to maintain an effective IND, conduct the clinical investigation according to the protocol, ensure IRB review and approval, and submit annual reports. Dr. Ritter's response, acknowledging reliance on a CRO, was deemed inadequate due to the lack of concrete corrective actions. The FDA emphasized Dr. Ritter's responsibility as a sponsor-investigator to ensure the rights, safety, and welfare of study subjects and compliance with all applicable regulations. The document is relevant to the query because it details specific manufacturing failures related to adherence to expanded access requirements for an investigational drug, highlighting the importance of compliance with FDA regulations in the manufacture and clinical investigation of medical products.

FDA Warning Letter to Dr. Angela Stupi

angela-m-stupi-md-665471-08082023.txt

This document is a warning letter from the FDA to Dr. Angela Stupi regarding objectionable conditions observed during an inspection of her clinical site. The inspection, conducted as part of the Bioresearch Monitoring Program, revealed failures to adhere to the investigational plan for two protocols involving an investigational drug. These failures included enrolling subjects who did not meet inclusion criteria related to salivary flow rate and radiologic evidence, as well as administering the study drug in incorrect body locations. The FDA found the company's response to be inadequate, citing a lack of detail in the corrective action plan. The FDA emphasizes the importance of adhering to regulations to protect the rights, safety, and welfare of study subjects and to ensure the integrity of study data. The warning letter indicates violations of the Federal Food, Drug, and Cosmetic Act (FD&C Act) and related regulations. The key information is the investigator's failure to adhere to the investigational plan, which raises concerns about data integrity and subject safety.

FDA Warning Letter to Anna Health, LLC

anna-health-llc-613294-03162021.txt

This warning letter from the FDA to Anna Health, LLC addresses violations related to the marketing and sale of unapproved drugs. The FDA reviewed Anna Health's website and found that they were selling products like Fucoidan, Prostate Health, Children Liquid Vitamins, and Immune Health with claims that they could treat or prevent diseases, including COVID-19. These claims classify the products as drugs under the Federal Food, Drug, and Cosmetic Act, and because they are not generally recognized as safe and effective for their intended uses, they require FDA approval before being introduced into interstate commerce. The products are also considered misbranded because they lack adequate directions for safe use by a layperson. The FDA requests that Anna Health cease the sale of these unapproved products and respond in writing within 15 days with the steps they will take to correct the violations and prevent recurrence. The warning letter indicates that failure to comply may result in legal action, including seizure and injunction. This document pertains to the query because it discusses failures to comply with regulations in the manufacture and sale of medical products.

FDA Warning Letter to Tampon Innovations

annes-daye-ltd-dba-tampon-innovations-696362-12172024.txt

This document is a warning letter from the FDA to Anne’s Daye Ltd dba Tampon Innovations regarding violations of the Federal Food, Drug, and Cosmetic Act (FD&C Act). The violations stem from the firm's manufacturing and marketing of Cannabinoid (CBD) coated tampons and vaginal microbiome screening kits without the necessary premarket approvals or notifications. The FDA inspection revealed that the CBD Daye Tampons are being marketed for period pain relief, an indication not covered by their existing clearance, and the Vaginal Microbiome Screening Kits are marketed with diagnostic claims beyond the scope of general wellness devices. The FDA also found the firm's complaint handling system inadequate. As a result, the FDA has determined that the devices are subject to refusal of admission into the United States. The letter requests a written response from the firm within fifteen business days, detailing the steps taken to address the violations and prevent their recurrence. The document discusses manufacturing failures related to medical devices.

FDA Warning Letter to antibodiescheck.com Regarding COVID-19 Test Kit

antibodiescheckcom-607681-06152020.txt

This document is a warning letter from the FDA to antibodiescheck.com regarding the sale and distribution of the Antibodies Test Kit for Covid19 without proper approval, clearance, or authorization. The FDA identifies that the test kit is adulterated and misbranded, violating sections of the Federal Food, Drug, and Cosmetic Act. The letter emphasizes the public health risks associated with at-home testing for COVID-19 using unapproved devices. It instructs the company to cease the sale of the test kits and take immediate corrective actions to address the violations. The company is also warned about potential legal consequences, including seizure and injunction, and being added to a list of firms violating FDA regulations. The document highlights the company's failure to obtain premarket approval and notify the agency of their intent to distribute the device, which are critical aspects related to the query about common failures in the manufacture of medical devices.

FDA Warning Letter on Clinical Trial Deficiencies

antonio-e-blanco-mdvista-health-research-llc-668519-09262023.txt

This document is a warning letter from the FDA to Antonio E. Blanco, M.D./Vista Health Research, LLC, detailing objectionable conditions observed during a clinical site inspection. The inspection revealed failures to adhere to statutory requirements in the Federal Food, Drug, and Cosmetic Act (FD&C Act) and regulations in Title 21 of the Code of Federal Regulations, part 312, regarding clinical investigations and human subject protection. The warning letter highlights specific instances where the clinical investigator failed to ensure the investigation was conducted according to the investigational plan. This included enrolling subjects who did not meet eligibility criteria and failing to perform protocol-required safety imaging procedures. The FDA found the company's proposed corrective actions inadequate, citing a lack of sufficient detail about implementation and training. The FDA emphasizes concerns about subject safety, data integrity, and the potential for regulatory action. The document is related to failures in clinical trials and the importance of adhering to FDA regulations to ensure the safety and welfare of study subjects.

FDA Warning Letter to Anytime COVID Test LLC

anytime-covid-test-llc-611366-04132021.txt

This document is a warning letter from the FDA to Anytime COVID Test LLC regarding their COVID-19 Test Kit. The FDA states that the test kit is being sold directly to consumers for at-home use without the required marketing approval, clearance, or authorization. This makes the product adulterated and misbranded under the Federal Food, Drug, and Cosmetic Act. The letter emphasizes the public health risks associated with unapproved at-home testing, including the potential for inaccurate results and the misleading implication of FDA approval due to the unauthorized use of the FDA logo on the company's website. The company is urged to cease the sale of the test kit and address the violations immediately. The warning letter highlights the absence of premarket approval or authorization for the COVID-19 test kit, the misleading use of the FDA logo, and the distribution of the kit for at-home use without proper clearance. The company's failure to comply with these regulations has led to the FDA issuing this warning and demanding immediate corrective action.

Apollo Health and Beauty Care Warning Letter

apollo-health-and-beauty-care-inc-593033-12232019.txt

This warning letter addresses significant violations of current good manufacturing practice (CGMP) regulations at Apollo Health and Beauty Care, Inc. The FDA inspection revealed failures in calibration, inspection, and checking of equipment, leading to discrepancies in data records. The firm also lacked process validation for manufacturing processes and failed to thoroughly investigate discrepancies or failures of batches. The company's responses to the FDA's findings were inadequate, lacking sufficient detail and corrective actions. The violations cited in this letter indicate failures in data integrity, process validation, and investigation of discrepancies, which are critical aspects of medical device manufacture. The FDA has recommended engaging a consultant to assist the firm in meeting CGMP requirements.

FDA Warning Letter to Appleton City Feed Service

appleton-city-feed-service-llc-662279-11012023.txt

This document is a warning letter from the FDA to Appleton City Feed Service LLC, detailing significant violations of Current Good Manufacturing Practice, Hazard Analysis, and Risk-Based Preventive Controls for Food for Animals requirements. The FDA inspection revealed failures in preparing a written food safety plan, evaluating raw materials for mycotoxins, preventing contamination of animal food, excluding pests, using VFD drugs and combinations not in accordance with approvals, distributing non-conforming VFD feed, and properly labeling medicated feeds. The company's responses to the FDA were deemed inadequate due to a lack of documentation of completed and consistently implemented corrective actions. The violations could lead to adulterated or misbranded animal feed, potential harm to animals, and regulatory actions. The document emphasizes the company's responsibility to investigate and prevent recurrence of these violations to ensure compliance with federal law and FDA regulations. The warning letter addresses failures in manufacturing processes, potential violations of the FD&C Act, and the impact on animal food safety, but does not address medical devices.

FDA Warning Letter to Applied Biological Laboratories

applied-biological-laboratories-inc-627062-03242022.txt

This document is a warning letter from the FDA and FTC to Applied Biological Laboratories Inc. regarding the sale of unapproved and misbranded products, specifically Biovanta Dual Action Throat Spray and Biovanta Triple Action Lozenges, with claims of preventing or treating COVID-19. The letter states that these products violate section 505(a) and 502 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) and that the company is making unsubstantiated claims. The letter requests that the company cease the sale of these products and take immediate action to address the violations. The company will be added to a published list on FDA's website of firms and websites that have received warning letters from FDA. The document is important to the query because it highlights failures related to regulatory compliance and the marketing of medical products with unproven claims, which can be considered a failure in the broader context of medical device manufacturing and regulation.

FDA Warning Letter to Applied Therapeutics

applied-therapeutics-inc-696833-12032024.txt

This document is a warning letter from the FDA to Applied Therapeutics, Inc. regarding objectionable conditions observed during an FDA inspection of a clinical investigation. The FDA found that Applied Therapeutics failed to permit the FDA access to and copy and verify records related to the clinical investigation, as a third-party vendor deleted electronic data, including audit trails, from a web-based administration system. The FDA also found that Applied Therapeutics failed to provide the FDA with a description and analysis of information regarding dosing errors related to a mislabeled drug product. The warning letter indicates that Applied Therapeutics did not adhere to the applicable statutory requirements in the Federal Food, Drug and Cosmetic Act (FD&C Act) and applicable regulations. The FDA expresses concerns about the validity and reliability of data collected for the clinical investigation. The company's failure to disclose critical information raises concerns about its oversight and conduct of clinical investigations. The document is related to manufacturing failures due to mislabeling of the drug product and data management failures.

FDA Warning Letter to Aqualex Co., Ltd.

aqualex-co-ltd-672292-06122024.txt

This warning letter from the FDA to Aqualex Co., Ltd. outlines significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. The FDA inspected the facility and found failures in establishing adequate written procedures, validating manufacturing processes, and maintaining equipment. The company's quality control unit also failed to ensure drug product compliance with CGMP. The letter also addresses the marketing of an unapproved new drug, “DBH Beverly Hills, EGF FGF DNA, UV Shield,” and misbranding violations, as the product's labeling was found to be false or misleading. The FDA has placed the firm on Import Alert and may withhold approval of new applications until compliance is confirmed. The company's planned corrective actions were deemed inadequate, lacking detail and impact assessments. The document is relevant to the query because it provides a detailed account of manufacturing failures related to process validation, equipment maintenance, quality control, testing, and stability, as well as regulatory violations pertaining to drug approval and branding.

FDA Warning Letter to Ardil Comercial S.R.L. Hand Sanitizer

ardil-comercial-srl-612018-09222021.txt

This document is a warning letter from the FDA to Ardil Comercial S.R.L. regarding violations related to the manufacture of 'Alcohol Isopropilico Hand Sanitizer Limar.' The FDA found that the product was adulterated because it contained undeclared ethanol instead of the labeled isopropyl alcohol (IPA). The product was also found to be misbranded due to inaccurate labeling, misleading packaging resembling a water bottle, and failure to include necessary information on the label. The FDA requested information from the company regarding their manufacturing processes and corrective actions, but the company's responses were inadequate. As a result, the FDA placed all drugs and drug products manufactured by the firm on Import Alert 66-78. The warning letter details the specific violations of the Federal Food, Drug, and Cosmetic Act (FD&C Act) and emphasizes the need for the company to address these deficiencies to ensure compliance with CGMP requirements. The key issue is the adulteration and misbranding of a hand sanitizer product, posing potential safety risks to consumers.

FDA Warning Letter to ARG Laboratories, Inc.

arg-laboratories-inc-670899-06112024.txt

This document is a warning letter from the FDA to ARG Laboratories, Inc. regarding significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. The FDA inspected the drug manufacturing facility and found that the company's methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP. The company also introduced unapproved new drugs into interstate commerce and misbranded drug products. The letter details specific CGMP violations, including failures in the quality unit, component testing, production and process control, and stability testing. The FDA also addresses the unapproved new drug and misbranding violations related to "Golden Tiger Natural Pain Relieving Cream" and "Pain Wizard Natural Relief for Muscular & Arthritic Pain." The FDA recommends engaging a consultant to assist in meeting CGMP requirements and requests a written response within 15 working days detailing corrective actions taken to address the violations and prevent their recurrence. The violations include not having an adequate quality unit, not testing components, and not validating production processes. These issues led to the marketing of unapproved and misbranded drugs, violating FDA regulations.

FDA Warning Letter to Ariella Naturals

ariella-naturals-632509-08042022.txt

This document is a warning letter from the FDA to Ariella Naturals regarding the marketing and sale of "Ariella Skin Tag Remover & Mole Corrector and Repair Lotion Set" and "Ariella Skin Tag Remover and Mole Remover 2 pcs." The FDA has determined that these products are unapproved new drugs sold in violation of the Federal Food, Drug, and Cosmetic Act (FD&C Act). The letter states that there are no over-the-counter (OTC) drugs that can be legally sold for mole or skin tag removal, and the FDA has safety concerns about drugs marketed OTC directly to consumers for these uses. The FDA claims that the products are not generally recognized as safe and effective for their intended uses and that there are no FDA-approved applications in effect for these products. The letter notifies Ariella Naturals of the FDA's concerns and provides an opportunity to address them. Failure to adequately address this matter may result in legal action, including seizure and/or injunction. The warning letter highlights the violation of sections 505(a) and 301(d) of the FD&C Act due to the marketing of these products. The company is expected to respond with corrective actions and prevent recurrence of the violations.

FDA Warning Letter to Art of Beauty Company

art-beauty-company-inc-674144-05222024.txt

This warning letter from the FDA to Art of Beauty Company, Inc. outlines significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. The FDA inspection revealed failures in quality control, testing of components, microbial testing, process validation, and equipment maintenance. The company's quality unit lacked adequate oversight and procedures, leading to potential contamination and distribution of adulterated drug products. The company failed to adequately test incoming components for identity and contaminants like diethylene glycol (DEG) and ethylene glycol (EG). The FDA also found failures in microbial testing of water systems and finished hand sanitizer products. Additionally, the company did not validate its manufacturing processes and lacked adequate cleaning and maintenance procedures for equipment, increasing the risk of cross-contamination. The FDA's concerns are centered around the lack of adequate quality control measures and adherence to CGMP regulations, which could result in unsafe and ineffective drug products reaching the market. The company's response to the FDA's initial findings was deemed inadequate, with a need for more comprehensive corrective actions and preventive measures to ensure product safety and compliance.

Warning Letter to The Art Of Cure Regarding COVID-19 Products

art-cure-606596-04152020.txt

This document is a warning letter from the FDA and FTC to The Art Of Cure regarding the sale of unapproved and misbranded homeopathic drug products that claim to mitigate, prevent, treat, diagnose, or cure COVID-19. The letter states that the company's products violate sections of the Federal Food, Drug, and Cosmetic Act (FD&C Act) and the FTC Act because they are unapproved new drugs and are being misleadingly represented as safe and effective for COVID-19 treatment without scientific evidence. The company is urged to immediately cease the sale of these products and correct the violations, or face legal action, including seizure and injunction. The FDA is advising consumers against purchasing or using such unapproved products and has added the firm to a published list of those in violation. The warning letter highlights the sale of unapproved drugs for the treatment of COVID-19.

FDA Warning Letter to Aruba Aloe Balm N.V.

aruba-aloe-balm-nv-674911-05132024.txt

This document is a warning letter from the U.S. Food and Drug Administration (FDA) to Aruba Aloe Balm N.V. regarding significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. The FDA inspected the drug manufacturing facility and found that the methods, facilities, and controls for manufacturing, processing, packing, or holding do not conform to CGMP. The firm failed to test samples of each component for identity, purity, strength, and quality, particularly incoming lots of active pharmaceutical ingredients (APIs) like ethanol and glycerin. The use of ethanol contaminated with methanol led to a recall of hand sanitizers due to potential toxicity. The firm also failed to adequately monitor the microbiological quality of the water system and lacked adequate stability testing programs. Furthermore, the company changed the concentration of two ingredients without adequate change control or justification for failing to validate this revised process. The letter also cites that the ISLAND REMEDY ALL-DAY REVITALIZING MOISTURIZER is misbranded under section 502(f)(2) of the FD&C Act, 21 U.S.C. 352(f)(2) because the product label does not include all of the applicable warnings as required under the Over-the-Counter Monograph M020. The FDA recommends engaging a consultant to evaluate operations and assist in meeting CGMP requirements. The document is related to manufacturing failures due to the company failing to test incoming raw materials and process controls.

FDA Warning Letter to Asesores en Mantenimiento

asesores-en-mantenimiento-hidraulico-e-industrial-sa-de-cv-610108-02222021.txt

This document is a warning letter from the FDA to Asesores en Mantenimiento Hidraulico e Industrial, S.A. de C.V. regarding the adulteration and misbranding of their ARGENT Defense Group HAND SANITIZER. The FDA's laboratory testing revealed that the hand sanitizer, which was labeled to contain 70% ethyl alcohol, actually contained methanol, a toxic substance. The FDA determined that the substitution of ethanol with methanol constitutes an adulteration violation under section 501(d)(2) of the FD&C Act and indicates that the company's quality assurance is not functioning in accordance with CGMP requirements. The product is also considered an unapproved new drug and is misbranded under sections 505(a), 502(j), (a) and (ee) of the FD&C Act. The FDA recommended the firm consider removing all of their hand sanitizer products and the firm stated that no commercial product was in distribution in the U.S. and thus, your firm took no market action. The warning letter requests a detailed investigation into the substitution, a list of all raw materials used in manufacturing hand sanitizers, a list of all batches shipped to the U.S., and copies of complete batch records. The company was notified that all drugs and drug products manufactured by the firm were placed on Import Alert 66-78.

FDA Warning Letter to Asiaticon on Hand Sanitizer

asiaticon-sa-de-cv-609162-10292020.txt

This document is a warning letter from the FDA to Asiaticon, SA de CV, regarding the adulteration and misbranding of their V-KLEAN HAND SANITIZER GEL. FDA laboratory testing revealed that the product, labeled to contain 70% ethyl alcohol, actually contained an average of 33% ethanol and 38% methanol. This substitution violates section 501(d)(2) of the FD&C Act. The presence of methanol, a toxic substance, also renders the product adulterated under section 501(a)(2)(B) due to failures in quality assurance and CGMP compliance. The product is further classified as an unapproved new drug and misbranded under sections 505(a), 502(j), (a), (e), and (ee) of the FD&C Act. Asiaticon was requested to provide a detailed investigation into the methanol substitution, a list of raw materials and suppliers, a list of all batches shipped to the United States, and copies of complete batch records. The company initiated a voluntary recall of all lots of certain hand sanitizers that were distributed in the U.S. The warning letter highlights critical failures in Asiaticon's manufacturing processes, quality control, and regulatory compliance, particularly regarding the substitution of ingredients and the distribution of an unapproved and misbranded drug. The FDA has requested immediate corrective actions and preventive measures to address these violations and prevent their recurrence.

FDA Warning Letter to Aspen Biopharma Labs

aspen-biopharma-labs-private-limited-698665-03052025.txt

This warning letter from the FDA to Aspen Biopharma Labs details significant deviations from Current Good Manufacturing Practice (CGMP) for active pharmaceutical ingredients (API). The FDA inspected the drug manufacturing facility and found failures in facility design, process validation, cleaning validation, document control, and stability testing programs. The facility lacked proper separation for toxic materials, and manufacturing areas were open to the environment. The company failed to demonstrate that its manufacturing process could reproducibly manufacture API meeting quality attributes and lacked cleaning validation studies. There were also issues with data integrity, including backdating documents and a lack of original data to support drug shipments. The stability program was inadequate, failing to ensure APIs met quality criteria throughout their shelf-life. As a result, the company initiated a voluntary recall of all drugs in the U.S. market. The FDA recommends engaging a consultant to assist in remediation and emphasizes the company's responsibility for ensuring ongoing CGMP compliance. The letter indicates violations of the Federal Food, Drug, and Cosmetic Act (FD&C Act).

FDA Warning Letter to Aspire Pharmaceuticals, Inc.

aspire-pharmaceuticals-inc-630328-11222022.txt

This document is a warning letter from the FDA to Aspire Pharmaceuticals, Inc., detailing significant violations of the Federal Food, Drug, and Cosmetic Act (FD&C Act) and related regulations. The violations include failures in dietary supplement and drug manufacturing processes, such as using inappropriate testing methods, failing to conduct material reviews when specifications were not met, and falsifying laboratory data. The letter also addresses misbranded dietary supplements and failures in quality control operations. The FDA expresses concerns about data integrity and the lack of comprehensive investigations into discrepancies and failures. The company's responses to the FDA's observations were deemed inadequate due to a lack of supporting documentation and failure to address underlying issues. The document emphasizes the importance of adhering to Current Good Manufacturing Practice (CGMP) regulations and maintaining data integrity to ensure the safety, effectiveness, and quality of drug products and dietary supplements. The FDA's warning letter highlights the company's failure to ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs they manufacture.

FDA Warning Letter to AstraZeneca on Breztri AEROSPHERE

astrazeneca-pharmaceuticals-lp-664789-08042023.txt

This document is a warning letter from the FDA to AstraZeneca Pharmaceuticals regarding false or misleading claims in the promotional material for Breztri AEROSPHERE, a drug used for chronic obstructive pulmonary disease (COPD). The FDA found that the promotional material overstated the drug's efficacy, particularly concerning its impact on all-cause mortality and severe exacerbations. The claims suggested that Breztri treatment had a positive impact on all-cause mortality and reduced the risk of death in COPD patients, which was not supported by the cited references. The FDA also noted that the presentation of claims regarding the reduction in severe exacerbations created a misleading impression of statistical significance. The letter requests that AstraZeneca cease any violations of the Federal Food, Drug, and Cosmetic Act (FD&C Act) and provide a written response addressing the concerns, including a plan for corrective communications. The warning letter highlights the importance of accurate and non-misleading promotional materials in the pharmaceutical industry, especially concerning the efficacy of drugs and their potential impact on patient outcomes.

Warning Letter to Atlanta Supersource, Inc.

atlanta-supersource-inc-693399-01082025.txt

This warning letter addresses significant violations of Current Good Manufacturing Practice (CGMP) regulations at Atlanta Supersource, Inc.'s drug manufacturing facility. The FDA inspection revealed failures to clean and sanitize equipment, inadequate testing of drug products and components, and misbranding of hand sanitizer products. The firm also used the same equipment to manufacture commercial industrial chemical products, labeled with warnings such as “cause severe skin burns” and “may cause allergic skin reactions,” on the same manufacturing equipment as their OTC drug products. The products were deemed adulterated and misbranded under the Federal Food, Drug, and Cosmetic Act (FD&C Act). The company's response to the FDA's findings was inadequate, lacking sufficient detail and evidence of corrective actions. The company was also found to have violated the FD&C act by misbranding hand sanitizers. The FDA recommends engaging a consultant to evaluate operations and ensure CGMP compliance. The violations include failures in cleaning, maintenance, sanitation, testing, and monitoring of water systems, all of which are vital to the manufacture of medical devices.

FDA Warning Letter to Auro Pharmacies, Inc.

auro-pharmacies-inc-dba-central-drugs-compounding-pharmacy-608369-06032020.txt

This document is a warning letter from the FDA to Auro Pharmacies, Inc., detailing significant violations of the Federal Food, Drug, and Cosmetic Act (FDCA). The FDA inspection revealed insanitary conditions, including vermin in production areas and dirty equipment in aseptic processing areas, which could lead to contamination of sterile drug products. The firm also failed to perform adequate smoke studies and media fills, and personnel blocked airflow during aseptic manipulations. Microbial contamination was detected in the ISO 5 area for three consecutive months, yet sterile production continued without appropriate corrective actions. The firm also compounded drugs without valid prescriptions for individually-identified patients. The company voluntarily ceased sterile production and recalled affected products. The FDA emphasizes the need for a comprehensive assessment of operations and the implementation of quality oversight and controls to prevent future violations. The warning letter highlights the company's failure to comply with CGMP regulations, potentially leading to adulterated and misbranded drug products.

FDA Warning Letter to Aurobindo Pharmaceutical Limited

aurobindo-pharmaceutical-limited-618091-01122022.txt

This document is a warning letter from the FDA to Aurobindo Pharmaceutical Limited regarding significant deviations from current good manufacturing practice (CGMP) for active pharmaceutical ingredients (API). The FDA inspected the company's drug manufacturing facility and found failures in evaluating the potential effect of changes on the quality of intermediates and API, as well as failures in the quality unit to ensure that critical deviations are investigated and resolved. The company's responses to the FDA's findings were deemed inadequate, and the FDA recommends engaging a consultant to assist the firm in meeting CGMP requirements. The FDA found that the company failed to fully evaluate whether increasing the acceptable limit for an impurity would impact the quality of the API, and that the company failed to fully investigate discrepancies during method transfer for GC-MS. The FDA also noted that the company had repeated similar CGMP deviations, indicating that executive management oversight and control over the manufacture of drugs is inadequate. The warning letter indicates that the company violated section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act). The company must take corrective actions to address the deviations and prevent their recurrence to avoid further regulatory action.

FDA Warning Letter to Aurolife Pharma, LLC

aurolife-pharma-llc-607087-10162020.txt

This warning letter from the FDA to AuroLife Pharma, LLC details significant violations of current good manufacturing practice (CGMP) regulations. The FDA inspected the drug manufacturing facility and observed failures including inadequate investigation of out-of-specification (OOS) results, poor facility maintenance leading to water leaks, insufficient cleaning procedures resulting in potential cross-contamination, and flawed production and process controls. The company's responses to the FDA's findings were deemed inadequate, particularly in addressing the root causes and scopes of the necessary corrective actions. The FDA requested comprehensive reviews, remediation plans, and retrospective assessments to ensure CGMP compliance. The violations could lead to legal action, contract restrictions, and withheld approvals. The document highlights the importance of robust quality control systems, thorough investigations, and adherence to manufacturing standards to ensure the safety and efficacy of drug products.

FDA Warning Letter to Auto-Chlor System LLC

auto-chlor-system-llc-641808-12202022.txt

This warning letter from the FDA to Auto-Chlor System LLC details significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. The FDA inspected the drug manufacturing facility and found that the methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, leading to adulterated drug products. The company failed to establish written procedures for cleaning and maintenance of equipment, did not adequately test components for identity and conformity, and lacked validated processes for manufacturing hand sanitizer drug products. The quality control unit also failed to provide adequate oversight. Furthermore, HAND KLEEN FOAMING INSTANT HAND SANITIZER is an unapproved new drug and is misbranded. The FDA recommends engaging a consultant to assist in meeting CGMP requirements and suggests a comprehensive audit of the operation. The company's manufacturing failures primarily concern violations of CGMP regulations and the introduction of an unapproved and misbranded hand sanitizer product, highlighting a lack of quality control and adherence to established standards.

Warning Letter on CGMP Violations at Avaria Corp

avaria-health-beauty-corp-663507-08032023.txt

This warning letter addresses significant violations of Current Good Manufacturing Practice (CGMP) regulations at Avaria Health & Beauty Corp. The firm failed to conduct identity testing of incoming components, specifically for diethylene glycol (DEG) and ethylene glycol (EG) contamination in glycerin used in OTC drug products, hand sanitizers, and topical drug products. The FDA requires a commitment to provide DEG and EG test results, a full risk assessment for drug products within expiry, and corrective actions to secure supply chains. The company's quality unit (QU) did not effectively oversee the quality of drug manufacturing operations, particularly in the approval or rejection of components. The FDA placed the firm on Import Alert 66-40 and may withhold approval of new applications or supplements. The company is expected to conduct a comprehensive assessment and remediation plan to ensure the QU's effective function. The violations pertain to section 501(a)(2)(B) of the FD&C Act due to failure to conform to CGMP regulations.

Warning Letter to Baja Fur S.A. de C.V.

baja-fur-sa-de-cv-590791-12132019.txt

This warning letter addresses significant violations of current good manufacturing practice (CGMP) regulations at Baja Fur S.A. de C.V. The FDA inspected the site and found that the company failed to thoroughly investigate out-of-specification microbiological contamination, did not include adequate production details in batch records, and failed to establish adequate written procedures for cleaning and maintenance of equipment. The company's responses to the FDA were deemed inadequate because they lacked sufficient detail and evidence of corrective actions. The FDA recommends engaging a CGMP consultant and performing a comprehensive audit of the operation. Violations of this type may result in the FDA withholding approval of any new drug applications or supplements. The company was found to be in violation of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B). The FDA requires a written response within 15 working days detailing corrective actions taken to prevent recurrence of these violations.

FDA Warning Letter: Failure to Submit IND Application

balamurali-k-ambati-md-phd-585585-08132019.txt

This warning letter addresses the objectionable conditions observed during an FDA inspection at a clinical site. The main issue was the failure to submit an Investigational New Drug (IND) application before conducting a clinical investigation of an unapproved drug, (b)(4), in combination with (b)(4), for the (b)(4). Twelve human subjects were enrolled and treated with the unapproved drug from April 2017 to December 2018 without the required IND. The FDA deemed the subsequent submission of an IND as inadequate, as it should have preceded the clinical investigation. The letter emphasizes the need for adherence to FDA regulations and the establishment of procedures to ensure compliance in future studies. The company must respond in writing within fifteen working days, outlining the actions taken to prevent similar violations. The document is a warning letter regarding failure to comply with regulations surrounding IND submission for a clinical trial.

FDA Warning Letter to Baltimore Beauty Security

baltimore-beauty-security-square-mall-614182-05042021.txt

This document is a warning letter from the FDA to Baltimore Beauty Security Square Mall regarding the sale of GenBody COVID-19 Ag and IgM/IgG test kits without the necessary FDA approvals, clearances, or authorizations. The FDA states that these test kits are considered adulterated and misbranded under the Federal Food, Drug, and Cosmetic Act. The letter instructs the company to immediately cease the sale of these unapproved products and to respond within 48 hours with a detailed plan to address the violations and prevent their recurrence. The warning emphasizes that failure to comply may result in legal action, including seizure and injunction, and that the company will be added to a public list of firms violating COVID-19 product regulations. The FDA's concerns stem from the absence of premarket approval or investigational device exemption for the test kits, as well as the failure to notify the agency of the intent to distribute them commercially. The core issue is the distribution of medical devices without proper FDA authorization during a public health emergency.

FDA Warning Letter to Banco Vida Corp

banco-vida-corp-597197-03042020.txt

This warning letter from the FDA to Banco Vida Corp. outlines significant deviations from regulations regarding Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps), specifically umbilical cord blood. The FDA conducted inspections and found failures in donor screening, testing, environmental controls, process validation, contamination prevention, deviation investigation, and procedure maintenance. The company's responses to the FDA's observations were deemed inadequate, particularly concerning ZIKV risk factors and process validation. The letter emphasizes the need for prompt corrective action to avoid regulatory action. The key information for the query is the specific manufacturing failures related to HCT/Ps, the regulatory violations, and the company's insufficient response to the FDA's concerns.

FDA Warning Letter to Banco Vida Corp.

banco-vida-corp-606288-08122020.txt

This warning letter from the FDA to Banco Vida Corp. outlines significant deviations from current good manufacturing practice (CGMP) and current good tissue practice (CGTP) in the manufacture of human umbilical cord blood for allogeneic use. The FDA conducted inspections and found deficient donor screening practices, inadequate aseptic practices, unvalidated manufacturing processes, and deficient environmental monitoring. These failures raise concerns about potential contamination with microorganisms or other serious product quality defects. The company distributed HCT/Ps from umbilical cord blood to third-parties without an approved biologics license application (BLA) or an investigational new drug application (IND) in effect. The FDA has identified Zika virus (ZIKV) as a relevant communicable disease agent, and the company's donor screening processes were inadequate in assessing the risk of ZIKV. The company's responses to the FDA's findings were deemed inadequate, particularly regarding ZIKV screening and the lack of an IND or BLA. The manufacturing failures described in this document pertain to deviations from FDA regulations and pose a significant risk to product safety and quality.

Warning Letter to Baxter Healthcare Corporation

baxter-healthcare-corporation-654136-07252023.txt

This warning letter addresses significant violations of Current Good Manufacturing Practice (CGMP) regulations at Baxter Pharmaceuticals India Pvt. Ltd. The FDA inspection revealed failures in investigating discrepancies, endotoxin testing, visual inspection of injectable drug products, equipment cleaning, and production/process controls. The company failed to thoroughly investigate discrepancies, particularly in endotoxin testing and the automated visual inspection system. They did not adequately address particulate matter contamination and failures of the inspection machine to detect defects. Cleaning procedures were also inadequate, leading to cross-contamination. The company's quality system was deemed ineffective, with a lack of proper authority and insufficient implementation of responsibilities. The FDA recommends engaging a consultant to assist in meeting CGMP requirements and requests a comprehensive assessment and remediation plan for visual inspection systems, cleaning effectiveness, and the CAPA program. The company's response to the FDA's findings was considered inadequate, particularly in addressing the use of unqualified equipment and the high number of contaminated samples. The issues in the document include failures in endotoxin testing, visual inspection, equipment cleaning, and adherence to CGMP regulations.

FDA Warning Letter to Baylab USA, LLC

baylab-usa-llc-679001-06272024.txt

This warning letter from the FDA to Baylab USA, LLC addresses significant violations related to the manufacture and distribution of medical devices, specifically the Class II BAYLAB 3-Ply Surgical Mask (BEACON I), the ASTM Level 1 Baylab 3-Ply Earloop Face Mask, and the KN95 Respirator. The FDA inspection revealed that these devices are adulterated and misbranded due to the lack of required premarket approvals, failure to adhere to quality system regulations, and non-compliant labeling. The company failed to establish and maintain design controls, supplier requirements, quality audits, and complaint handling procedures. The FDA also found that major changes were made to the ASTM Level 3 Mask without submitting a new premarket notification, including the introduction of new colors, materials, and expansion of the user population to include pediatric sizes. These changes could potentially affect the safety and effectiveness of the devices, particularly in vulnerable populations. The company's masks are available for purchase on their website in various colors and with various logos. The FDA requests that Baylab USA LLC cease activities that result in the misbranding or adulteration of their masks and respirators and take prompt action to address the identified violations. The company must respond in writing within fifteen business days, outlining the steps taken to correct the violations and prevent their recurrence. The violations include failure to comply with medical device reporting requirements, failure to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 – Medical Device Reporting, and failure to develop, maintain, and implement written medical device reporting (MDR) procedures as required by 21 CFR 803.17.

FDA Warning Letter to Becton, Dickinson and Company

becton-dickinson-and-companycarefusion-303-inc-691601-11222024.txt

This FDA warning letter addresses significant violations at Becton, Dickinson, and Company/CareFusion 303, Inc., concerning the manufacture of Pyxis Medication Management System medical devices. The FDA inspection revealed failures in establishing procedures for corrective and preventive actions, complaint handling, and design validation. The company's responses to the FDA's observations were deemed inadequate due to a lack of evidence of implementation of corrective actions. The devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. The company also failed to submit timely reports of corrections and removals, as required by 21 CFR § 806.10. This includes failures to report issues such as door/drawer failures, software errors, and dispensing medications without proper validation. The FDA emphasizes that failure to address these violations may result in regulatory action, including seizure, injunction, and civil money penalties. The warning letter highlights the company's failure to comply with FDA regulations and the potential risks to patient safety associated with these violations.

FDA Warning Letter to Bedfont Scientific, Ltd.

bedfont-scientific-ltd-604311-02122020.txt

This document is a warning letter from the FDA to Bedfont Scientific, Ltd. regarding violations of the Federal Food, Drug, and Cosmetic Act. The violations stem from an inspection of their manufacturing facility, which revealed failures to comply with current good manufacturing practice requirements. These failures include inadequate procedures for design validation, corrective and preventive action, control of non-conforming products, calibration of test equipment, and quality audits. The FDA found the company's initial responses to these observations inadequate due to a lack of documentation and specific timelines for corrective actions. The document mentions carbon monoxide gas analyzers and Steribreath tubes as the medical devices affected by these manufacturing failures. The company must respond in writing within fifteen business days with specific steps to correct the violations and prevent future occurrences, including documentation of corrections and a timetable for implementation. The FDA may advise other U.S. federal agencies and may deny Certificates to Foreign Governments if the violations are not addressed.

FDA Warning Letter to Beijing Xinggu Lvsan

beijing-xinggu-lvsan-technology-co-ltd-formerly-known-beijing-lvsan-technology-co-ltd-633904.txt

This warning letter from the FDA to Beijing Xinggu Lvsan Technology Co., Ltd. outlines significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. The FDA inspected the drug manufacturing facility and found that the company's methods, facilities, and controls did not conform to CGMP, leading to the adulteration of drug products. The company failed to conduct identity testing of components, failed to validate supplier's test analyses, and used the same equipment for drug and non-drug industrial products, leading to potential cross-contamination. The firm also failed to perform microbial testing on finished hand sanitizer products and failed to validate manufacturing processes. The quality control unit did not provide adequate oversight. The letter also addresses unapproved new drug and misbranding violations related to SierraSoft Alcohol Hand Sanitizer and SierraSoft Non-Alcohol Foam Hand Sanitizer. The FDA recommends engaging a CGMP consultant and has placed the firm on Import Alert 66-40. The company's response to the FDA's findings was deemed inadequate, particularly in addressing the deficiencies in the quality unit and data integrity. The FDA requires a comprehensive investigation into data inaccuracies and a detailed corrective action plan to ensure data reliability and completeness. The document is related to failures in manufacturing, quality control, and regulatory compliance in the production of hand sanitizers.

FDA Warning Letter to Belmont Eyecare LLC

belmont-eyecare-llc-670186-12012023.txt

This warning letter issued by the FDA to Belmont Eyecare LLC addresses the marketing and sale of unapproved new drugs, specifically eye drops, violating sections 301(d) and 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act). The products, including Colloidal Silver Eye Drops, MSM Eye Drops, Organic Daytime Oil Eye Drops, and Organic Evening Oil Eye Drops, are not recognized as safe and effective for their intended uses, posing a risk to public health. The letter instructs Belmont Eyecare LLC to notify the FDA within fifteen working days with corrective actions and documentation to prevent recurrence. Failure to comply may result in legal action, including seizure and injunction. The FDA emphasizes the importance of adhering to federal laws and regulations, particularly regarding drug approval and marketing standards. The key information relevant to the query is the specific regulatory violations related to marketing unapproved medical devices, potential safety risks, and the FDA's requirements for corrective action.

FDA Warning Letter to Berkeley Biologics on CGMP Violations

berkeley-biologics-llc-previously-operating-elutia-inc-orthobiologics-business-unit-formerly-aziyo.txt

This warning letter from the FDA to Berkeley Biologics, LLC (formerly Elutia, Inc. – Orthobiologics Business Unit, formerly Aziyo Biologics, Inc.) outlines significant violations of the Federal Food, Drug, and Cosmetic Act (FD&C Act) and Public Health Service Act (PHS Act) related to the manufacture of viable bone matrix products. The FDA inspection revealed failures in donor eligibility determination, deviations from current good tissue practice (CGTP) and current good manufacturing practice (CGMP) requirements, and a lack of validation of manufacturing processes. These violations include the use of donors with sepsis, inadequate process controls, contamination during aseptic processing, and insufficient laboratory controls. The products in question, Viable Bone Matrix (VBM), Fiber Viable Bone Matrix (FVBM), Cellular Fiber Matrix (CFM)/Excel Viable Bone Matrix (EFM), and Osteo Viable Bone Matrix (OVM), are considered unapproved new drugs and adulterated due to the manufacturing deficiencies. The company's responses to the FDA's observations were deemed inadequate, particularly in addressing the handling of donors with sepsis and the lack of comprehensive validation. The FDA expects the company to take immediate action to correct these violations and prevent their recurrence, warning of potential regulatory action such as seizure or injunction. The key issues are the company's failure to adhere to CGTP and CGMP, potentially compromising the safety and efficacy of their bone matrix products.

FDA Warning Letter to BGP, LLC Regarding COVID-19 Claims

bgp-llc-613144-05192021.txt

This document is a warning letter issued by the FDA and FTC to BGP, LLC regarding the sale of an unapproved and misbranded drug product, "BIOCENCE WS Multi-use Selective Antibacterial / Antiviral Human OTC Drug". The product was marketed as effective against COVID-19 and other conditions, violating the Federal Food, Drug, and Cosmetic Act. The letter outlines specific claims made on the company's website and social media that misled consumers about the product's safety and effectiveness. The FDA and FTC requested that BGP, LLC cease the sale of unapproved products and address the violations within 48 hours. Failure to comply may result in legal action, including seizure and injunction. The company was also advised to review its marketing materials to ensure compliance with regulations. The warning letter indicates that the company's marketing of the drug product without FDA approval and with misleading claims constitutes a failure to comply with FDA regulations.

FDA Warning Letter to Bhargava Phytolab Private Limited

bhargava-phytolab-private-limited-691610-12182024.txt

This warning letter from the FDA to Bhargava Phytolab Private Limited outlines significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals and deviations from CGMP for active pharmaceutical ingredients (APIs). The FDA inspection revealed failures in testing APIs, inadequate testing for impurities, and issues with the design and maintenance of a water system. The firm also supplied aseptically filled products without adequate validation of their aseptic process. The company committed to cease production of certain products for the U.S. market and to perform a comprehensive assessment of their manufacturing operations. The FDA recommends engaging a consultant to evaluate operations and assist in meeting CGMP requirements. The violations could lead to adulterated drugs, potentially containing harmful impurities or microbiological contamination. The FDA placed products offered for import into the U.S. from the firm on Import Alert 66-40. The document addresses the firm's failures to adhere to manufacturing standards, potentially leading to unsafe products.

FDA Warning Letter to BioPure Healing Products

bhp-holdings-inc-dba-biopure-healing-products-597687-06172020.txt

This document is a warning letter from the FDA to BHP Holdings Inc. dba BioPure Healing Products regarding serious violations of the Federal Food, Drug, and Cosmetic Act (the Act) and applicable regulations. The FDA conducted an inspection of the facility and identified violations of Current Good Manufacturing Practice (CGMP) regulations, causing the dietary supplement products to be adulterated. The company failed to review product complaints related to adverse events and did not properly investigate these complaints to identify root causes. Additionally, the company's Cocktail Liposomal, Neem Synergy, and Matrix Electrolyte Powder products are misbranded dietary supplements due to non-compliance with labeling requirements, including failure to declare soy allergen sources, failure to identify the part of the plant from which botanical dietary ingredients are derived, and incorrect presentation of nutrition information on the labeling. The FDA requires the company to take prompt action to correct these violations to avoid legal action, including seizure of violative products and/or injunction. The company's failure to adhere to manufacturing best practices, as evidenced by the FDA's warning letter, led to a variety of violations and potential safety risks.

FDA Warning Letter to Bingbing Pharmaceutical Co.

bingbing-pharmaceutical-co-ltd-584327-10032019.txt

This warning letter from the FDA to Bingbing Pharmaceutical Co., Ltd. outlines significant violations of current good manufacturing practice (CGMP) regulations. The FDA inspected the drug manufacturing facility and found failures in maintaining records, testing drug products, and ensuring quality control. The company failed to maintain manufacturing records, released OTC drugs without testing active ingredients, and had a quality unit that did not provide adequate oversight. The firm's responses to the FDA's findings were deemed inadequate, lacking supporting documentation and comprehensive reviews. The FDA recommends retaining a qualified consultant to assist in remediation and provides guidance on data integrity. The violations cited in this letter include not maintaining production records, failing to test active ingredients, and a deficient quality control unit, all impacting the quality and compliance of drug products manufactured by Bingbing Pharmaceutical Co., Ltd.

FDA Warning Letter to BioLab Sciences, Inc.

biolab-sciences-inc-621465-08232022.txt

This document is a warning letter from the FDA to BioLab Sciences, Inc., addressing significant deviations from current good manufacturing practice (CGMP) requirements and violations of the Federal Food, Drug, and Cosmetic Act (FD&C Act) and the Public Health Service Act (PHS Act). The letter outlines failures in various manufacturing processes related to products derived from human amniotic fluid and epidermal skin tissue. The FDA conducted an inspection and found that BioLab Sciences had not validated aseptic processes, sterilization processes, or cleaning processes for their facilities and equipment. There were also issues with environmental monitoring, personnel practices, and the design of aseptic processing areas. The company failed to thoroughly investigate discrepancies in microbiological monitoring and did not have adequate testing programs for components and drug products. The FDA also noted that the company was marketing products without the required biologics license application (BLA) or investigational new drug application (IND). The warning letter highlights the company's inadequate responses to previous inspectional observations and emphasizes the need for corrective actions to address the identified violations. The FDA requests a written response outlining the steps taken to correct the violations and prevent their recurrence. The information in the document is relevant to the query because it provides specific examples of manufacturing failures in the production of medical devices, as well as the regulatory consequences and the company's response to these failures.

FDA Warning Letter to BioLyte Laboratories, LLC

biolyte-laboratories-llc-603584-03182021.txt

This warning letter from the FDA to BioLyte Laboratories, LLC, outlines significant violations of current good manufacturing practice (CGMP) regulations for finished pharmaceuticals and misbranding regulations for dietary supplements. The FDA inspected the company's drug manufacturing facility and found that their methods, facilities, and controls did not conform to CGMP, leading to adulterated drug products. The company released over-the-counter (OTC) topical drug products without adequate quality control testing, including identity and strength of each active ingredient. The firm failed to conduct at least one test to verify the identity of each component of a drug product and did not establish a written testing program to assess the stability characteristics of drug products. The company's products, including silver gels, pain relief creams, and magnesium oil sprays, were found to be unapproved new drugs and misbranded due to unsubstantiated claims and improper labeling. The FDA's primary concern is that the company is not performing adequate testing to ensure the identity, strength, quality, and purity of their drug products, which poses a risk to consumers.

FDA Warning Letter to BioMD Plus LLC

biomd-plus-llc-618460-05042022.txt

This document is a warning letter from the FDA to BioMD Plus LLC, addressing violations of the Federal Food, Drug, and Cosmetic Act (FD&C Act) related to the marketing and sale of unapproved products containing cannabidiol (CBD) and Delta-8 tetrahydrocannabinol (THC). The FDA reviewed the company's website and social media accounts and found that the products are marketed as drugs for humans and animals without the required FDA approval. These products are also considered misbranded and adulterated under the FD&C Act. The warning letter highlights concerns about the safety and efficacy of Delta-8 THC and the potential health risks to consumers. The letter instructs BioMD Plus LLC to respond within fifteen working days with a plan to correct the violations and prevent their recurrence. The FDA emphasizes that failure to address the issues may result in legal action, including seizure and injunction. The document indicates that BioMD Plus is non-compliant with FDA regulations regarding the marketing and sale of CBD and Delta-8 THC products.

FDA Warning Letter to Biomedix WAI on Failures

biomedix-wai-598171-02122020.txt

This warning letter from the FDA to Biomedix WAI details significant failures in their manufacturing processes for SELEC-3 gravity I.V. administration sets and extension sets. The FDA inspection revealed that the company failed to establish and maintain adequate procedures for controlling non-conforming products, validating processes, monitoring process parameters, ensuring in-process product requirements are met, and managing design changes. The company's responses to the FDA's observations were deemed inadequate, with requests for further documentation, retrospective reviews, and revised procedures to address the identified nonconformities and failures. The FDA has requested that Biomedix WAI take prompt action to correct these violations, including submitting certifications from an outside expert consultant and the company's CEO, and notifying the FDA of the specific steps taken to correct the violations and prevent their recurrence. The identified failures relate to violations of section 501(h) of the Federal Food, Drug, and Cosmetic Act and the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. The document indicates a lack of proper procedures for handling non-conforming products, inadequate process validation, and insufficient monitoring of process parameters, which are critical aspects of medical device manufacturing and quality assurance.

FDA Warning Letter to Biopolygen Corp

biopolygen-corp-613137-07092021.txt

This document is a warning letter from the FDA to Biopolygen Corp. regarding the sale of unapproved COVID-19 self-detection test kits. The FDA found that the company's COVID-19 Self Detection Test Kits are being sold without the necessary premarket approval, clearance, or authorization, making them adulterated and misbranded under the Federal Food, Drug, and Cosmetic Act. The warning letter requests that Biopolygen Corp. cease the sale of these unapproved products immediately and outlines the specific violations. It also mentions the potential public health risks associated with at-home testing without proper oversight. The company is required to respond within 48 hours with a plan to address the violations and prevent their recurrence. The FDA is advising consumers not to purchase or use such unapproved products and will add the firm to a list of those selling fraudulent COVID-19 products. The document is relevant to the query because it explicitly describes manufacturing failures related to regulatory compliance and the distribution of medical devices without proper FDA approval.

FDA Warning Letter to BioStem Life Sciences

biostem-life-sciences-673788-01172025.txt

This warning letter from the FDA to BioStem Life Sciences addresses significant violations of current good manufacturing practice (CGMP) requirements. The violations pertain to cellular products derived from human umbilical cord and amniotic membrane, including OROPRO®, PROVISCUS®, NEOFYL®, and RHEO®. These products are considered drugs and biological products, and the FDA found that BioStem's manufacturing processes did not conform to CGMP standards. The FDA's inspection revealed failures in environmental monitoring, cleaning and disinfection, process validation, laboratory controls, and stability testing. The company's responses to the FDA's findings were deemed inadequate, and the FDA has requested a detailed plan of corrective actions to prevent recurrence. The FDA has serious safety concerns regarding the use of these products on patients via injection because the products are not sterile. The FDA's concerns include the company's failure to adhere to CGMP regulations, which are essential for ensuring the safety, purity, and potency of drug products. The FDA emphasizes that injectable products must be sterile to ensure patient safety and that BioStem needs to address the impact of CGMP deficiencies on distributed products. The company has removed some products from the market, but the FDA requires a plan to address the impact of CGMP deficiencies on distributed products that remain within expiry.

FDA Warning Letter to BIOTA Biosciences LLC

biota-biosciences-llc-605164-04092020.txt

This document is a warning letter from the FDA to BIOTA Biosciences LLC, addressing violations of the Federal Food, Drug, and Cosmetic Act (FD&C Act). The letter states that the company's website offers injectable drug products, including "Canabidiol (CBD) Complex," "Cannabidiol+Curcumin," and "Curcumin Complex," which are considered unapproved new drugs and misbranded drugs. These products are marketed with claims to treat various conditions, including opioid addiction, without FDA approval. The FDA expresses concern about the potential harm to users due to the direct injection of these products into the bloodstream, bypassing natural defenses against toxins and dangerous organisms. The letter instructs the company to take prompt action to correct the violations and prevent their recurrence, or face legal action, seizure, and injunction. The document is relevant to the query because it addresses failures related to the manufacturing and marketing of unapproved and misbranded medical products, specifically injectable CBD drugs. It highlights violations of FDA regulations and the potential consequences of these failures.

FDA Warning Letter to Molecular Testing Labs

blackfly-investments-llc-dba-molecularr-testing-labs-680324-10112024.txt

This warning letter from the FDA to Blackfly Investments, LLC dba Molecular Testing Labs (MTL) addresses the company's marketing and sale of an unauthorized HIV Dried Blood Spot (DBS) card self-collection kit. The FDA asserts that the kit is being offered for sale without the necessary marketing authorization, violating the Federal Food, Drug, and Cosmetic Act (FD&C Act). The FDA has determined that the HIV DBS card self-collection kit is adulterated and misbranded because it lacks an approved premarket approval application (PMA) or an approved application for an investigational device exemption (IDE). The company has been in communication with the FDA regarding the kit, but has not submitted a De Novo request or any other premarket submission to the FDA seeking authorization to market this kit. The FDA also clarified that they did not state an intent to exercise enforcement discretion as to the statutory or regulatory requirements applicable to the HIV DBS card self-collection kit. The company has been requested to cease any activities that result in the misbranding or adulteration of their HIV DBS card self-collection kit. The FDA is concerned about the safety and effectiveness of the self-collection kit, particularly whether individuals can reliably collect their own samples and if the samples are affected by transport conditions. The FDA has requested a written response within fifteen working days of the letter receipt, outlining the specific steps taken to correct any violations and prevent their recurrence. The company is in violation of the FD&C Act because the HIV DBS card self-collection kit does not have an approved premarket approval application (PMA) and notification of the intent to introduce the device into commercial distribution has not been provided to the agency.

FDA Warning Letter to Block Scientific

block-scientific-609533-03182021.txt

This document is a warning letter from the FDA to Block Scientific regarding the sale of unapproved COVID-19 antibody and antigen test kits. The FDA found that these products were being offered for sale without the necessary marketing approval, clearance, or authorization, violating sections of the Federal Food, Drug, and Cosmetic Act. The letter instructs Block Scientific to cease the sale of these unapproved products and to provide a plan to prevent future violations. The FDA is taking measures to protect consumers from products claiming to mitigate, prevent, treat, diagnose, or cure COVID-19 without proper authorization. The document is related to the query because it describes failures related to regulatory compliance in the context of manufacturing and distributing medical devices.

EVs and Exosomes Use Cases Report

Executive Summary

Several warning letters issued by the FDA and FTC address the marketing and sale of unapproved and misbranded products, some of which involve **exosomes** and other cellular and tissue-based products. A prevalent theme is the promotion of these products with claims of treating or preventing various diseases and conditions, including **COVID-19**, without the necessary FDA approvals or scientific evidence. The intended use of these products spans a wide range of applications, including wound healing, tissue regeneration, orthopedic treatments, and addressing neurodegenerative diseases. Many of the warning letters cite significant deviations from current good manufacturing practice (CGMP) and current good tissue practice (CGTP) requirements. These violations include failures in aseptic processing, sterility testing, environmental monitoring, donor screening, and process validation. The FDA emphasizes that products marketed for therapeutic purposes are regulated as drugs and biological products, requiring premarket review and a valid biologics license application (BLA) or investigational new drug application (IND). Companies failing to meet these requirements are considered to be in violation of the Federal Food, Drug, and Cosmetic Act (FD&C Act) and the Public Health Service Act (PHS Act). The documents reveal a trend in the marketing of products derived from human umbilical cord, amniotic fluid, and other perinatal tissues. These products are often promoted as having regenerative properties and are intended for allogeneic use. However, the FDA has determined that many of these products do not meet the criteria for regulation solely under section 361 of the PHS Act and are subject to additional regulation as drugs and biological products. The FDA raises concerns about potential contamination, product quality defects, and the safety risks associated with using unapproved and improperly manufactured products. The FDA emphasizes the importance of regulatory compliance and scientific validation in the development and marketing of health products, including those related to EVs and exosomes. The agency demands that companies take corrective action to address the violations and prevent their recurrence, or face potential legal action, such as seizure or injunction. The regulatory landscape surrounding EVs and exosomes is evolving, and companies must adhere to strict manufacturing and quality control standards to ensure the safety and efficacy of their products.

EVs and Exosomes Use Cases Report

Tags Summary

Exosomes and **EVs** are most prominent, suggesting a focus on fundamental research. **Therapeutics** and **Diagnostics** are notable, pointing to translational interest. Lower **Drug Delivery**, **Neurodegenerative Diseases**, and **Immunomodulation** counts may indicate niche areas. The low **Cancer** count is an anomaly, potentially signifying a gap in coverage.

Tag Frequency



Document Relevancy



Questions And Answers

1. What is the intended use of the product or products discussed in this document related to EVs or exosomes?



2. What specific regulations or guidelines, if any, are referenced in this document regarding products involving EVs or exosomes?



3. What are the potential safety concerns or adverse effects, if any, highlighted in this document concerning products related to EVs or exosomes?



4. What specific violations or deviations from regulatory standards are mentioned in the document regarding EVs or exosomes?



5. To what extent does this document discuss the marketing and distribution of products related to EVs or exosomes?



6. What evidence, if any, is presented in this document to support the claims made about products related to EVs or exosomes?



7. What manufacturing or quality control issues are identified in this document pertaining to products involving EVs or exosomes?



8. What claims, if any, are made about the therapeutic or diagnostic applications of EVs or exosomes in this document?



Top Matches

FDA Warning Letter to Evolutionary Biologics Inc.

evolutionary-biologics-inc-681586-12302024.txt

This document is a warning letter from the FDA to Evolutionary Biologics Inc. regarding their products EXO RNA™ (exosome product), EVO JEL™ (an umbilical cord-derived product), and EVO HYBRID™ (a cellular product). The FDA has determined that these products are unapproved new drugs and unlicensed biological products, violating section 301(d) of the FD&C Act. The letter details that the products are marketed for various therapeutic uses, such as treating inflammation, repairing tissue, and addressing neurodegenerative diseases. The FDA states that EVO JEL™ and EVO HYBRID™ fail to meet criteria for homologous use and minimal manipulation under 21 CFR Part 1271. Additionally, the FDA references a public safety notification regarding exosome products due to reports of adverse events. The company is required to respond within fifteen working days, outlining steps to address the violations. The warning letter focuses on the company's claims regarding the therapeutic applications of their products, including EXO RNA's potential benefits for neurodegenerative diseases, EVO JEL's orthopedic applications, and EVO HYBRID's regenerative properties. The FDA is concerned with the lack of premarket review and approval, as well as the potential safety issues associated with these products.

FDA Warning Letter to Kimera Labs re: Exosomes

kimera-labs-inc-649343-09012023.txt

This document is a warning letter from the FDA to Kimera Labs, Inc., addressing significant violations of the Federal Food, Drug, and Cosmetic Act (FD&C Act) and the Public Health Service Act (PHS Act) in the manufacturing and distribution of their exosome products (XoGlo® and XoGlo®Pro) and amniotic fluid product (Amnio2X®). The FDA conducted an inspection and found significant deviations from current good manufacturing practice (CGMP) requirements. The letter outlines numerous CGMP violations, including failures in aseptic processing, environmental monitoring, sterility testing, and validation of manufacturing processes. The FDA emphasizes that these products are intended to treat various diseases or conditions, thus requiring premarket review and approval, which Kimera Labs has not adequately obtained. The company continued to market and distribute these products despite previous warnings and without approved biologics license applications (BLA) or investigational new drug applications (IND) in effect for all products. The warning letter also references a Public Safety Notification on Exosome Products issued by the FDA, following reports of serious adverse events. The FDA demands a written response outlining steps to address the violations and prevent recurrence, or face potential regulatory action. The document is highly relevant to the query as it directly discusses the regulatory and safety aspects of exosome products and their use in treating diseases.

FDA Warning Letter to Chara Biologics Regarding Products

chara-biologics-inc-698004-01172025.txt

This document is a warning letter from the FDA to Chara Biologics, Inc., addressing violations related to the manufacturing and distribution of their products CharaExo, CharaCore, and CharaOmni. These products are marketed for various therapeutic uses, including treatment of autoimmune disorders, neurodegenerative conditions, and other diseases. The FDA has determined that these products are unapproved new drugs and unlicensed biological products, violating the Federal Food, Drug, and Cosmetic Act (FD&C Act) and the Public Health Service Act (PHS Act). The letter also cites significant violations of current good manufacturing practice (CGMP) and current good tissue practice (CGTP) requirements. These violations include failure to establish a quality unit, inadequate documentation of donor eligibility, and misbranding of products. The FDA considers Chara Biologics' responses to previous observations as inadequate and demands a written response outlining steps taken to address the violations. The document is relevant to the query because it discusses the unapproved therapeutic and diagnostic applications of EVs and exosomes, specifically in the context of CharaExo, which contains extracellular vesicles. It also highlights regulatory issues and lack of evidence supporting the claims made about these products.

FDA Warning Letter to DR Vitamins, LLC

dr-vitamins-llc-dba-dr-vitamin-solutions-663127-09112023.txt

This document is a warning letter from the U.S. Food and Drug Administration (FDA) to DR Vitamins, LLC, regarding the marketing and sale of unapproved new drugs, specifically eye drops such as "Vision Clarity Eye Drops," “Life Extension Brite Eyes III,” “Can-C Eye Drops,” and “Longevity Science Visual Ocuity.” The FDA found that these products are being marketed with claims to treat conditions like cataracts and dry eyes, which classifies them as drugs under the Federal Food, Drug, and Cosmetic Act (FD&C Act). However, the FDA states that these products have not undergone the required approval process and are thus being illegally introduced into interstate commerce. The warning letter addresses violations of the FD&C Act related to unapproved new drugs and misbranding. The FDA emphasizes that the company must take corrective action to address these violations and prevent their recurrence. The products contain N-Acetyl-Carnosine (NAC), which is claimed to treat cataracts, but is not a permitted ingredient. The FDA considers these products to be related to therapeutics and diagnostics for eye conditions.

FDA Warning Letter to Human Microbes Regarding FMT

human-microbes-672740-02092024.txt

This document is a warning letter issued by the FDA to Human Microbes regarding their fecal microbiota for transplantation (FMT) products. The FDA has reviewed Human Microbes' website and found that they are offering FMT for sale for the treatment or prevention of various diseases or conditions, such as C. difficile, IBS, IBD, Parkinson's disease, and mental health disorders. The FDA considers these products to be unapproved new drugs and unlicensed biological products because they lack the required BLA or approved application. The warning letter states that Human Microbes is in violation of the FD&C Act and the PHS Act. The company's practices do not align with the FDA's enforcement discretion policy, particularly for uses beyond C. difficile infection. The FDA also raises concerns about inadequate donor screening and potential safety issues. The letter instructs Human Microbes to take corrective action and notify the FDA of the steps taken to address the violations. The document is relevant to the query because it discusses the therapeutic applications of FMT and the regulatory issues associated with its marketing and distribution.

FDA Warning Letter on Unapproved COVID-19 Products

21st-century-lasermed-pain-institute-dba-create-wellness-clinics-607654-07212020.txt

This document is a warning letter from the FDA and FTC to 21st Century LaserMed Pain Institute d/b/a Create Wellness Clinics regarding the sale of unapproved and misbranded products related to Coronavirus Disease 2019 (COVID-19). The letter addresses the company's claims about umbilical cord stem cell products, exosome products, immune support bundles, and COVID-19 test kits. The FDA and FTC found that the company was marketing these products with claims to mitigate, prevent, treat, diagnose, or cure COVID-19, which violates the FD&C Act and the FTC Act. The letter specifically mentions that the umbilical cord stem cell product is an unapproved new drug and a misbranded drug and that the COVID-19 Test Kit is adulterated and misbranded. The company is also marketing an exosome product for diseases or conditions, such as macular degeneration and alpha 1 antitrypsin deficiency. The warning letter instructs the company to take immediate action to cease the sale of these products and correct the violations cited. It also advises consumers not to purchase or use these products and informs the company that failure to correct the violations may result in legal action. The information relevant to the query is the discussion of exosome products being marketed for various conditions, which falls under the use cases for EVs and exosomes.

FDA Warning Letter to Amnio Technology Regarding Biologics

amnio-technology-llc-646460-10012024.txt

This document is a warning letter from the FDA to Amnio Technology, LLC, concerning their amniotic membrane and amniotic fluid derived products, PalinGen® Flow® and PalinGen® Inov Flo®. The FDA inspection revealed that these products are being marketed as drugs and biological products without the required premarket review and approval. The letter also cites significant deviations from current good manufacturing practice (CGMP) requirements, including failures in process validation, stability testing, and complaint handling. The FDA states that PalinGen® Flow® does not meet the criteria for regulation solely under section 361 of the PHS Act because it is more than minimally manipulated and is not intended for homologous use only. PalinGen® Inov Flo® is also considered a drug and biological product requiring premarket approval. The letter emphasizes that the products are unapproved new drugs and their distribution violates the FD&C Act and the PHS Act. The company's responses to the FDA's observations were deemed inadequate, and the FDA requests a written response outlining corrective actions. The document is relevant to the query because it discusses regulatory issues related to products derived from amniotic fluid, which may contain EVs or exosomes, and their intended use in wound healing and tissue regeneration.

FDA Warning Letter to BioStem Life Sciences

biostem-life-sciences-673788-01172025.txt

This warning letter from the FDA to BioStem Life Sciences addresses significant violations of current good manufacturing practice (CGMP) requirements and other regulatory issues related to their cellular products derived from human umbilical cord and amniotic membrane. The products, including OROPRO®, PROVISCUS®, NEOFYL®, and RHEO®, are intended for regenerative medicine applications, such as treating damaged tissues and joints. The FDA's inspection revealed that these products do not meet the criteria to be regulated solely under section 361 of the PHS Act and are also regulated as drugs and biological products, requiring a valid biologics license application (BLA), which they lack. The letter details CGMP violations, including inadequate systems for environmental monitoring, cleaning and disinfection, process validation, laboratory controls, and stability testing. The FDA also raises concerns about the products not being sterile despite being intended for injection, posing a safety risk to patients. BioStem Life Sciences' responses to the FDA's initial observations were deemed inadequate. The FDA requests a written response outlining steps taken to address the violations and prevent recurrence. The document is important to the query because it discusses the therapeutic and diagnostic applications of regenerative medicine products, the intended use of these products in treating damaged tissues and joints, and potential safety concerns associated with their use. It also highlights regulatory standards and violations related to manufacturing and quality control.

FDA Warning Letter to Invitrx Therapeutics re: Exosomes

invitrx-therapeutics-inc-630712-11092022.txt

This document is a warning letter from the FDA to Invitrx Therapeutics, Inc., concerning the manufacturing and distribution of cellular and acellular products, including exosome products Invitra EX™ and Invitra EV-OP™. The FDA inspection revealed significant deviations from current good manufacturing practice (CGMP) and current good tissue practice (CGTP) requirements, as well as violations of the Federal Food, Drug, and Cosmetic Act (FD&C Act) and the Public Health Service Act (PHS Act). The warning letter addresses issues such as deficient donor screening practices, inadequate aseptic practices, unvalidated manufacturing processes, deficient environmental monitoring, and the lack of approved biologics license applications (BLA) or investigational new drug applications (IND) for the products. The FDA expresses concerns about the potential for product contamination and other serious quality defects, highlighting the risk to patients. The letter also notes that Invitrx continued to manufacture and distribute these products even after a previous warning letter in March 2020. The document is related to the query because it describes common use cases for EVs and exosomes, specifically their therapeutic and diagnostic applications, while also highlighting safety and regulatory concerns.

FDA Warning Letter to RenatiLabs Inc. on WJMAX™

renatilabs-inc-646353-06012023.txt

This document is a warning letter from the FDA to RenatiLabs Inc. regarding their product WJMAX™, which is derived from human umbilical cord and intended for allogeneic use. The FDA conducted an inspection and found that the product is being marketed as a drug and biological product without the necessary approvals or licenses. The product is intended to be administered by intra-articular injection or topically to open wounds and purports to be sterile, and is intended to treat various diseases or conditions. The letter details significant deviations from current good manufacturing practice (CGMP) requirements, including failures in sterility testing, aseptic processing, production and process control, and laboratory controls. The FDA also found that the company's responses to the inspectional observations were inadequate. The letter emphasizes that RenatiLabs must take immediate action to address these violations and prevent their recurrence to avoid regulatory action such as seizure or injunction. The document is important to the query because it describes the therapeutic applications of a product, WJMAX™, and the regulatory issues and safety concerns associated with its manufacturing and distribution.

FDA Warning Letter to Safari Stem Cell, LLC

safari-stem-cell-llc-661023-04052024.txt

This document is a warning letter from the FDA to Safari Stem Cell, LLC, addressing violations of the Federal Food, Drug, and Cosmetic Act (FD&C Act) concerning the marketing and manufacturing of unapproved new animal drugs. The company recovers, processes, and distributes cell- and tissue-based products, including platelet-rich plasma, conditioned media, and stem cells from canine and feline donors, intended to treat various diseases. The FDA found that Safari's products are unapproved new animal drugs due to a lack of recognition among qualified experts as safe and effective, and they are not subject to an approved new animal drug application. The letter also cites significant deviations from Current Good Manufacturing Practice (CGMP) regulations, including failures in establishing written procedures for production, in-process controls, laboratory testing, environmental monitoring, equipment maintenance, and complaint handling. These violations cause the animal drug products to be adulterated under the FD&C Act. The FDA emphasizes that Safari's marketing of stem cell products for treating conditions like arthritis, kidney disease, and immunological disorders violates federal law, as the products are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in animals, making them drugs under the FD&C Act. The document is relevant to the query as it discusses the unapproved therapeutic applications and regulatory violations related to stem cell products, which may involve EVs or exosomes.

FDA Warning Letter to Stemell Inc Regarding Biologics

stemell-inc-579013-08282019.txt

This document is a warning letter from the FDA to Stemell, Inc. regarding violations of the Federal Food, Drug, and Cosmetic Act (FD&C Act) and the Public Health Service Act (PHS Act). The letter addresses the manufacturing and marketing of umbilical cord products (StemL UCB-Plus™ and StemL UCT-Plus™) and an exosome product (StemL XPlus™) for allogeneic use. Stemell is cited for marketing these products as regenerative cellular therapies for various conditions, including arthritis, without the required FDA approvals, such as a biologics license application (BLA) or an investigational new drug application (IND). The FDA inspection revealed significant deviations from current good manufacturing practice (CGMP) and current good tissue practice (CGTP), raising concerns about product safety and quality. These deviations include deficient donor eligibility practices, unvalidated manufacturing processes, inadequate aseptic practices, and deficient environmental monitoring. The FDA also notes that Stemell's website contains the FDA logo, which is unauthorized. The letter requests a written response from Stemell outlining corrective actions and warns of potential regulatory actions, including seizure or injunction, if the violations are not addressed. The document is important to the query because it discusses the regulatory aspects, potential safety concerns, and manufacturing issues related to products involving exosomes and EVs.

FDA Warning Letter to Vitti Labs Regarding Biologics

vitti-labs-llc-627699-07282022.txt

This document is a warning letter issued by the FDA to Vitti Labs, LLC, concerning their manufacture and distribution of products derived from human umbilical cord and amniotic membrane, including EV-PURE+, WJ-PURE+, VITTI-PURE, NS-PURE, and EV-OPTI DROPS. The FDA inspection revealed that these products, intended for injection, ophthalmic administration, and topical application, are being marketed for clinical use in humans to treat various diseases and conditions. The core issues raised in the letter concern significant deviations from CGMP requirements, including failures in aseptic processing, sterilization, environmental monitoring, and quality control. The firm also lacks appropriate validation, testing, and stability data for their products. The FDA emphasizes that Vitti Labs' products do not meet the criteria for regulation solely under section 361 of the PHS Act and require premarket review and a valid biologics license, which they currently lack. The warning letter also addresses the absence of an IND for clinical use. The document is relevant to the query because it discusses regulatory violations and quality control issues related to biologics, some of which are named EV-PURE.

FDA Warning Letter to XO Biologix Regarding MaviX™

xo-biologix-llc-697717-12122024.txt

This document is a warning letter from the FDA to XO Biologix, LLC, concerning their product MaviX™, derived from amniotic fluid. The FDA conducted an inspection and found that MaviX™ is being marketed and distributed as an unapproved new drug and an unlicensed biological product, violating the Federal Food, Drug, and Cosmetic Act (FD&C Act) and the Public Health Service Act (PHS Act). The letter also states that the product is adulterated due to significant violations of current good manufacturing practice (CGMP) requirements. Furthermore, MaviX™ is misbranded because its labeling is false or misleading, with inconsistencies in the stated expiry period and a misrepresentation of the product's form. The intended use of MaviX™ is for the diagnosis, cure, mitigation, treatment, or prevention of disease, with promotional materials claiming it helps reduce pain, inflammation, and regenerate tissue. The FDA requires XO Biologix to respond with corrective actions to address these violations.

FDA Warning Letter to EUCYT Laboratories Regarding Exosomes

eucyt-laboratories-llc-607182-06042020.txt

This document is a warning letter from the FDA to EUCYT Laboratories LLC regarding the manufacture and distribution of unapproved biological products, including an exosome product called XOsomes™ and COVIXO for COVID-19 treatment. The letter details significant deviations from current good manufacturing practice (CGMP) and current good tissue practice (CGTP). These deviations include deficient donor eligibility practices, unvalidated manufacturing processes, deficient environmental monitoring, and inadequate aseptic practices, raising potential safety concerns. The FDA emphasizes that these products require premarket review and approval, which EUCYT has not obtained. The warning letter also notes that EUCYT's products do not meet the criteria for regulation solely under section 361 of the PHS Act and are therefore regulated as drugs and biological products under the FD&C Act and/or section 351 of the PHS Act. The letter requests a written response from EUCYT outlining the steps taken to correct the violations and prevent their recurrence. The document is related to the query because it discusses the use of EVs (exosomes) for therapeutic purposes (COVID-19 treatment) and highlights regulatory concerns and safety issues associated with their manufacturing and distribution.

FDA Warning Letter to Predictive Biotech Regarding CoreCyte™

predictive-biotech-608322-08172020.txt

This warning letter from the FDA to Predictive Biotech addresses the marketing and distribution of their umbilical cord-derived product, CoreCyte™, for the treatment or prevention of COVID-19. The FDA states that CoreCyte™ is being marketed without the necessary approval and violates the Federal Food, Drug, and Cosmetic Act and the Public Health Service Act. The product is claimed to mitigate, prevent, treat, diagnose, or cure COVID-19, as well as being used for autoimmune conditions, dementia, and for cushioning and protection. The FDA asserts that CoreCyte™ does not meet the criteria for regulation solely under section 361 of the PHS Act and is considered an unapproved new drug and a misbranded drug. The letter emphasizes that there is no approved biologics license application (BLA) or investigational new drug (IND) application in effect for CoreCyte™. Predictive Biotech was marketing CoreCyte™ to healthcare providers, claiming it could treat or prevent COVID-19, even referencing a non-existent Emergency Use Authorization from the FDA. The document is related to the query because it discusses the unapproved therapeutic use of a product that could potentially contain EVs or exosomes, though they are not explicitly mentioned.

FDA Warning Letter to Utah Cord Bank

utah-cord-bank-llc-614021-05112021.txt

This document is a warning letter from the FDA to Utah Cord Bank, LLC, detailing significant deviations from regulations for human cells, tissues, and cellular and tissue-based products (HCT/Ps). The FDA conducted an inspection and found failures in process validation, environmental monitoring, and maintenance of procedures to prevent contamination. The letter also points out inadequate record-keeping and seeks clarification on the intended uses of the products, specifically whether they are intended for autologous use only or also for allogeneic use in relatives. The warning letter emphasizes the need for corrective actions to address these violations and prevent their recurrence. The document is relevant to the query as it discusses regulatory issues related to HCT/Ps, which may include EVs or exosomes, and highlights the importance of quality control and compliance in their processing and handling.

FDA Warning Letter to Burst Biologics

smart-surgical-inc-dba-burst-biologics-614361-02022022.txt

This document is a warning letter from the FDA to Smart Surgical, Inc dba Burst Biologics, concerning their products BioBurst Fluid and BioBurst Rejuv, which are derived from human umbilical cord blood. The FDA conducted an inspection and found that the products are intended to treat various diseases or conditions and are administered via injection. The FDA considers these products to be drugs and biological products that do not meet the criteria for regulation solely under section 361 of the PHS Act. The warning letter details significant deviations from current good manufacturing practice (CGMP) and current good tissue practice (CGTP) requirements. These deviations include failure to determine donor eligibility based on Zika virus risk, inadequate validation of aseptic processes, failure to monitor environmental conditions, failure to sample and test components, and failure to thoroughly investigate sterility failures. These issues raise concerns about potential contamination and product quality. The FDA has requested a written response from Burst Biologics outlining the steps they will take to address the violations and prevent their recurrence. The warning letter emphasizes that failure to adequately address these matters may lead to regulatory action. The document suggests the products are related to exosomes due to the nature of umbilical cord blood derived products, but it does not explicitly mention exosomes.

FDA Warning Letter to Surgenex LLC Regarding Biologics

surgenex-llc-615254-11152021.txt

This document is a warning letter from the FDA to Surgenex LLC regarding violations of the Federal Food, Drug, and Cosmetic Act (FD&C Act) and the Public Health Service Act (PHS Act). The letter addresses the manufacture and distribution of cellular products, including SurCord®, SurForce®, and SurFactor®, which are derived from human umbilical cord and amniotic membrane. These products are intended for injection and are purported to be sterile, with claimed uses to treat diseases or conditions, including orthopedic issues. The FDA found that these products do not meet the criteria for regulation solely under section 361 of the PHS Act and are subject to additional regulation as drugs and biological products, requiring premarket review and a valid biologics license. The warning letter cites significant deviations from current good manufacturing practice (CGMP) requirements, raising safety concerns due to potential microbial contamination and product quality defects. The firm has ceased manufacturing of these three product lines [SurCord®, SurForce®, and SurFactor®] effective April 16, 2021 and, will cease distribution in a responsible manner to their health care providers and the patients they treat. The letter requests a written response outlining steps to correct the violations and prevent recurrence.

FDA Warning Letter to Utah Cord Bank LLC

utah-cord-bank-llc-dba-utah-cell-bank-614013-08102021.txt

This warning letter from the FDA to Utah Cord Bank LLC and FIOR Bioscience addresses significant violations of the Federal Food, Drug, and Cosmetic Act (FD&C Act) and the Public Health Service Act (PHS Act) related to the manufacture and distribution of human cellular products. These products, derived from umbilical cord blood, umbilical cord, and amniotic membrane, are intended for allogeneic use and are purported to treat various diseases or conditions. The FDA inspection revealed deviations from current good manufacturing practice (CGMP) and current good tissue practice (CGTP) requirements, including failures in aseptic processing, sterilization, laboratory controls, and complaint handling. The firm also lacks an approved biologics license application (BLA) or an investigational new drug application (IND) for these products. The FDA has requested a written response outlining steps to address the violations and prevent their recurrence. The document does not discuss EVs or exosomes directly, but addresses violations and regulatory concerns regarding cellular products with therapeutic applications.

FDA Warning Letter to Ardent Animal Health

ardent-animal-health-llc-662394-10222024.txt

This document is a warning letter from the U.S. Food and Drug Administration (FDA) to Ardent Animal Health, LLC, addressing the marketing of unapproved new animal drugs, Acti-Stem Therapy and PureVet PRP. These products are intended for use in dogs and cats and are marketed for regenerative therapy. The FDA states that the products are in violation of the Federal Food, Drug, and Cosmetic Act (FD&C Act) because they lack the necessary approval or index listing. The letter references claims made on Ardent Animal Health's website and social media, highlighting the intended uses of the products for treating various conditions, including osteoarthritis and soft tissue injuries. The FDA emphasizes that these products are considered unsafe and adulterated under the FD&C Act due to the absence of FDA approval. The warning letter serves as a notification of the FDA's concerns and provides Ardent Animal Health an opportunity to address the violations. It also states that failure to comply may lead to legal action. The document is relevant to the query because it discusses the unapproved marketing and regulatory issues surrounding cell and tissue-based regenerative therapy products, which may relate to the use of EVs or exosomes in veterinary medicine, although EVs and exosomes are not explicitly mentioned.

FDA Warning Letter to BioLab Sciences, Inc.

biolab-sciences-inc-621465-08232022.txt

This document is a warning letter from the FDA to BioLab Sciences, Inc., addressing violations of the Federal Food, Drug, and Cosmetic Act (FD&C Act) and the Public Health Service Act (PHS Act) related to the manufacturing and marketing of products derived from human amniotic fluid and epidermal skin tissue. The letter states that the products are intended to treat various diseases or conditions and are regulated as drugs and biological products, requiring premarket review and approval. The FDA found significant deviations from current good manufacturing practice (CGMP) requirements, including issues with sterilization, environmental monitoring, and quality control. The warning letter also addresses the lack of an approved biologics license application (BLA) or an investigational new drug application (IND) for the products, which is required for lawful marketing. The letter requests a written response outlining the steps BioLab Sciences will take to correct the violations and prevent their recurrence. The FDA identified the products are intended to treat various diseases or conditions, however, the FDA requires an approved biologics license showing that the product is safe, pure, and potent.

FDA Warning Letter to Frontier Biologics, LLC

frontier-biologics-llc-686059-11012024.txt

This document is a warning letter from the FDA to Frontier Biologics, LLC, addressing violations related to their human amniotic fluid and membrane-derived products, specifically regarding unapproved new drugs and unlicensed biological products. The FDA inspection revealed that the products, marketed for wound healing, inflammation reduction, and orthopedic uses, do not have the required biologics license application (BLA) or an investigational new drug (IND) application. The letter also cites significant failures in adhering to current good manufacturing practice (CGMP) regulations, including inadequate sterilization processes, lack of proper validation, and insufficient environmental monitoring. The company's products, such as Purified Fluid Allograft and Allograft Matrix, are intended for various applications, including muscle tears, soft tissue injuries, wound treatment, osteoarthritis, and joint pain. However, the FDA has found that these products are being marketed without the necessary approvals, and their manufacturing processes do not meet the required standards to ensure safety and efficacy. The warning letter emphasizes the need for the company to address these violations and prevent their recurrence to avoid further regulatory action.

FDA Warning Letter to Invitrx Therapeutics Inc.

invitrx-therapeutics-inc-581182-03162020.txt

This document is a warning letter issued by the FDA to Invitrx Therapeutics Inc. regarding violations of the Federal Food, Drug, and Cosmetic Act (FD&C Act) and the Public Health Service Act (PHS Act). The letter addresses the firm's processing and distribution of products, including human umbilical cord blood, umbilical cord-derived products, amniotic fluid-derived product, and amniotic membrane-derived product, intended for allogeneic use. These products are intended for injection and are claimed to treat a variety of diseases or conditions, including orthopedic conditions. The FDA inspection revealed significant deviations from current good manufacturing practice (CGMP) and current good tissue practice (CGTP). These deviations include failures in donor eligibility determination, screening for communicable diseases (e.g., Zika virus), prevention of microbiological contamination, validation of aseptic processes, and investigation of discrepancies. The firm also failed to reject products not meeting established standards, validate cleaning processes, and maintain adequate environmental monitoring. The warning letter also mentions Invitrx's exosome product, Invitra EXTM, noting that exosome products intended to treat diseases or conditions in humans are regulated as drugs and biological products. The FDA emphasizes that the firm's actions have violated the FD&C Act and the PHS Act, and the products are not the subject of an approved biologics license application (BLA) nor is there an IND in effect for any of them. The document is focused on regulatory compliance and safety concerns related to Invitrx's products, including potential violations related to exosome products intended for therapeutic use.

FDA Warning Letter to Neobiosis, LLC

neobiosis-llc-662985-06052024.txt

This document is a warning letter from the FDA to Neobiosis, LLC, addressing violations related to the manufacturing and marketing of products derived from human amniotic fluid and umbilical cord, including Purified Amniotic Fluid (PAF), Wharton's Jelly Cellular, and Wharton's Jelly Acellular. The FDA inspection revealed that Neobiosis' products are intended for allogeneic use and are being marketed for wound healing and orthopedic applications without the required FDA approvals, such as Biologics License Applications (BLAs) or Investigational New Drug (IND) applications. The company has been distributing these products to various entities, including medical centers and pain clinics, while claiming they are for research purposes, which does not align with the regulatory requirements for clinical investigations. The warning letter also highlights significant deviations from Current Good Manufacturing Practice (CGMP) regulations, including failures in aseptic processes, environmental monitoring, laboratory controls, and cleaning and disinfection procedures. The FDA has acknowledged Neobiosis' initial responses and corrective actions but found them inadequate to address the identified deficiencies. The letter also raises concerns about a (b)(4) product manufactured by Neobiosis for a client, which is being marketed without the necessary approvals. The document emphasizes Neobiosis' responsibility to comply with CGMP and other applicable regulations, and it requests a written response outlining the steps taken to address the violations and prevent their recurrence. Relevant to the query, the document indicates that while Neobiosis is manufacturing products from perinatal tissues they are not following proper manufacturing guidelines and are marketing the products for uses such as wound healing and orthopedic uses without proper FDA approval.

Warning Letter to Allure Imports re: COVID-19 Products

allure-imports-613211-04072021.txt

This document is a warning letter from the FDA and FTC to Allure Imports regarding the sale of unapproved and misbranded products intended to mitigate, prevent, treat, diagnose, or cure COVID-19. The letter states that the company's websites and social media offer products like Silver Soul Immune Support, Silver Soul Body Spray, and Vitality C60 for sale in the United States, claiming they can help with COVID-19. The FDA asserts that these products violate the Federal Food, Drug, and Cosmetic Act (FD&C Act) because they are unapproved new drugs and misbranded drugs. The letter also mentions that Vitality C60 is intended for use in animals, making it an unsafe and adulterated animal drug. The company is urged to cease the sale of these unauthorized products immediately and to review their websites and promotional materials to ensure compliance with the FD&C Act. The letter also states that the FTC finds the company in violation of the FTC Act for advertising that a product can prevent, treat, or cure disease without competent and reliable scientific evidence. The document does not contain any information about EVs or exosomes.

FDA Warning Letter to Ambaya Gold Health Products

ambaya-gold-health-products-llc-648130-12052023.txt

This document is a warning letter from the U.S. Food and Drug Administration (FDA) to Ambaya Gold Health Products, LLC, addressing violations of the Federal Food, Drug, and Cosmetic Act (the Act). The FDA reviewed Ambaya Gold's website and social media and found that the company was marketing several products, including Brain Balance, Immune System Boost, Dentist In A Bottle, Essensiac, Fulvic Green, Silver Solution, Detox Cleanse Renew, Magnesium Oil Spray, Silver Spray, and Pet Health+, with claims that classify them as drugs without the necessary FDA approvals. The warning letter outlines specific claims made on the company's website and social media that suggest the products are intended for use in the cure, mitigation, treatment, or prevention of disease, and/or intended to affect the structure or any function of the body. These claims include assertions about the products' ability to treat mental health problems, combat allergies, prevent tooth decay, reduce inflammation, fight infections, detoxify the body, and improve pet health. The FDA concludes that these products are unapproved new drugs and misbranded drugs, in violation of the Act. The letter demands that Ambaya Gold take corrective action to address the violations and prevent their recurrence. The warning letter indicates that the company is marketing products with therapeutic claims without providing adequate evidence of their safety and efficacy, which is relevant to the query about common use cases for EVs and exosomes, as it highlights the importance of regulatory compliance and scientific validation in the marketing of health products.

FDA Warning Letter to Aqualex Co., Ltd.

aqualex-co-ltd-672292-06122024.txt

This document is a warning letter from the U.S. Food and Drug Administration (FDA) to Aqualex Co., Ltd. regarding significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. The FDA inspected Aqualex's drug manufacturing facility and found that their methods, facilities, and controls for manufacturing, processing, packing, or holding drugs do not conform to CGMP. Additionally, the product "DBH Beverly Hills, EGF FGF DNA, UV Shield" is an unapproved new drug and is misbranded. The letter details specific violations, including failure to establish adequate written procedures for production and process control, failure to use appropriately designed equipment, failure of the quality control unit to ensure drug products comply with CGMP, failure to conduct appropriate laboratory testing, and failure to establish an adequate written testing program for assessing the stability characteristics of drug products. The FDA also notes the risk of contamination with diethylene glycol (DEG) or ethylene glycol (EG) in products containing glycerin. The warning letter highlights that "DBH Beverly Hills, EGF FGF DNA, UV Shield" is marketed as an OTC sunscreen drug product but does not comply with the requirements for such products, particularly regarding active ingredients and indications. The FDA concludes that the product is a new drug marketed in violation of the FD&C Act and is also misbranded due to false or misleading labeling. The FDA placed the firm on Import Alert 66-40 on February 9, 2024, and may withhold approval of any new applications or supplements listing the firm as a drug manufacturer until compliance is confirmed.

FDA Warning Letter to Banco Vida Corp

banco-vida-corp-606288-08122020.txt

This document is a warning letter from the FDA to Banco Vida Corp. regarding violations of the Federal Food, Drug, and Cosmetic Act (FD&C Act) and the Public Health Service Act (PHS Act) related to the manufacturing and distribution of human umbilical cord blood products. The FDA conducted inspections and found significant deviations from current good manufacturing practice (CGMP) and current good tissue practice (CGTP). These deviations include failure to screen donors adequately for relevant communicable diseases like Zika virus, inadequate aseptic practices, unvalidated manufacturing processes, and deficient environmental monitoring. The firm distributes umbilical cord blood for allogeneic use for further manufacturing, intending the products to treat a variety of diseases or conditions. The FDA emphasizes that the products do not meet the criteria for regulation solely under section 361 of the PHS Act and are instead regulated as drugs and biological products, requiring a valid biologics license or an investigational new drug application (IND). The FDA raises concerns about potential contamination and product quality defects due to the firm's deficient practices. The document does not include any information about EVs or exosomes, but addresses violations related to umbilical cord blood products.

FDA/FTC Warning Letter to Beepothecary LLC

beepothecary-llc-608383-10232020.txt

This document is a warning letter from the FDA and FTC to Beepothecary LLC regarding the sale of unapproved and misbranded products related to Coronavirus Disease 2019 (COVID-19). The letter states that Beepothecary LLC is offering various bee products for sale, including “Elderberry, Honey & Propolis Syrup,” “BEEbread,” and “BEEHive Delight,” and claiming that these products can mitigate, prevent, treat, diagnose, or cure COVID-19. The FDA and FTC found that these products are unapproved new drugs sold in violation of section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) and are misbranded drugs under section 502 of the FD&C Act. The letter requests that Beepothecary LLC take immediate action to cease the sale of such unapproved and unauthorized products. The claims made by Beepothecary LLC are not supported by competent and reliable scientific evidence, and the company is advised to review its websites, product labels, and other labeling and promotional materials to ensure compliance with the FD&C Act. This document does not relate to EVs or Exosomes, but rather to bee products and their unapproved use in treating Covid-19.

FDA Warning Letter to Berkeley Biologics

berkeley-biologics-llc-previously-operating-elutia-inc-orthobiologics-business-unit-formerly-aziyo.txt

This document is a warning letter from the FDA to Berkeley Biologics, formerly Elutia, Inc., regarding violations in the manufacture of viable bone matrix products (VBM, FVBM, CFM/EFM, and OVM). These products are intended for orthopedic or reconstructive bone grafting procedures. The FDA inspection revealed failures in donor eligibility determination, deviations from CGTP and CGMP requirements, inadequate process validation, and contamination control issues. The letter states the products are unapproved new drugs being introduced into interstate commerce in violation of the FD&C Act and the PHS Act. The firm failed to determine as ineligible a donor who is identified as having a risk factor for sepsis. The company has not validated the manufacturing processes for VBM, CFM/EFM, and OVM with respect to identity, strength, quality, and purity. The warning letter addresses the firm's failure to have an IND in effect to study their VBM, CFM/EFM, and OVM products or their lack of an approved BLA to lawfully market these products. The document is relevant to the query because it discusses regulatory issues and manufacturing deficiencies related to biologics, which may have implications for the development and use of EVs and exosomes in similar applications.

FDA Warning Letter to Blue Willow Biologics

blue-willow-biologics-613948-08032021.txt

This document is a warning letter from the FDA to Blue Willow Biologics regarding their NanoBio Protect Nasal Antiseptic. The FDA found that the product was being marketed with claims that it could kill the COVID-19 virus and provide protection against infection for up to 8 hours, which the FDA considered unapproved new drug claims. The FDA stated that the product violates the Federal Food, Drug, and Cosmetic Act (FD&C Act) because it is an unapproved new drug and is misbranded. The product's claims of extended efficacy, especially against serious-disease related pathogens, were found to endanger public health by creating a false sense of security. The FDA also noted that the product is intended to be applied inside and around the nostrils, which is not permitted under the relevant TFM. The warning letter instructs Blue Willow Biologics to take immediate action to correct these violations and threatens legal action if they are not adequately addressed. The FDA is advising consumers not to purchase or use products that have not been approved, cleared, or authorized by the FDA and that are being misleadingly represented as safe and/or effective for the treatment or prevention of COVID-19. The document does not mention EVs or exosomes.

FDA Warning Letter to California IVF Fertility Center

california-ivf-fertility-center-598552-02262020.txt

This warning letter, issued by the FDA to California IVF Fertility Center, addresses significant deviations from regulations regarding human cells, tissues, and cellular and tissue-based products (HCT/Ps). The inspection revealed failures in donor screening and testing for relevant communicable diseases like West Nile Virus (WNV) and Zika Virus (ZIKV). The letter emphasizes the importance of adhering to Title 21 CFR Part 1271, which outlines requirements for testing, screening, and determining donor eligibility. The clinic's procedures were found inadequate in screening for risk factors associated with ZIKV and WNV, as well as in testing donors for HIV, HBV, and HCV. The FDA insists on complete donor eligibility determinations and proper quarantine procedures for HCT/Ps from donors with incomplete screenings. The document does not mention EVs or exosomes. It is focused on regulatory compliance issues within a fertility center, specifically related to infectious disease screening and testing of reproductive cells and tissues.

FDA Warning Letter to Cholrem Regarding RemChol

cholrem-pty-ltd-dba-cholrem-and-cholrem-pharmaceuticals-684036-07092024.txt

This document is a warning letter from the FDA to Cholrem Pty Ltd regarding the marketing and sale of unapproved new drugs, specifically the RemChol product line. These products contain Cavadex, a cyclodextrin, and are claimed to treat and prevent atherosclerosis and heart disease. The FDA states that Cholrem's marketing claims suggest the products are intended for the diagnosis, cure, mitigation, treatment, or prevention of disease, making them drugs under the FD&C Act. Because RemChol products are being sold without FDA approval, the FDA has determined that Cholrem is in violation of federal law. The warning letter does not discuss EVs or exosomes. The document focuses on violations related to unapproved drug products and their marketing claims. Therefore, the information in this document is unrelated to the query about common use cases for EVs and exosomes.

FDA/FTC Warning Letter to ChromaDex on COVID-19 Claims

chromadex-607692-11172020.txt

This document is a warning letter from the FDA and FTC to ChromaDex regarding the marketing and sale of Tru Niagen products with claims of preventing, treating, or curing COVID-19. The letter states that these products are unapproved new drugs sold in violation of the Federal Food, Drug, and Cosmetic Act and are misbranded drugs. The letter cites claims made on ChromaDex's websites and social media suggesting that Tru Niagen products, which increase NAD+ levels, can support immunity to coronaviruses and reduce recovery time in COVID-19 patients. The FDA and FTC request that ChromaDex cease the sale of these unapproved products and correct the violations. The letter emphasizes that claims about preventing, treating, or curing human disease must be supported by competent and reliable scientific evidence. The warning letter highlights the regulatory concerns and lack of sufficient evidence for the claimed therapeutic benefits of Tru Niagen products related to COVID-19.

FDA Warning Letter to Cooper Institute

cooper-institute-619233-12152021.txt

This document is a warning letter from the FDA to Cooper Institute for Advanced Reproductive Medicine, addressing significant deviations from regulations for human cells, tissues, and cellular and tissue-based products (HCT/Ps). The FDA conducted an inspection and found failures in donor screening and testing, including not testing for West Nile Virus, HIV, hepatitis B and C, and other diseases. The institute also failed to properly screen donors for risk factors and document donor eligibility. The letter instructs the institute to correct these violations and prevent their recurrence, or face further regulatory action. The document is relevant to the query because it discusses the use of reproductive cells and tissues, but it does not mention EVs or exosomes.

FDA/FTC Warning Letter to Cureganics re: COVID-19

cureganics-627288-03282022.txt

This document is a warning letter from the FDA and FTC to Cureganics regarding the sale of unapproved and misbranded cannabidiol (CBD) products. The letter states that Cureganics' website claims these products can mitigate, prevent, treat, diagnose, or cure COVID-19, which violates the Federal Food, Drug, and Cosmetic Act (FD&C Act) and the FTC Act. The FDA and FTC found that the company is marketing CBD products with claims that they can prevent COVID-19 infection, referencing a study about cannabinoids blocking cellular entry of SARS-CoV-2. However, these claims are not supported by sufficient evidence, and the products have not been approved or authorized by the FDA. The letter demands that Cureganics cease the sale of these unapproved products and correct the violations within 48 hours. It also warns of potential legal action, including seizure and injunction, if the violations are not addressed. The document is related to the query because it discusses claims related to disease treatment, which could be relevant to EVs and exosomes in therapeutic applications, although the document itself does not mention EVs or exosomes.

FDA Warning Letter to Duoc Thao Tre Xanh

duoc-thao-tre-xanh-llc-611685-03162021.txt

This document is a warning letter from the FDA to Duoc Thao Tre Xanh, LLC, addressing violations related to the marketing of products such as Immune Health, Ganoderma Lucidum Red Reishi Mushroom, Papaya Leaf Extract, and Fucoidan. The FDA reviewed the company's website and found claims that these products are intended for use in the cure, mitigation, treatment, or prevention of diseases, which classifies them as drugs under the Food, Drug, and Cosmetic Act. The warning letter specifically calls out claims related to the treatment of conditions like high blood pressure, diabetes, asthma, Alzheimer's disease, chronic fatigue syndromes, insomnia, leukemia, hepatitis, cancer, and COVID-19. The FDA asserts that these products are not generally recognized as safe and effective for these uses and are therefore considered new drugs that require prior approval from the FDA. The letter indicates that the company is in violation of federal law and FDA regulations. It demands immediate action to cease the sale of unapproved and unauthorized products and requests a written notification within fifteen working days detailing the steps taken to correct the violations. The information in this document is important to the query because it identifies violations and deviations from regulatory standards.

FDA/FTC Warning Letter to Synchronicity Hemp Oil

functional-remedies-llc-dba-synchronicity-hemp-oil-627208-03282022.txt

This document is a warning letter from the FDA and FTC to Functional Remedies, LLC D/B/A Synchronicity Hemp Oil, addressing the company's marketing and sale of unapproved and misbranded hemp oil and CBD products. The letter states that the company's website claims these products can mitigate, prevent, treat, diagnose, or cure COVID-19, which violates the Federal Food, Drug, and Cosmetic Act (FD&C Act) and the FTC Act. The FDA and FTC found that the company was marketing their hemp oil and CBD products with claims that they could possibly reduce viral inflammation and inhibit the virus's ability to bind to a host. However, these claims lack scientific evidence and proper approval or authorization. The letter demands that the company cease the sale of these unauthorized products and correct the violations within 48 hours. The document emphasizes the absence of scientific evidence supporting the company's claims regarding the effectiveness of its products against COVID-19 and highlights the regulatory violations associated with these claims.

FDA Warning Letter to Hemp XR Regarding THC/CBD Products

gchnc-llc-dba-hemp-xrgate-city-hemp-dba-hemp-xrallaziya-enterprises-llc-dba-hemp-xr-656057-09282023.txt

This document is a warning letter from the FDA to GCHNC LLC dba Hemp XR regarding the company's Delta-8 THC and CBD-containing food products. The FDA has determined that these products are adulterated under the Federal Food, Drug, and Cosmetic Act because they contain unsafe food additives. Specifically, Delta-8 THC and CBD are not approved food additives and lack GRAS status. The FDA also raises concerns about potential adverse health effects associated with Delta-8 THC and CBD, including potential harm to the central nervous and cardiopulmonary systems, liver injury, and interference with neurodevelopment. The letter informs the company of these violations and provides an opportunity to address them, warning of potential legal action if the issues are not resolved. The document does not mention EVs or exosomes. Therefore, the information in this document is unrelated to the query about common use cases for EVs and exosomes.

FDA/FTC Warning Letter to Greenway Herbal Products

greenway-herbal-products-llc-627042-03282022.txt

This document is a warning letter from the FDA and FTC to Greenway Herbal Products LLC (Tanasi) regarding the marketing and sale of unapproved cannabidiol (CBD) products that claim to mitigate, prevent, treat, diagnose, or cure COVID-19. The letter states that these products are unapproved new drugs sold in violation of the Federal Food, Drug, and Cosmetic Act (FD&C Act) and are misbranded drugs. The FDA and FTC reviewed the company's website and social media and found claims suggesting that CBD products could defend against COVID-19, prevent infection, speed recovery, and prevent cytokine storms. The warning letter cites specific examples of claims made on the company's website and social media, such as references to studies suggesting that cannabinoids can help prevent a Sars-Cov-2 infection. The letter also notes that the company's products are being misleadingly represented as safe and effective for a COVID-19-related use without FDA approval. The document does not contain specific details on EVs or exosomes, but it is related to potential therapeutic applications of certain products.

FDA Warning Letter to Heavenly Natural Products

heavenly-natural-products-607470-12022020.txt

This document is a warning letter from the FDA and FTC to Heavenly Natural Products regarding the sale of unapproved and misbranded products, specifically C60 and colloidal silver, with claims to mitigate, prevent, treat, diagnose, or cure COVID-19. The letter states that these products violate the Federal Food, Drug, and Cosmetic Act (FD&C Act) because they are being marketed without FDA approval and with misleading claims. The letter also addresses concerns regarding the lack of scientific evidence supporting the claims made about the products' effectiveness against COVID-19. The warning letter addresses the company's marketing practices, including claims made on their website and social media platforms. It emphasizes the need for immediate action to cease the sale of unapproved products and correct the violations. The letter highlights the absence of competent and reliable scientific evidence to support the claims made about the products' ability to prevent, treat, or cure COVID-19, as required by the FTC Act. The document is relevant to the query because it discusses the unapproved marketing of products with claims related to antiviral activity and immune support, which are common claims associated with EVs and exosomes in therapeutic and diagnostic applications, although this document does not directly mention EVs or exosomes.

FDA Warning Letter to Honest Globe, Inc.

honest-globe-inc-597177-03152021.txt

This document is a warning letter from the FDA to Honest Globe, Inc. regarding violations of CGMP regulations and the marketing of unapproved and misbranded drug products containing CBD. The FDA inspected the company's manufacturing facility and reviewed its website, finding that the "ELIXICURE PAIN RELIEF with CBD" products are being marketed with claims of pain relief and other therapeutic benefits without proper FDA approval. The warning letter details specific violations, including inadequate quality control, deficient batch production records, and failure to validate manufacturing processes. The FDA states that the products are unapproved new drugs and misbranded drugs because they do not meet the requirements for marketing under section 505G of the FD&C Act. The letter also addresses the company's misleading claims about FDA registration and certification. The document does not contain information on EVs or exosomes; the information important to the query relates to regulatory violations, therapeutic claims, and the intended use of CBD-containing products.

FDA Warning Letter to Kingdom Harvest Regarding CBD

kingdom-harvest-625058-05042022.txt

This document is a warning letter from the FDA to Kingdom Harvest regarding their CBD and Delta-8 THC products. The FDA found violations of the Federal Food, Drug, and Cosmetic Act (FD&C Act) because the products are unapproved new drugs, misbranded, and adulterated. Claims made on the company's website and social media suggest the products treat various conditions, including pain, anxiety, and even COVID-19, without FDA approval. The FDA is concerned about the safety of these products, especially those marketed for food-producing animals and children. Some products contain unsafe food additives, and there is a lack of data on the safety of CBD and Delta-8 THC. The document does not contain information about common use cases for EVs and exosomes. The document focuses on the regulatory violations and safety concerns related to CBD and Delta-8 THC products marketed by Kingdom Harvest.

FDA Warning Letter to LightEyez Limited

lighteyez-limited-665450-02152024.txt

This document is a warning letter from the FDA to LightEyez Limited regarding their MSM Eye Repair Drops and other eye drop products. The FDA found that the MSM Eye Repair Drops were adulterated due to gross microbial contamination, including bacteria like Pseudomonas spp. and Mycobacterium spp. This poses a high risk of ocular infections, potentially leading to vision-threatening or life-threatening conditions. The FDA also determined that LightEyez's manufacturing processes did not conform to Current Good Manufacturing Practice (CGMP) regulations. Additionally, the FDA considers LightEyez's MSM, color changing, and eye lightening eye drop products to be unapproved new drugs because they are marketed with claims to diagnose, cure, mitigate, treat, or prevent disease and/or affect the structure or any function of the body without FDA approval. The company's website makes claims about the products' ability to repair eyes, lessen eye floaters, alleviate dry/irritated eyes, help with bloodshot eyes, assist with vision problems, stop eye allergies, reduce glaucoma or cataracts, soften eye tissues, equalize eye pressure, repair damaged membranes, and speed up eye color change. The FDA has requested that LightEyez issue a voluntary recall of all batches of MSM Eye Repair Drops and other sterile drug products. The information in this document does not appear to relate to EVs or exosomes.

FDA Warning Letter to Natural Native LLC

natural-native-llc-593385-11222019.txt

This document is a warning letter from the U.S. Food and Drug Administration (FDA) to Natural Native LLC regarding the marketing and distribution of unapproved drug products containing cannabidiol (CBD). The FDA reviewed the company's websites and social media and found that the products are being marketed as treatments for various conditions in both humans and animals. The letter states that these products are unapproved new drugs and misbranded drugs in violation of the Federal Food, Drug, and Cosmetic Act (FD&C Act). The FDA is particularly concerned about the marketing of these products for infants. The letter also addresses that the products are adulterated because CBD is not GRAS for use in conventional foods. The FDA determined that the company is marketing the unapproved new animal drug “Native Pet CBD Oil (150mg, 300mg, & 600mg).” The FDA's concerns about the safety and efficacy of CBD products highlight the importance of regulatory oversight in the development and marketing of therapeutic and diagnostic products, including those related to EVs and exosomes. The document emphasizes the need for rigorous testing and compliance with federal laws to ensure the safety and effectiveness of these products.

FDA Warning Letter: Reproductive Medicine Center Violations

new-hope-center-reproductive-medicine-658251-06272023.txt

This document is a warning letter from the FDA to The New Hope Center for Reproductive Medicine, detailing significant deviations from regulations regarding human cells, tissues, and cellular and tissue-based products (HCT/Ps). The FDA inspection revealed failures in donor screening, testing, and eligibility determination, including missing screening questions, inadequate testing procedures, and incomplete donor eligibility assessments. The letter emphasizes the importance of adhering to Title 21 CFR Part 1271 and outlines specific corrective actions required. The warning letter does not contain information on EVs or exosomes. The document is related to the query because it discusses regulatory issues with biologics but it does not contain any information about EVs or exosomes.

FDA Warning Letter to Next Science LLC

next-science-llc-698114-02212025.txt

This warning letter from the FDA to Next Science LLC addresses violations related to the marketing and manufacturing of wound gels and irrigation solutions, including XPERIENCE®, BLASTX®, and SURGX®. The FDA found that the products are adulterated and misbranded due to a lack of premarket approval for their current marketing claims, which exceed the scope of their cleared indications. These claims include uses in orthopedic surgeries, biofilm disruption, and broad-spectrum efficacy. The letter also cites violations of the Quality System Regulation (QSR) related to design validation, complaint handling, and corrective and preventive actions. Specific concerns include the failure to validate the design of XPERIENCE® for claimed uses, inadequate investigation of complaints related to excessive bleeding, and the lack of a CAPA after receiving multiple reports of bleeding. The FDA also found that the firm failed to submit timely Medical Device Reports (MDRs) for adverse events. The FDA's primary concern is that Next Science is marketing these products for uses that have not been reviewed or approved, potentially endangering patients. The information in the document is important to the query because it highlights the regulatory scrutiny and potential safety concerns associated with medical products marketed with claims that have not been substantiated with sufficient evidence.

FDA Warning Letter to Noble Elements LLC

noble-elements-llc-643745-01302023.txt

This document is a warning letter from the FDA to Noble Elements, LLC, regarding their Coated Silver product. The FDA has determined that the product is being marketed as a drug without the necessary approvals. The FDA reviewed the company's website and found claims that the Coated Silver product can cure, mitigate, treat, or prevent diseases, including mpox, making it an unapproved new drug. The warning letter cites specific examples of claims made on the company's website and blog posts, such as the product having antimicrobial properties and being effective against viruses, bacteria, and fungi. The FDA states that the product is misbranded because it does not have adequate directions for use. The letter instructs Noble Elements, LLC, to cease the sale of unapproved products and to respond to the FDA within fifteen working days with corrective actions. The FDA is concerned that Noble Elements, LLC is marketing an unapproved new drug for the treatment and prevention of disease, referencing the company's claims regarding the product's antibacterial and antiviral properties.

FDA Warning Letter to OsteoLife Biomedical I LLC

osteolife-biomedical-i-llc-626889-03312022.txt

This document is a warning letter from the FDA to OsteoLife Biomedical I LLC, addressing significant deviations from regulations for human cells, tissues, and cellular and tissue-based products (HCT/Ps). The FDA conducted an inspection and found failures in preventing contamination, validating manufacturing processes, monitoring environmental conditions, and investigating HCT/P deviations. The letter details specific instances of positive microbiological cultures in bone products and inadequate responses to these deviations. The FDA also raises concerns about the company's corrective actions and requests a meeting to discuss the steps taken to address the violations. This document does not relate to EVs or exosomes. It highlights manufacturing and quality control issues in bone products, with failures to prevent contamination during processing, inadequate validation of manufacturing processes, and insufficient environmental monitoring.

FDA/FTC Warning Letter to PA Green Wellness

pa-green-wellness-llc-dba-predictive-biotech-certified-facility-608144-08172020.txt

This document is a warning letter issued by the FDA and FTC to PA Green Wellness LLC regarding their product CoreCyte™. The letter addresses the company's claims that CoreCyte™ can mitigate, prevent, treat, diagnose, or cure COVID-19. It states that CoreCyte™ is an unapproved new drug and a misbranded drug, violating the FD&C Act and the PHS Act. The FDA and FTC assert that PA Green Wellness is marketing CoreCyte™ with misleading claims of safety and effectiveness without proper authorization or scientific evidence. The letter also points out that PA Green Wellness does not qualify for any exception in 21 C.F.R. § 1271.15, and CoreCyte TM fails to meet all the criteria in 21 C.F.R. § 1271.10(a). Furthermore, the agencies request that PA Green Wellness immediately cease the marketing, sale, and distribution of CoreCyte™ for COVID-19 related uses. The document is relevant to the query because it discusses the unapproved use of a product with claims related to therapeutic applications of EVs or exosomes.

FDA Warning Letter to Phoenix Biotechnology, Inc.

phoenix-biotechnology-inc-612178-12152020.txt

This document is a warning letter from the FDA to Phoenix Biotechnology, Inc. and Avila Herbals, LLC regarding their product "Oleander 4X." The FDA states that the companies are marketing and selling "Oleander 4X" as an unapproved new drug in violation of the Federal Food, Drug, and Cosmetic Act (FD&C Act). The product is being promoted as a treatment for COVID-19 and other conditions. The FDA highlights claims made on the companies' websites and social media platforms, which suggest that "Oleander 4X" can mitigate, prevent, treat, diagnose, or cure COVID-19. The warning letter emphasizes that these claims are concerning from a public health perspective, as the product has not been approved or authorized by the FDA. The FDA requests that the companies take immediate action to cease the sale of this unapproved new drug. The document is unrelated to EVs and exosomes but the claims made about Oleander 4X are similar to claims sometimes made about exosomes.

FDA Warning Letter to Rat's Army

rats-army-612020-12022020.txt

This document is a warning letter from the FDA and FTC to Rat's Army regarding their product “VIRUS BIOSHIELD”. The letter states that the product is being sold as an unapproved new drug and is misbranded, violating the Federal Food, Drug, and Cosmetic Act. The company claims that the product can mitigate, prevent, treat, diagnose, or cure COVID-19. The FDA and FTC found that the claims made by Rat's Army are not supported by scientific evidence and that the product is being misleadingly represented as safe and effective. The letter requests that Rat's Army cease the sale of the product and take corrective actions to address the violations. It also mentions that failure to comply may result in legal action. The document is relevant to the query because it involves therapeutic claims related to a specific product.

FDA Warning Letter to Re-Gen Active Lab

re-gen-active-lab-inc-620763-05272022.txt

This document is a warning letter from the FDA to Re-Gen Active Lab, Inc., concerning the manufacture and distribution of cellular products derived from amniotic membrane and human umbilical cord tissue. These products, including ActiveFlow™, ActiveShot™, and ActivePro™, are intended for injection and are purported to treat various diseases or conditions. The FDA inspection revealed that Re-Gen Active Lab does not qualify for any exception in 21 CFR 1271.15, and their HCT/Ps derived from umbilical cord and/or amniotic membrane fail to meet all the criteria in 21 CFR 1271.10(a). The warning letter cites significant deviations from current good manufacturing practice (CGMP) requirements, including failures to validate aseptic processes, use non-sterile protective equipment, and establish appropriate written procedures for environmental monitoring. The firm also failed to calibrate equipment routinely and lacked validated cleaning and disinfecting processes. The FDA has not received sufficient information to determine if the corrective actions are adequate. The products are claimed to treat diseases, but the company lacks an approved biologics license application (BLA) or an investigational new drug application (IND). Because the document does not discuss EVs or exosomes, these tags are not relevant.

FDA Warning Letter to Regenative Labs re: Biologics

row1-inc-dba-regenative-labs-638823-06212023.txt

This document is a warning letter from the FDA to Row1 Inc. (dba Regenative Labs) regarding the manufacture and distribution of cellular products derived from human umbilical cord. The FDA found that the products do not meet the criteria for regulation solely under section 361 of the PHS Act and are instead regulated as drugs and biological products, requiring a biologics license or an investigational new drug application (IND). The company has been distributing these products to physicians and medical clinics throughout the United States. The letter details significant deviations from current good manufacturing practice (CGMP) requirements, including failures to prevent microbiological contamination, validate manufacturing processes, and establish a written testing program for stability. The FDA also notes that the company's corrective actions are inadequate and that they continue to manufacture and distribute products under violative conditions. The letter states that the products are intended for clinical use to treat a variety of diseases or conditions, but the FDA has not approved a biologics license application (BLA), nor is there an IND in effect for any of them. The information important to the query is that the company is not in compliance with FDA regulations in manufacturing practices.

FDA Warning Letter to CellGenuity Regenerative Science

stratus-biosystems-llc-dba-cellgenuity-regenerative-science-631303-06052023.txt

This document is a warning letter from the FDA to Stratus Biosystems, LLC dba CellGenuity Regenerative Science, addressing significant violations of the Federal Food, Drug, and Cosmetic Act (FD&C Act) and the Public Health Service Act (PHS Act) in the manufacture of their products, AmnioAMP-WJ™ and AmnioAllograft. These products, derived from umbilical cord, amniotic membrane, and amniotic fluid, are intended for allogeneic use and are marketed for treating various diseases or conditions. The FDA inspection revealed failures to adhere to current good manufacturing practice (CGMP) requirements, including inadequate procedures to prevent microbiological contamination, failures in cleaning and disinfecting processes, and a lack of scientifically sound specifications. The company has not validated aseptic processes, lacks appropriate environmental monitoring, and has deficient gowning procedures. Sterility and environmental monitoring failures were not thoroughly investigated, and products were assigned expiration dates without stability testing. The FDA has determined that the products do not meet the criteria for regulation solely under section 361 of the PHS Act and require premarket review and approval. The company markets its products for a wide range of applications, including neuro/spine, orthopedics, cardiac, oncology, and nerve-related treatments. However, the warning letter indicates that the company does not have an approved biologics license application (BLA) or an investigational new drug application (IND) in effect for their products.

FDA Warning Letter to Thriftmaster Texas, LLC

thriftmaster-texas-llc-dba-thriftmaster-global-holdings-inc-and-tm-global-biosciences-llc-641057.txt

This document is a warning letter from the FDA to Thriftmaster Texas, LLC, regarding their CBD products. The FDA reviewed the company's websites and social media and found that they were selling unapproved new drugs and misbranded drugs in violation of the Federal Food, Drug, and Cosmetic Act. The FDA also determined that some of the company's food products containing CBD were adulterated. The warning letter states that the company's CBD products are intended to treat, mitigate, prevent, or diagnose diseases, including COVID-19 and Alzheimer's, without FDA approval. The FDA is concerned about the safety of these products, especially those intended for oral inhalation, and the potential for liver injury and other harmful effects from CBD. The letter also notes that the company is marketing and distributing these products through their websites and social media platforms. The information in the document is related to the query because it discusses the use of CBD, which is a component of EVs and exosomes, for therapeutic purposes and the regulatory issues associated with these products.

FDA Warning Letter to University of Kentucky

university-kentucky-600258-03262020.txt

This warning letter issued by the FDA to the University of Kentucky details objectionable conditions observed during an inspection of their laboratory. The inspection, conducted to assess compliance with regulations for nonclinical laboratory studies, revealed serious violations of Title 21, Code of Federal Regulations (CFR) Part 58 – Good Laboratory Practice for Nonclinical Laboratory Studies, particularly in a study of the Novalung System, a medical device. The letter addresses failures by the Study Director in ensuring data accuracy and adherence to GLP regulations, as well as shortcomings in the Quality Assurance Unit's (QAU) responsibilities. The university's responses and planned corrective actions are also discussed, with the FDA requesting further documentation to determine the adequacy of these measures. The violations could potentially affect the overall safety and risk of the device prior to clinical trials involving human subjects. The document is related to the query because it discusses regulatory compliance and quality control issues in a laboratory setting. However, it does not directly discuss EVs or exosomes, focusing instead on a medical device and adherence to GLP regulations. Therefore, while the document provides insights into regulatory standards and potential violations, it does not offer specific information about the use cases, safety concerns, or therapeutic applications of EVs or exosomes.

FDA Warning Letter to USH Diagnostics

ush-diagnostics-inccovidinstanttestnet-612084-07092021.txt

This document is a warning letter from the FDA to USH Diagnostics, Inc. regarding the sale of unapproved COVID-19 test kits. The FDA reviewed the company's websites and social media and found that they were selling "Rapid Dual Antibody Test," "Rapid 10 Minute Antigen Test," and a "Saliva Test Kit" for at-home use without the required FDA approvals or authorizations. The letter states that these products are adulterated and misbranded under the Federal Food, Drug, and Cosmetic Act. The FDA is concerned about the public health risks associated with at-home testing, including the ability of laypersons to accurately collect specimens, run tests, and interpret results. The letter also notes that the company is falsely claiming that their products are "FDA Submitted/EUA Approved," "FDA EUA Authorized," or "EUA/FDA Certified," and is using the FDA logo without authorization. The warning letter requests that USH Diagnostics immediately cease the sale of any unapproved, uncleared, and unauthorized products for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19. The letter also threatens legal action if the violations are not adequately corrected. The document does not contain any information about EVs or exosomes but is related to diagnostic tests.

FDA/FTC Warning Letter to Vibrant Health Care, Inc

vibrant-health-care-inc-608426-11182020.txt

This document is a warning letter from the FDA and FTC to Vibrant Health Care, Inc., regarding the marketing of an unapproved umbilical cord derived cellular product. The company claims the product can mitigate, prevent, treat, diagnose, or cure COVID-19, as well as treat other conditions like diabetes and autoimmune diseases. The FDA and FTC state that the product is an unapproved new drug and a misbranded drug, violating the FD&C Act and the PHS Act. The company is marketing these products without proper licensure, approval, or authorization, and making claims without competent and reliable scientific evidence. The letter instructs Vibrant Health Care to cease marketing the product for COVID-19 and other uses and to correct the violations within 48 hours, or face legal action. The document does not provide any evidence to support the claims made about the product's effectiveness. Instead, it emphasizes the lack of scientific validation and the potential for misleading consumers. The warning specifically addresses the marketing of stem cell therapy for various conditions, including COVID-19, without the necessary regulatory approvals and scientific backing.

FDA Warning Letter to VapeScorpion.com Regarding E-Liquids

east-coast-vapors-llc-dba-vapescorpioncom-609573-07242020.txt

This document is a warning letter from the FDA to East Coast Vapors, LLC d/b/a VapeScorpion.com, addressing the misbranding of an e-liquid product due to the absence of the required nicotine warning statement on their website. The letter cites violations of the Federal Food, Drug, and Cosmetic Act (FD&C Act) and its implementing regulations, specifically 21 CFR 1143.3(b). The company is instructed to correct these violations and provide a written response to the FDA within 15 working days. The document does not relate to EVs or exosomes. It is focused on the regulation of tobacco products, specifically e-liquids, and the requirement for nicotine warning statements in advertising. Therefore, it does not provide information relevant to the query about common use cases for EVs and exosomes.

FDA Warning Letter to Strong Fertility Center

strong-fertility-center-593262-10292019.txt

This document is a warning letter from the FDA to Strong Fertility Center, citing significant deviations from regulations for human cells, tissues, and cellular and tissue-based products (HCT/Ps). The FDA inspection revealed failures in testing anonymous or directed donors of reproductive cells/tissue for West Nile Virus (WNV), determining donor eligibility before HCT/P transfer, and screening donors for communicable disease risk factors. The letter emphasizes the need for thorough donor screening, testing, and adherence to regulatory requirements to prevent the spread of communicable diseases. The violations include not testing donors for WNV, determining donor eligibility after HCT/Ps were transferred, and using incomplete donor medical history forms. The document does not discuss EVs or exosomes; it is focused on regulatory violations in the context of reproductive tissue donation and handling.

FDA Warning Letter to TEI Biosciences, Inc.

tei-biosciences-inc-573474-03062019.txt

This document is a warning letter from the FDA to TEI Biosciences, Inc., an Integra LifeSciences Company, regarding violations of current good manufacturing practice requirements for collagen-based medical devices, including Xenform Soft Tissue Repair Matrix. The FDA conducted an inspection and found that the devices were adulterated due to non-conformity with quality system regulations. The letter outlines failures in process validation, contamination prevention, environmental control, and corrective action verification. Specific issues include inadequate validation of the (b)(4) process for extracellular bovine matrix (EBM) medical devices and lack of data for bacterial endotoxin testing validation. The firm also failed to prevent contamination of equipment and product and did not maintain adequate control over environmental conditions in the ISO 7 clean rooms. The FDA concludes that the firm's responses to the initial observations were inadequate and requires prompt corrective action to avoid further regulatory action. This document does not relate to EVs or exosomes. It is about quality control and manufacturing deficiencies in collagen-based medical devices.